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SUMMARY
This thesis focuses on the molecular causes of two inherited diseases, identified in South
African families, namely the long QT syndrome (LQTS) and a familial form of myoclonic
epilepsy (FME).
The long QT syndrome is a cardiac repolarization disorder characterized by the occurrence of
life threatening cardiac arrhythmias that can present as fainting attacks. and the occurrence of
sudden cardiac death in young otherwise healthy individuals. Linkage analysis demonstrated
genetic heterogeneity in LQTS. and mutations in four cardiac ion channels. namely those
encoding a voltage-gated potassium channel (/{YUJT/). the gene encoding human minimal
potassium (hminK). also known as (KCNE). human ether-a-go-go gene (HERG) and a cardiac
sodium channel (S( 'N5A), as well as an as yet unidentified gene on chromosome 4. were
shown to result in the phenotypic expression of this disease. Five South African families of
Afrikaner descent were shown to harbour an Ala212Vai mutation in KVLQTl. these families
also shared the same haplotype at this locus. suggesting the presence of a founder effect.
The epilepsies are a clinically variable and genetically heterogeneous group of neurologic
disorders characterized by the transient disturbances of neuronal synchrony. Linkage analysis
has established the chromosomal location in well over hundred rare epilepsy syndromes. which
show a simple inheritance pattern. Some of the first epilepsy genes identified were also
voltage-gated or ligand-gated ion channels.
An important mutual characteristic of LQTS and epilepsy is episodic loss of consciousness: the
latter is a common reason for misdiagnoses of LQTS as epilepsy. In the present study. both
these disorders were investigated with the aim of employing genetic markers to determine the
chromosomal locus in both diseases. as an adjunct to clinical diagnosis.
In the LQTS study, all probands referred with the clinical diagnosis of LQTS were first
screened for the Ala212Vai mutation in KVLQT 1 by allele specific restriction enzyme analysis
(AS REA ). Using the probands. pedigrees were constructed where possible. and linkage
analysis was performed at four of the known LQTS loci. if the Ala212Vai mutation was
absent. Mutation screening employing ASREA and polymerase chain reaction (Pt.R )-based
single strand conformational polymorphism (SSCP) analysis was used to search for known and
novel mutations after linkage analysis had implicated the disease-causing gene or locus.
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Four of a panel of 12 LQTS probands carried the KVLQTi Ala212Vai mutation. Three
pedigrees of different South African population groups, namely Afrikaner, Mixed ancestry and
Indian descent were constructed from the panel. The KVLQTi Ala212Vai mutation was
present in the family of Afrikaner descent; however. in the other two families, this mutation
was absent, subsequently, linkage analysis was performed in these pedigrees. In the family of
Mixed ancestry. significant negative LOD scores (-3.12. -5.01 and -3.23) were generated at the
HERG, SCN5A and chromosome 4 loci, respectively; however at the KVLQTi locus an
equivocal lad score of 0.92 was generated. Mutation screening of KVLQTI hy AS REA and
PCR-SSCP analysis identified an intronic polymorphism. but no disease-causing sequence
variation in this family. In the Indian family. significant negative 1.0D scores (-2.78. -2.62 and
-2.78) were found at the SCN5A. KVLQTl ami chromosome 4 loci. respectively. and an
equivocal LOD score of 0.20 was generated at the [-IERG locus.
In the epilepsy study, one family with a form of familial myoclonic epilpesy (FME) was
identified. and the responsible disease-causing locus or genes of three plausible candidate
forms of epilepsy were investigated for their involvement in this disease. These epilepsy
syndromes included progressive myoclonus type one (EPM I). dcntato-rubro-pallidoluysian-
atrophy (DRPLA) and a chromosome 8p disease-associated locus. Linkage analysis was used
to test linkage of"FME to these three plausible candidate loci. Significant negative LOD scores
were generated at all three loci at 8 = 0.00. at the EPMl locus LOD scores 01'-14.29. -12.83
and -6.82 were found at the marker loci D21.','20../0' D2/S/912 and D2lSl959, respectively.
At the DRP LA locus a LOD score of 14.50 was found at (1 = 0.00 and at the chromosome 8p
locus. the LOD scores generated were 0.69. -4.46 and 0.68 at the marker loci D8S50../, D8S26../
and D8/;"/78l. respectively, at 0 = 0.00.
The application of genetic markers was useful in solving the differential diagnosis in the LQTS
affected families. The KVLOTl Ala212Vai mutation was identified as cause of LQTS in the
family of Afrikaner descent. a different KVLQTl mutation was implicated as cause of the
disease in a family of Mixed ancestry and HERG was implicated as causative gene in a family
of Indian decent. This is the first report of genetic heterogeneity in South African LQTS
families. In the epilepsy study. three highly plausible candidate epilepsy syndromes were
excluded as cause of FME.
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The results obtained in the LQTS study have important implications. The precipitating factors,
incidence and lethality of cardiac events, and consequently choices concerning patient
management and treatment, vary according to the disease-causing gene involved. The results
obtained in the epilepsy study provided evidence to support the hypothesis that FME is a new
clinical and genetic entity.
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OPSOMMING
Hierdie tesis konsentreer op die molekulêre oorsake van twee oorertlike siektes. geïdentifiseer
in Suid Afrikaanse families. naamlik lang QT syndroom (LQTS) en familêre myoklonicse
epilepsie (FME).
Die lang QT syndroom is a kardie-repolarisasie siekte wat gekenmerk word deur die voorkoms
van lewens gevaarlike ritme stoornisse. wat kan presenteer as floute aanvalle en skielike
kardiale dood in jong. andersins gesonde individue. Genetiese heterogeniteit was met behulp
van koppeling analise in LQTS gedemonstreer. Mutasies in vier knrdio-ioon kanale naamlik 'n
stroom beheerde kalium kanaal (KVLQT1). die geen wat koddeer vir die menslike minimale
kalium protein (hminK). KCNE. menslike eter-a-go-go geen (HERG) en 'n kardio natrium
kanaal (S( 'N5A) sowel as 'n tot nou toe ongeïdentifiseerde geen op chromosoom 4 was bewys
om verantwoordelik te wees in meeste gevalle van die fenotypiese uitdrukking van die siekte.
In vorige studies. is bewys dat vyf Suid Afrikaanse families van Afrikaner afkoms die
Ala111Vai mutation in KVU)Tl dra. en geaffekteerde lede van hierdie familie dieselfde
luiplotipe by hierdie lokus deel. dit dui op "n stigtings effek in hierdie subpopulasie groep.
Die epilepsies is 'n kliniese differse en geneties heterogeniese groep van neurologiese siektes.
gekenmerk deur 'n kortstondige versteuring van neuronale synchronisasie. Koppelings analise
het die chrornosornale posisies van meer as honderd skaars epilepsic syndrome met eenvoudige
oorerfings pattone geïdentifiseer. Van die eerste epilepsie gene wat geidentitiseer is. was
stroom-beheerde of ligand-beheerde ioon kanale.
'n Belangrike gemeenskaplike eienskap van LQTS en epilepsie is die episodiese verlies van
bewussyn. 'n algemene rede vir die misdiagnose van LQTS as epilepsie. In die huidige studie
was albei hierdie siekte toestande ondersoek met die doelom genetiese merkers te gebruik om
die chrornosomale posisies van beide siektes te bepaal en sodoende 'n bydrae te lewer in die
kliniese diagnose.
In die LQTS studie was die indeks gevalle wat verwys was met die kliniese diagnose van
LQTS eers getoets vir die Ala212Val mutasie in KVLQTl met behulp van alleel-spesifieke
restriksie ensiem analise (ASREA). Waar moontlik was stambome saamgestel vanaf die indeks
gevalle en koppelings analise was uitgevoer by vier van die bekende LQTS lokusse indien die
Ala212Vai mutasie afwesig was in die indeks geval. Mutasie analise met behulp van ASREA
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en polimerase ketting reaksie (PKR) gebasseerde enkel string konformasie polimorfisme
analise was gebruik om te soek vir bekende en nuwe mutasies in die geen geïmpliseer deur
koppelings analise as die siekte-veroorsakende geen.
Die Ala212Vai mutasie was teenwoordig in vier uit die paneel van twaalf LQTS indeks
gevalle. Drie stambome. van verskillende Suid Afrikaanse subpopulasie groepe. naamlik
Afrikaner, gemengde herkoms en Indieër oorsprong was saamgestel vanaf die paneel. Die
Ala212Vai mutasie was teenwoordig in die familie van Afrikaner afkoms, maar nie in die
ander twee families nie. gevolglik was koppelings analise in hierdie families uitge , oer. 111 die
familie van gemengde herkoms was betekenisvolle negetiewe LOD waardes (-3.12. -5J) 1 en -
3.23) gegenereer by HERG. 5;CN5.4 en die chromosome 4 lokus onderskeidelik. By die
KVUJTl lokus was 'u swak positiewe LOD waarde van 0.92 bereik. In die lndieër familie was
weereens betekenisvolle negatiewe LO 0 waardes (-3.78, -2.62 en -2.78) gegenereer by
onderskeidelik SCN5A. KVLQT1 en die chromosome 4 lokus terwyl 'n swak positiewe LOD
waarde van 0.20 by HERG behaal is.
Een Iamilie met FME was geïdentifiseer en die kliniese eienskappe van hierdie vorm van
epilepsic was vergelyk met ander bekende epilepsies en sodoende was drie hoogs waarskynlike
kandidaat vorms van epilepsic syndrome geïdentifiseer. Hierdie drie epilepsic syndrome was
verder ondersoek en sluit in proggressiewe myokloniese epilepsic tipe I (EPM I), denrato-
rubro-pallidoluysian-atrofie (DRPLA) en "n vorm van epilepsic wat geposisioneer is op
chromosoom 8p. Koppeling analise was toegepas tussen FME en die drie kandidaat epilepsic
syndrome. Betekenisvolle negatiewe LOD waardes was bereik by by al drie lokusse by (:)=
0.000. by die EPAfl lokus was LOD waardes van -14.29, 12.53 en 6.52 gevind by merkers
D21S20...JO, D2!S!9!2 en D21S1959.onderskeidelik. By die DRPLA lokus was 'n LOO waarde
van -14.80 gevind en LOO waardes van 0.69. -4A6 en 0.68 by die chromosoom 8 lokus by
merkers D8S50...J. D85,'26...Jen D8S! iS! onderskeidelik.
Die gebruik van genetiese merkers was waardevol in die uitlê van die differensieële diagnose
in die LQTS families. Die Ala212Val mutatasie was bevestig in 'n familie van Afrikaner
afkoms. 'n under KVLQT! mutasie was geïmpliseer as oorsaak van die siekte in die familie van
gemengde herkoms en HERG was geïmpliseer as siekte-veroorsakende geen in die lndieër
LQTS familie. Dit is die eerste verslag van genetiese heterogeniteit in Suid Afrikaanse LQTS
Stellenbosch University http://scholar.sun.ac.za
viii
families. In die epilepsie studie was drie hoogs aanneemlike kandidaat epilepsie syndrome
uitgesluit as oorsaak van die siekte in FME.
Die resultate verkry in die LQTS studie het belangrike implikasies. aangesien die presipitasie
faktore. behandeling en medikasie verskil. afhangende van die spesifieke siekte-veroorsakende
geen betrokke. Die resultate verkry in die epilepsie studie verskaf bewyse in guns van die
hipotese dat FME 'n nuwe kliniese en genetiese entiteit is.
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3INTRODUCTION
It is sometimes difficult to make an unequivocal clinical diagnosis in the case of episodic loss
of consciousness, because of the complexity of possible underlying causes. It may be difficult
to determine if the patient is displaying syncope, as in the case with Long QT Syndrome
(LQTS), or if he is having an epileptic seizure (Schott et al., 1977; Ballardie et al., 1983;
O'Callaghan and Trump 1993; Singh et al., 1993; Paci et al., 1994). The diagnostic confusion
between LQTS and various epileptic conditions as a result of their clinical presentation
provided the rationale, and the availability of three affected South African families in which
LQTS segregates, as well as a family in which a type of genetic epilepsy segregates, provided
an opportunity to investigate the molecular causes of both these disorders. In the first two
sections of this report, the development of scientific knowledge regarding aspects of these two
conditions, since they were first observed or described, will be summarized. This will be
followed by a section which describes the basis for the diagnostic confusion between these two
disorders. Thereafter, relevant molecular genetic techniques will be discussed and a section on
the application of these techniques in studies of LQTS and two genetic forms of epilepsy will
succeed this.
1.1 BACKGROUND ON EPILEPSY
1.1.1 History of Epilepsy
Epilepsy is as old as mankind and the first written description of a secondarily generalized
convulsion was found in the oldest written language, Akkadian, in Mesopotamia (now Iraq)
dating back to about 3,000 years ago (reviewed by Goldensohn et al., 1997). At that time,
people believed that supernatural forces controlled all events and individual behavior, and the
presence of the seizures was attributed to the god of the moon. About 2,000 years ago, cases of
epilepsy were also described in Egypt, China, India, and Babylonia (reviewed by Goldensohn
et al., 1997).
The first known attempt at a scientific explanation of epilepsy was made about 400 B.C. in a
book entitled "On the Sacred Disease" (reviewed by Engel, 1989). This book was written by a
Greek physician of the school of Hippocrates and he dedicated this book to Hippocrates, who
considered epilepsy to be a disease of the brain caused by superfluity of the phlegm that led to
abnormal brain consistency. In this book, the author rejected the belief that individual Greek
gods caused epilepsy and that superstitions and magic could prevent or cure epilepsy and he
pointed out that epilepsy is hereditary and attributed it to a dysfunction of the brain (reviewed
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4by Engel, 1989). Although Hippocrates (460-357 B.C) and physicians of his school considered
epilepsy as a disease of the brain, Charles le Pois (I563-1636) was the first one to clearly state
that all epilepsies were of brain origin (reviewed by Schmidt and Wilder, 1968).
The European physicians were unaware of "On the Sacred Disease" because generally they
did not read Greek, and the book was not translated into Latin. Thus, they still attributed
epilepsy to supernatural forces, through the 15th century until the 16th century, when Da
Vinci's drawings of anatomic dissections, and those by Vesalius, provided new insight to the
possible physiological cause of epilepsy (reviewed by Goldensohn et al., 1997). Despite these
interventions, people suffering from epilepsy were still considered to be possessed by evil
spirits, unclean and contagious, because most natural therapies suggested for epilepsy were
ineffective and some supernatural therapies appeared to be more beneficial (Engel, 1989).
Much progress in the field of epilepsy research has been made since the first description of the
disease, but to discuss all this information is beyond the scope of this review. However, the
age-old stigma and myths associated with epilepsy began to lift, as more insight relevant to the
understanding of epilepsy became available.
1.1.2 Classification of the Epilepsies
" The epilepsies have been classified and reclassified upon the basis of each of their attributes -
seizure pattern, temporal occurrence, aetiology and accompaniments. There are quite clearly as
many classifications as there are needs to classify" (Williams, 1988).
Due to the confusion created by the different classification systems, the Commission of
Classification and Terminology of the International League Against Epilepsy (!LAE) saw the
need for a standard classification. The first International Classification of Epileptic Seizures
was made in 1970 (reviewed by Goldensohn, 1997), this system was revised in 1981 leading to
the detailed classification of seizure types (Commission on Classification and Terminology of
the !LAE, 1981). The classification of the seizure types primarily distinguishes between
generalized onset seizures, which are presumed to involve the entire brain from the onset and
partial onset seizures, in which seizures begin in a localized brain region (Commission on
Classification and Terminology of the !LAE, 1981).
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(EEG) characteristics regardless of their polyaetiological background. These forms have
important differences in course and prognosis, and based on this, could be divided into
epileptological entities or epileptic syndromes (Duchownny and Harvey, 1996). In 1985, the
ILAE presented a classification of epilepsies into epileptic syndromes, which was revised in
1989 (Commission on Classification and Terminology of the ILAE, 1989). This classification
system combines information on seizure type, age at onset, aetiology, clinical course and EEG
findings.
The syndrome classification primarily distinguishes between generalized and partial epilepsies
and can further be subclassified according to their aetiology into the idiopathic, cryptogenic
and symptomatic groups (Commission on Classification and Terminology of the ILAE, 1989).
The set of syndromes presumed to be genetic in origin are referred to as "idiopathic", whereas
the epilepsies with unknown aetiological factors that are not included in the idiopathic
syndromes are referred to as "cryptogenic". The remainder with identified aetiological factors
are called "symptomatic" (reviewed by Jain, 1997).
The observation of familial aggregation of either the epilepsy, or the associated EEG
abnormality, and the higher concordance rates in monozygotic than dizygotic twins have led to
the interpretation that most idiopathic generalized epileptic syndromes are genetic in origin
(Jain, 1997). Partial epilepsies have long been considered as too complex to justify them as
candidates for genetic studies, because they occur in strong association with a variety' of
cerebral lesions. However, clinical observations have suggested that genetic factors also may
play some role in the pathogenesis of partial epilepsies (Jain, 1997).
1.1.3 The Role of Genetics in Epilepsy
As is clear from their classification, the epilepsies comprise a heterogeneous group of disorders
in which there is a predisposition to recurrent seizures or fits. Seizures in tum represent an
"occasional excessive and disorderly discharge of neurons" (Ryan, 1995). Thus, epileptic
behavior is modulated by mechanisms that alter both neuronal excitability and neuronal
synchronization (Engel, 1989). Regulation of the cortical excitability in the normal brain
depends upon ionic fluxes across membranes, neuronal morphology, transmitter and receptor
interaction, neuronal circuity and extracerebral systems that influence cerebral function. All
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contribution of genetics in epilepsy. However, when a single phenotype has many causes, it
becomes difficult to determine patterns of genetic transmission (Engel, 1989).
In the past, epileptic disorders were considered to be either genetically or environmentally
induced, but today it is recognized that a variety of genetic, environmental and physiological
factors influence the appearance of the more common forms of epilepsy (Ottman et aI., 1996).
However, an epidemiological study performed by Ottman in 1997 identified a substantial
genetic contribution to epilepsy and showed that genetic, and not environmental, factors
account for most of the familial aggregation seen in seizure disorders (Ottman, 1997). There
are well over 100 rare single gene mendelian disorders in which epileptic seizures appear as
part of the phenotype (Ryan, 1999). The susceptibility loci and genes in most of these
disorders have been identified, as linkage analysis in clinically homogeneous disorders with
simple inheritance is relatively straight forward and is often achieved with a single large family
or multiple small families. Table 1.1 shows some of these epilepsy syndromes in which the
susceptibility loci and genes have been identified. However, epilepsy attributable to these
disorders comprises only a small portion of all epilepsies, the remainder are thought to be
mainly multifactorial diseases with oligogenic or polygenic backgrounds (Berkovic, 1997). In
most of the epilepsies, especially the more common forms, the mode of inheritance is unknown
and molecular approaches have been unsuccessful and controversial (Berkovic, 1998). The
more complex inheritance pattern seen in many common epilepsies could result from low
penetrance, genetic heterogeneity or both (Ryan, 1999).
Some of the first genes identified in human epilepsy syndromes were voltage-gated or ligand-
gated ion channels (Steinlein et aI., 1995; Singh et al., 1998; Charlier et aI., 1998; Ryan, 1999)
(Table 1.1). Ion channel defects was also found in a number of diseases known to occur
intermittently in otherwise healthy individuals. These discoveries suggested that subtle,
prevalent genetic variations in ion channel genes could also be involved in the aetiology of the
common forms of idiopathic epilepsies with complex modes of inheritance (Ryan, 1999).
However, to date, no ion channel variants have been implicated convincingly in susceptibility
to common epilepsies (Ryan, 1999).
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7TABLE 1. The genetic localization and disease-causing genes associated with some known
forms of epileptic syndromes
Epileptic Syndrome Genetic Locus Causative Gene
Idiopathic Generalised Epilepsies
Juvenile myoclonic epilepsy Chr. 6p
Benign familial neonatal convulsions Chr. 20q KCNQ2
Chr. 8 q KCNQ3
Benign familial infantile convulsions Chr. 19q
Progressive epilepsy with mental retardation Chr.8p
Benign adult familial myoclonic epilepsy Chr.8q
Generalized epilepsy with febrile seizures Chr. 19q SCNIB
Progressive Myoclonus Epilepsy
EPM1 Chr.21q CSTB
Neuronal ceriod lipofuscinoses, infantile Chr. 1
Neuronal ceroid-lipofuscinoses, juvenile Chr. 16p
Gaucher's disease Chr. 1
Sialidosis type! Chr. 10
MERRF mtDNA tRNALYs
Idiopathic Partial Epilepsy
Autosomal dominant nocturnal frontal lobe epilepsy Chr.20 CHRNA4
Partial epilepsy with auditory features Chr.10q
Autosomal dominant febrile seizures Chr.8q
N eurodegenerative disorders
DPRLA Chr.12p Atrophin
(Compiled from Delgado-Escueta et al., 1994; Johns, 1995; Duchowny and Harvey, 1996;
Berkovic, 1997; Ottman, 1997; Plaster et al., 1999; Ryan, 1999)
Chr = chromosome, CHRNA4 = Nicotinic acetylcholine receptor a4-subunit, CSTB = Cystatin
B, DRPLA= Dentato-rubro-pallido-Iuysian-atrophy, EPM1 = Progressive myoclonic epilepsy
type1, mDNA= Mitochondrial DNA, MERRF= Myoclonus epilepsy and ragged-red fibres,
KCNQ2 = Voltage sensitive K'<channel, KCNQ3 = Voltage sensitive K+-channel and SCNIB =
Voltage sensitve Na'<channel ~-subunit.
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heterogeneous group of disorders and a detailed discussion of all of the different types of
epilepsies are beyond the scope of the present review. In this study, the focus will be on three
specific types of epilepsy syndromes, namely Progressive myoclonus epilepsy type I (EPMI),
Dentato-rubro-pallido-Iuysian-atrophy (DRPLA) and form of epilepsy that showed linkage to
chromosome 8p, because of their relevance as plausible candidates for FME, the type of
epilepsy that forms the basis of this part of the study.
1.1.3.1 Progressive myoclonus epilepsy
Familial myoclonic epilepsy (FME) is a form of progressive myoclonus epilepsy (PME). The
PMEs are a clinically and aetiologically heterogeneous group of rare genetic disorders
characterized by myoclonus, tonic-clonic seizures and progressive neurological dysfunction,
particular ataxia and dementia (Berkovic et al., 1986). At least five diseases, or disease groups,
account for most cases ofPME worldwide. These are PME ofUnverricht-Lundborg type, also
known as EPM1, Lafora's disease, neuronal ceroid lipofuscinoses, mitochondrial disorders and
the sialidoses (Marseille Consenses Group, 1990). Based on characteristic clinical features four
of these disease groups could definitively be excluded as candidates for FME; however, the
fifth one, EPMl was considered as plausible candidate as will be discussed in section 4.3.
Unverricht described in 1891 the first clinical picture of familial myoclonus, which is
nowadays known as EPMl (Koskiniemi et aI., 1974). The first symptom he observed were
grand mal seizures at the age of 6 to 13 years, while muscle jerking, i.e. myoclonus, appeared
later. In the period between 1903 and 1912, Lundborg described 17 patients from nine families
in Sweden who apparently had the same disease. He found in addition to the muscle jerks and
grand mal seizures, a later onset, dementia and various neurological symptoms. This syndrome
was subsequently named the Unverricht-Lundborg's disease (Koskiniemi et al., 1974).
Although it is now known that the PMEs are a heterogeneneous group of disorders and a
specific diagnosis can be made on the specific type of PME, in the past, PME was often
regarded as a final clinical diagnosis (Berkovic, 1986).
Progressive myoclonus epilepsy type 1, or Unverricht-Lundborg disease, is now defined as an
autosomal recessive inherited disease that is characterized by myoclonus that can be
precipitated by movement, stress, or sensory stimuli and progressively increases in severity
and frequency, often becoming incapacitating (reviewed by Berkovic et aI., 1993). The mean
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9age of onset is 10.8 years (range 8-13 years) and myoclonic and tonic-clonic seizures occur in
all cases with absences and drop attacks in a minority of cases. At the onset of the disease,
neurological signs are absent or minimal, but dysarthria, ataxia and intention tremor is
eventually seen in all cases. Intellectual decline is very gradual, the progression of the disease
is at a variable rate, and periods of stabilization may occur (reviewed by Berkovic et al., 1986).
The diagnosis of EPM 1 is clinical; the key features are: (i) the patient's age at onset, (ii) the
severity and continuous nature of the myoclonus, (iii) the absence of severe or early dementia,
(iv) a clinical history of EPM1, (v) typical EEG abnormalities, and (vi) clinical exclusion of
the other four subtypes of PME (Berkovic et al., 1986; Lafreniere et al., 1995). On
histopathological examination, widespread degenerative changes are seen in the brain, with no
evidence of storage material, which is observed in the other four subtypes of PME (Koskiniemi
et al., 1974).
1.1.3.2 Dentato-rubro-pallido-Iuysian-atrophy
The first report of DRPLA was from Smith et al., (1958) who described a middle-aged patient
of Yugoslavin origin with ataxia and choreoathetotic movements and combined dentato-rubral-
and pallido luysian degeneration, by post-mortem examination. Smith proposed the term
"dentato-rubro-pallido-Iuysian-atrophy" based on his neuropathologic findings in sporadic
cases. Since its first description, DRPLA has been extensively characterized in the Japanese
population, where its prevalence is estimated at approximately one case per million people,
while it is thought to be exceeding rare in both Northern American and European kindreds.
(Miwa, 1994).
Consequently, DRPLA was defined as a rare neurodegenerative disorder characterized by
combined degeneration of the dentafugal and pallidofugal systems (Naito and Oyanagi 1982;
Takahashi et al., 1988). Although this disease may occur sporadically, it is more commonly
inherited as an autosomal dominant trait. The clinical features of the disease are diverse, with
varying combinations of myoclonus and other movement disorders, epilepsy, cerebellar ataxia
and cognitive impairment (Takahata et al., 1978). This is a progressive disorder, with the age
of onset ranging from the first to the seventh decade, with a mean age of onset of 30 years
(reviewed by Koide et al., 1994).
There seems to be a dose correlation between age of onset and clinical features, patients
presenting under the age 20 years (juvenile onset) show a form of PME characterized by
(J. s. '.
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myoclonus, epileptic seizures, dementia and ataxia (reviewed by Kornure et al., 1994).
However, patients presenting after the age of 40 years (late adult onset) have cerebellar ataxia,
choreoathetosis and dementia, while patients whose ages at onset range from 20-40 years show
transitional forms between the juvenile and late adult onset (reviewed by Komure et al., 1994).
There is an accelerated age at onset and enhanced severity of the disease in successive
generations that is more prominent in paternal than in maternal transmission (Sano et al.,
1994).
The identification of the clinical features associated with DRPLA paved the way to the
identification of the disease-causing gene. It was hypothesized that genes with trinucleotide
repeats, which are expressed in human brain, may be plausible candidates for DRPLA, the
basis of this hypothesis will be discussed in section 1.5.2.2 (Koide et al., 1994; Nagafuchi et
al., 1994). Through screening databases containing previously described genes containing
triplet repeats, a gene, CTG-B37 later named atrophin, was identified as the disease-causing
gene (Koide et al., 1994; Nagafuchi et al., 1994).
1.1.4 Treatment of epilepsy
Epilepsy is a chronic disorder, or group of disorders, characterized by seizures that usually
recur unpredictably in the absence of consistent provoking factors (Scheuer and Pedley, 1990).
Accurate classification of epileptic syndromes, and specifically type of seizure, is essential to
all aspects of managing seizures, from the initial diagnostic evaluation to the decision about
whether to treat, with what drug and for how long. The first level of treatment for epilepsy is
the administration of antiepileptic drugs, when seizures fail to respond to epileptic drugs, brain
surgery is a therapeutic alternative (Scheuer and Pedley, 1990).
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1.2 BACKGROUND ON LQTS
The Long QT Syndrome is a cardiovascular repolarization disorder that is characterized by the
occurrence of life threatening arrhythmias, such as torsade de pointes and ventricular
fibrillations. These arrhythmias can present as seizures, syncope and sudden cardiac death in
young otherwise healthy individuals (Keating et al., 1996).
This disorder was named the LQTS because of the prolonged QT interval on the
electrocardiogram (ECG) that is present in affected individuals (figure 1.1) (Marx, 1991). The
QT interval represents the time in the heartbeat when the heart muscle is recovering from one
contraction, before it can be triggered to contract again (Barinaga, 1998). Thus, the
prolongation of the QT interval lengthens the recovery time of the heart and makes it more
variable from cell to cell. This can cause the electrical impulse that allows the heart to contract
to sweep through the heart muscle in an irregular fashion. The latter can interfere with the
heart rhythm and can send the heart into fibrillation and sudden death (Barinaga, 1998).
The LQTSs can be inherited or acquired; hereditary LQTS is rare and affects 1 in 10 000
people but for those people the risk of death can be 50% over 10 years (Barinaga, 1998). The
LQTSs are genetically heterogeneous disorders and two distinct genetic forms of this disease,
an autosomal recessive form, the Jervell Lange-Nielsen Syndrome (JLNS) (Jervell and Lange-
Nielsen, 1957), and a autosomal dominant form the Romano-Ward Syndrome (RWS) (Ward,
1964; Romano et al., 1963) have been described to date. Families affected by RWS were
investigated in the present study.
1.2.1 Jervell Lange-Nielsen Syndrome
In 1957, Jervell and Lange-Nielsen reported the first case of LQTS in a family of six, where
four of the children had a combination of deaf-mutism and a peculiar heart disease (Jervell and
Lange-Nielsen, 1957). The deaf mute children suffered from "fainting attacks" occurring from
the age of three to five years, but otherwise seemed quite healthy. No signs of heart disease
could be discovered in the clinical examination. The ECGs, however, revealed a pronounced
prolongation of the QT-interval in all cases, and three of the deaf-mute children died suddenly
at the ages of four, five and nine years, respectively (Jervell and Lange-Nielsen, 1957).
Stellenbosch University http://scholar.sun.ac.za
:f.>~~Mp;'1 p.~t:f::tt::H:1
. . ,'. (
Olit ot p.ha$.e~The lelt Itt-ftC"
tree« rdioar« f~:~ ; ,,'" ~'lA. l" '!'·':l· "f! . :i.,.?:~. "
.... ~... ,,"., «~ .. /{$. ,,:~>.>,,~, ~:<0 h~/~ d>;;(:i:>'i:'? 4I!;,M
enB (itt rfgltt. shouss fIt :~:1'}ng l;J'I"~%¥ll,~~~:Q~;:'~~llno~>;t~l~t;~..,'£ .; •..
12
; .~
Fig.1.1 QT prolongation. The electrocardiograms show that the QT interval in a patient with
LQTS is longer (560ms) compared to an individual in which this condition is absent (400ms).
Thus the heart of a patient with LQTS takes longer to recover from an action potential than a
normalheart (figure taken fromMarx, 1991).
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1.2.2 Romano Ward Syndrome
In 1964, Ward observed a syndrome III an Irish family with the following features: (i)
prolonged, but variable, QT interval on the EeG at rest, (ii) attacks of ventricular flutter or
fibrillation following exertion or emotional disturbance, (iii) normal interval between heart
sounds, (iv) absence of valvular or gross myocardial disease and (v) familial incidence (Ward,
1964). At the same time, Romano et aI., (1963) described a three-month old female infant with
similar clinical features. In the families described by Romano and his associates, (Romano et
al., 1963) and by Ward (1964), a prolonged QT interval was observed and sudden death also
occurred, as in the condition described by Jervell and Lange-Nielsen. However, in Romano
and Ward's families the hearing was normal, and direct familial transmission was consistent
with an autosomal dominant mode of inheritance (Romano et al., 1963 and Ward, 1964), in
contrast to the autosomal recessive mode of inheritance described in the Jervell Lange-Nielsen
Syndrome (Fraser, 1964).
To assist in a better understanding of the natural history of this disease, its clinical features and
the long-term efficiency of different therapeutic approaches, the group of Schwartz and Moss
established a worldwide prospective study in 1979. In 1985, a preliminary report of the first
196 patients with LQTS in this program was published (Moss et al., 1985). The precipitating
factor of syncope in 58% of the cases was intense emotion (fright or anger), vigorous exercise
in 45% and a loud noise often producing a startling awakening in 9% of cases (Moss et al.,
1985). During the past 20 years, 728 families with clinically identified LQTS have been
enrolled in this International Long-QT Syndrome Registry (Zareba et al., 1998). The clinical
findings of this study identified a broad spectrum of clinical manifestations among LQTS
patients. Affected persons had a prolonged QT interval, relative sinus bradycardia and a
propensity to recurrent syncope, malignant ventricular tachyarrhythmias of the torsades de
pointes type and sudden death (Moss and Robinson, 1992). Brief episodes of alternation of the
T-wave could also develop in LQTS patients, following the same stimuli which usually trigger
synocopal attacks. Abnormal U-waves or T-U-waves were also seen in some patients
(Schwartz, 1975).
Molecular genetic techniques have been employed to determine the molecular cause of the
disease. The progress to date on the molecular genetic studies will be summarized in the
following paragraph; however, it will be discussed in detail in section 1.7.
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In 1991, Keating's group demonstrated linkage between the autosomal dominant form of
LQTS and the Harvey ras-l gene (H-ras-1) on the short arm of chromosome 11 (Keating et al.,
1991). Benhorin et al., (1993) provided evidence for genetic heterogeneity in LQTS in a large
Israeli family. Later that same year, Keating's group confirmed this finding in two of their
families which did not link to the chromosome 11 locus (Curran et al., 1993). This finding was
followed by Keating's group's report of two LQTS loci that mapped to chromosome 3 and 7,
and evidence for further heterogeneity (Jiang et al., 1994). In 1995, a fourth LQTS-causing
locus was mapped to chromosome 4 (Schott et al., 1995). The same year, Keating's group
identified the genes for both the chromosome 3 and 7 type of LQTS as a cardiac sodium
channel gene (SCN5A) (Wang et al., 1995a) and a cardiac potassium channel gene, the human
ether-a-go-go gene (HERG), respectively (Curran et al., 1995). In 1996, Keating's group also
identified the gene causing the chromosome 11 form of LQTS as that encoding a voltage-gated
potassium channel (KVLQTl) (Wang et al., 1996a). In 1996, the groups of Sanguinetti et al.,
(1996) and Barhanin et al., (1996) independently showed that KVLQTl associated with hminK
to form the channel underlying the IKs cardiac current. The group of Splawski et al., (1997)
identified a fifth disease-causing locus, as KCNEI, the gene encoding hmin K.
Fraser et al., (1964) speculated on the possibility that a factor common to both the heart and
the ear electrolyte disequilibrium could explain the pathogenesis of LQTS. They considered
the fact that the extra-cellular concentrations of, for example, the potassium ion (K+) are
important in cardiac conduction, and some of the EeG features in LQTS could result from K+
imbalance. Furthermore, the endolymph of the inner ear is unusual in that the K+ concentration
is similar to that normally found in intra-cellular fluids and this might be of importance to
normal conduction in the auditory nerve. However, Fraser could not demonstrate abnormalities
in the level of any intra- or extra-cellular electrolyte in the blood of LQTS-affected persons he
studied (Fraser et al., 1964).
Early in 1997, Neyroud et al., (1997) showed at a molecular level that JLNS and RWS can be
caused by mutations in the same gene, KVLQTJ. However Jeffrey et al., (1992) failed to find
linkage in another JLNS family between the disease and Il-ras-i, a polymorphic marker
located 2 eentimorgan (cM) distal to the KVLQTJ locus. This result could be explained by
either a recombination event that had occurred in this family between Il-ras-v and the disease
locus, or .genetic heterogeneity in JLNS (Neyroud et al., 1997). Genetic heterogeneity was
established in JLNS by Tyson et al., (1997) through exclusion of the KVLQTl locus with
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linkage analysis in a single small consanguineous family. The group subsequently showed that
a homozygous mutation in KCNEJ was responsible for the disease in this family. In the study
of Duggal et al., (1998), four JLNS families were investigated for mutations in KVLQT1 and
KCNEJ, in one of these families, KCNEI was implicated as the causative gene and KVLQT1 in
the second family. However, in the two remaining families no mutations were detected in
either of these genes, suggesting the possibility of additional genetic heterogeneity in this
disorder.
1.2.3 Acquired forms of LQTS
Although much research has been done on the inherited forms of LQTS, acquired and sporadic
forms of this disease have also been reported (Schwartz et al., 1985). Acquired forms ofLQTS
are most frequently the result of medications, often antiarrhythmic or psychoactive drugs such
as quinidine and thloridazum. However, the condition can also be caused by neurologic,
metabolic or other cardiac abnormalities (Keating, 1996).
1.2.4 Treatment of LQTS
The availability of effective therapy for this often lethal disease emphasizes the importance of
early and accurate diagnosis. At present, there are three modalities of treatment for patients
with LQTS: (i) ~-blockers (Moss, 1986), (ii) pacemakers (Eldar et al., 1987; Moss et al., 1991)
and (iii) left-cervicothoracic sympathetic ganglionectomy (Moss and McDonald, 1971;
Bhandari et aI., 1984; Schwartz, et aI., 1991a). The primary goal of therapy is to prevent life-
threatening arrhythmogenic syncope and sudden cardiac death. The therapy has to be
individualized for each patient, as will be discussed below.
The role of sympathetic tone, in the setting of overactivity of the left and/or underactivity of
the right stellate ganglion, in precipitating adrenergic-dependant torsade de pointes, has led to
the use of ~-adrenergic agents as primary therapy and left cervicothoracic sympathectomy as
secondary therapy (Moss and Robinson, 1992). ~-Blockers have proven to be effective in
preventing syncope in 75-80% of LQTS cases (Schwartz et aI., 1985; Jackman et aI., 1988).
Despite full dose ~-blockade, 20-25% of patients continue to have syncopal episodes and
remain at high risk for sudden cardiac death (Schwartz et aI., 1985; Jackman et al., 1988). It is
for these patients that left cervicothoracic sympathectomy should be considered (Moss and
McDonald, 1971). Implantation of an automatic defibrillator could provide additional
protection in those patients unresponsive to the latter therapy (Moss et aI., 1991). Permanent
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pacing has been reported to prevent torsade de pointes in a small number of patients with
LQTS. Pacing appears to be most beneficial in those patients developing profound bradycardia
with pharmacological therapy, or in those where pauses or slow ventricular rates precede the
initiation of torsade de pointes (Moss et al., 1991).
The recent advances in the molecular genetics of LQTS have opened a new avenue for the
application of gene specific therapies, but this will be discussed in detail in the section 1.8.
1.3 CONFUSION IN DIAGNOSIS
In their report in 1964, Fraser et al., (1964) described the synocopal attacks displayed by
LQTS-affected individuals in detail. They observed a resemblance of the synocopal attacks
displayed by LQTS patients to epilepsy or hysterical or behavioral episodes. In 1991, Schwartz
et al., gave further insight into why LQTS patients were first seen by a neurologist or a
psychiatrist (Schwartz et al., 1991b). The synocopal attacks displayed by LQTS patients were
due to a precipitous decrease in cardiac output that caused patients to lose consciousness, as a
result of the rapid rate of the ventricular tachycardia or torsades de pointes. If the hypofusion
was of sufficient duration, ensuing cerebral hypoxia might lead to convulsions. These events
usually occurred after situations with high emotional content, which is why these episodes
were frequently thought to represent a hysteric reaction; the presence of the convulsions often
leads to the erroneous diagnosis of a seizure disorder (Schwartz et al., 1991b).
The fact that LQTS is a rare disorder is also one of the reasons that it is not often included in
the primary differential diagnosis of syncope, thus misinterpretation as epilepsy may occur. If
siblings are also affected, genetic epilepsy may even be diagnosed (Schwartz et al., 1991b).
The misdiagnosis of LQTS as an idiopathic seizure disorder has led to inappropriate treatment
of patients, at the risk of their lives. The diagnosis of LQTS is difficult and even if an ECG is
performed and a family history of the disease is present, there are still a number of factors that
could influence the diagnosis. Firstly, the family history may be unremarkable, because many
LQTS gene carriers have relatively normal QT intervals. This realization was made in 1979,
already, with an extraordinary family studied by Coumel and Slama that included 11 children
affected by LQTS; among them were six sudden deaths including siblings with normal QT
intervals (reviewed by Schwartz, 1985).
Diagnosis can further be hampered by the overlapping of QT intervals between affected and
unaffected individuals (Vincent et al., 1992). This was demonstrated in a retrospective study of
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three chromosome II-linked kindreds in which gene earners could unequivocally be
identified, by using molecular genetic techniques, 83 individuals were classified as affected
and 116 as unaffected. This study demonstrated that the QT interval corrected for heart rate
(QTc) in gene carriers varied from OAIs to O.59s (mean = OA9s), and in non-carriers ranged
from O.38s to 0.47s (mean = OA2s). Diagnosis of LQTS based on a QTc of >0.44s led to the
misclassification of five gene carriers (6%) and 17 noncarriers (15%) (Vincent et al., 1992).
The QT interval is inherently variable, changing in a given person in relation to heart rate,
autonomic tone, age, sex, usage of medication and the presence of other disorders.
Furthermore, diagnosis could be missed because ECG is not routinely performed in young,
otherwise healthy, individuals (Vincent et al., 1992).
Correct diagnosis is of fundamental importance, to clearly distinguish between LQTS and
genetic forms of epilepsy that display similar clinical symptoms, because effective treatment
for both disorders is available. In the case of LQTS, the mortality among untreated
symptomatic patients is high, 20% in the first year after the initial syncope and approximately
50% within 10 years (Keating, 1992). The current diagnostic criteria have led to misdiagnosis
and missed diagnosis of affected LQTS patients; thus, there was a need to develop new
methods of diagnosis that can support the present one. Molecular genetic techniques could
provide a very accurate means of diagnosis. However, this technique requires the identification
and characterization of causative genes of the disease.
One strategy to identify the gene that is responsible for an inherited disorder is the application
of linkage analysis to firstly identifies the chromosomal localization of the gene. After the
disease locus has been positioned, a battery of molecular genetic techniques can be employed,
to ultimately identify and characterize the specific gene and mutations in the gene, that are
causing the defect leading to the clinical manifestation of the disease (reviewed by Keating,
1992).
In the next section, the basis of the molecular genetic techniques employed in previous studies
performed on LQTS and the three types of familial epilepsy that are examined in this report
will be discussed briefly. This will be followed by a section were the applications of these
techniques in the above-mentioned disorders will be highlighted.
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1. 4 MOLECULAR GENETIC TECHNIQUES
1.4.1 Identification of Disease-causing Loci with Linkage Analysis
The molecular genetic approach to familial diseases is to identify the genees) and the
associated mutation(s) that are causing the specific disease, in order to find explanations for
the basic mechanisms that result in the clinical expression of the disease.
Before the era of genetic linkage analysis, the search for the causative gene started with the
identification of proteins that might be important in the specific disorder under investigation.
These proteins were then studied and, if biochemical or physiological abnormalities were
found, it was possible to work back to the gene that encoded the protein and then to identify
disease-causing mutation(s) in the gene (reviewed by Keating, 1992). However, it is now
possible to start by closing in on the defective gene itself. This strategy begins with the
chromosomal localization of the gene that is responsible for a particular inherited disorder
(White and Lalouel, 1988).
The way genes are inherited is exploited by the linkage analysis strategy; in the late nineteenth
century, Mendel demonstrated that traits were inherited as independent units; and that the
inheritance of one trait did not influence the likelihood of the inheritance of a second
(reviewed by Keating, 1992). This fundamental rule of inheritance is known as Mendel's law
of independent assortment. Morgan and his co-workers proposed in the early 1900' s the
existence of an exception to this rule. These investigators noted, in their breeding experiments
with Drosophila, that certain traits, or genes, were inherited together more frequently than
would be predicted by chance, thus these genes were coinherited or linked. These genes were
coinherited or linked because they were physically located close to each other on the same
chromosome (reviewed by Keating, 1992).
Linkage analysis is a technique that can be used, in multigenerational families affected by a
disease showing a mend elian inheritance pattern, to identify the chromosome on which the
disease-causing gene is located. Polymorphic chromosomal markers positioned close to the
disease gene are employed in linkage analysis (figure 1.2) (reviewed by Keating, 1992).
However, it is the phenomenon of recombination that makes it possible to find linkage
between a marker and a disease (figure 1.2). If there were no recombination, only 22 markers,
that is one per autosome, would be required to determine on which chromosome a genetic
locus was located; however, it would not be possible to narrow the region of the chromosome
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on which the gene actually lies (White and Lalouel, 1988). Parental chromosomes are not
transmitted to offspring in their original form; during the generation of germ cells,
recombination, or crossing over, occurs between loci on homologous chromosomes (figure
1.2) (Keating, 1992). The closer together two loci lie on the same parental chromosome, the
less often their alleles are separated as deoxyribonucleic acid (DNA) is exchanged between
homologous chromosomes during meioses (figure 1.2) (White and Lalouel, 1988). Thus, two
genetic loci that are separated by a few thousand base pairs would rarely recombine,
conversely two loci on the same chromosome that are separated by 20 million base pairs would
recombine, in approximately 20% of meiosis (Keating, 1992). Statistical analysis can be used
to calculate the odds that an allele of the DNA marker and the disease gene are inherited more
often then would be expected by chance and are therefore linked. The odds are expressed in
logarithmic form called the logarithm of the odds score (LOD score). Once linkage between a
polymorphic marker and a disease locus has been identified, the detection of recombination
events between the disease locus and additional markers in the target search area can be used
to refine the location of the disease locus (Keating, 1992).
Two allelic forms of a genetic marker (one of maternal and the other of paternal origin) are
present in each individual. An individual is heterozygous (figure 1.3) for a marker if he has
two different alleles of a marker, conversely he is homozygous (figure 1.3) if the alleles are
identical (Keating, 1992). The genotype of each marker tested for each family member is
defined. The haplotype, the particular combination of alleles at linked loci in a defined region
of a chromosome, can be determined and, if all the affected individuals share the same
haplotype, there will be a high degree of probability that the marker is cosegregating with the
disease and linkage can be proven (Keating, 1992).
As the Human Genome Project (Collins and Galas, 1993), the cooperative effort to map and
sequence the entire human genome, progresses, the human gene map has become saturated
with polymorphic markers. This is the consequence of one of the main goals of the Human
Genome Project, namely to develop a 2-5 eentimorgan (cM) spaced high-resolution human
genetic map of highly informative markers. Another important implication of the Human
Genome project is the advances in genotyping technology that lead to the development of new
types of genetic markers, such as short tandem repeat polymorphisms (STRPs) also referred to
as microsatelite markers (Collins and Galas, 1993). These types of genetic markers replaced
Stellenbosch University http://scholar.sun.ac.za
1 :::::::::.
RECOMBINA TION
A
20
A
Homozygous chromosomes
1 :::::::::..
Recombinant joint
Fig. 1.2 Genetic recombination. The closer together two genetic loci lie on the same parental
chromosome the less often their alleles are separated during meiotic recombination between
homozygous chromosomes and these loci are said to be linked. The alleles of two genetic loci
that are situated far apart on the same chromosome have a higher chance of being separated
during recombination events. The numbers 1, 2, 3 and 4, represent the alleles of different
marker loci positioned on the homologous chromosome on which the mutant allele is located.
The letters A, B, C and D, represent the alleles of these marker loci positioned on the
homologous chromosome on which the wild type allele of a disease-causing locus is located.
The alleles 3 and 4 are linked to the mutant allele, as these alleles are not separated during
recombination, while alleles 1 and 2 are unlinked, alleles C and D are linked to the wild type
allele and alleles A and B are not linked to the wild type.
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Fig. 1.3 Heterozygous and homozygous allelic forms of a genetic marker. (A) Family in
which a genetic marker was genotyped. Where it can be deduced, the alleles inherited from the
mother and father are indicated. (B) Lanes 1, 2, 4 and 5 represent the heterozygous allelic form
of a genetic marker showing two different alleles of the marker, lanes 3, 6 and 7 show the
homozygous form of the genetic marker where the two alleles are identical. Allele two
segregates with the disease as it is present in all affected individuals. (0= allele inherited from
the father; 0= allele inherited from the mother; 0 = unaffected male; 0= unaffected female.= affected male; .=affected female).
Stellenbosch University http://scholar.sun.ac.za
22
the earlier forms of DNA markers such as restriction fragment length polymorphisms (RFLPs)
that required standard Southern blot and hybridization techniques (Weber and May, 1989).
The abundant interspersed repetitive units, that were identified in the human genome formed
the basis for the development of the STRP type of genetic marker (Weber, 1990). These
repetitive DNA sequences units can consist of di- tri- or tetra-nucleotide repeats, however, in
the present study, mostly dinucleotide repeats such as, (dC-dA)n (dG-dT)n, hereafter
designated (CA)n ,were used and, therefore, will be discussed in the next paragraph.
In the human genome, there are between 50,000 - 100,000 interspersed (CA)n blocks, with the
range ofn being roughly 15-30. Uniform spacing of the (CA)n blocks throughout the genome
would place them every 30-60 kb (Weber,1990). The function of these (CA)n blocks is
unknown, but it has been proposed that they serve as hot spots for recombination (Slighton et
aI., 1980) or participate in gene regulation (Hamada et al., 1984).
Linkage analysis allows mappmg of the causative gene to within a distance of 5-10 cM
between flanking markers; however, a distance of 2.2 cM is thought to contain about 100 gene
transcripts (Collins, 1992). Therefore, it is necessary to reduce the search area further, after
linkage analysis has indicated the approximate chromosomal position of the gene. One
approach is the usage of genetic fine mapping and physical mapping techniques (Wicking and
Williamson, 1991).
1.4.2 Linkage disequilibrium mapping
The presence of recombinants aids in the narrowing of the critical search area of a disease-
causing gene (Keating, 1992). Methods that would allow for increasing the number of
recombinants could contribute to the narrowing of the critical search region. One way to
achieve this is through increasing the number of families under study, however, this is not
always practical due to limited numbers of informative families. An alternative method of
obtaining additional recombinants, and thus mapping at a higher resolution, is through linkage
disequilibrium mapping, that is the non-random association of alleles at linked loci (Hastbacka
et al., 1992; Jorde, 1995).
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When a disease mutation is introduced into a population for the first time, either by a new
mutation or the immigration of a mutation carrier, the mutant allele would necessarily reside
on a single chromosome with a unique set of marker alleles, thus displaying a unique
haplotype (Jorde, 1995). Consequently, there would be a complete disequilibrium between
these markers and the disease mutation: that is, the disease mutation would only be found in
the presence of a specific set of marker alleles. Genetic markers nearest to the disease gene
will recombine least often and should show the highest degree of allelic association with the
disease. The disequilibrium would gradually decrease as recombinations between the disease
mutation and the marker polymorphisms occur through subsequent generations leading
subsequently to a decrease in the length of the characteristic haplotype (Jorde, 1995). Thus,
disequilibrium analysis increases the number of recombinants that can be detected, because the
number of recombinants that occur through many generations is far greater then that observed
from any pedigree based linkage study (Xiong and Guo, 1997).
By employing linkage disequilibrium mapping, it is possible to map genes at a scale finer then
1cM. The first step in this process is to determine the haplotypes of disease-bearing
chromosomes for an extremely dense collection of genetic markers, the linkage disequilibrium
is then measured by applying a statistical association test to haplotype data. However the
methodological development of linkage disequilibrium mapping requires profound knowledge
of population genetics of the population analyzed (Hastbacka et al., 1994).
1.4.3 Genetic Fine Mapping and Physical Mapping
To move from the linked marker to the disease-causing gene, a physical map of the area where
the marker is situated must be generated and new polymorphic markers covering the target
area must often be identified (Wicking and Williamson, 1991). Flanking markers, that are
tightly linked to, but are recombinant with, the disease phenotype, must be identified, which
will allow the gene to be approached from either direction and also define the interval in which
the gene resides. Recombination breakpoints, occurring in certain individuals in certain
families, can help to narrow the area of interest to an area flanked by very tightly linked
markers, this area can further be refined by physical mapping (Wicking and Williamson,
1991). The latter includes the cloning and subeloning of the contiguous stretch of DNA
between .the two genetic markers flanking the region containing the disease gene
(Keating, 1992).
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Cloning vectors that can be used include the PI bacteriophage cloning system (Sternberg,
1990), yeast artificial chromosomes (YACs) (Green and Maynard, 1990), bacterial artificial
chromosomes (BAC) (Willets and Skurray, 1987) and cosmid cloning vectors (Sternberg,
1990). The bacteriophage PI cloning vector contains PI components included in a circular
plasmid that can incorporate 70-90 kb of foreign DNA (Sternberg, 1990).The YAC cloning
system is based on the introduction of exogenous linear DNA molecules into a yeast host. The
YACs are capable of harbouring several hundred kilobase fragments of linear DNA and these
long stretches of DNA can then be analyzed in detail (Green and Maynard, 1990). The BAC
cloning system is based on the Esherichia coli (E.coli) fertility F' plasmid. The F' plasmid
copy number is 1-2 per E.coli cell, thus reducing the potential for recombination between
cloned DNA fragments that it carries (Willets and Skurray, 1987). The cosmid cloning system
permits cloning, isolation and recovering of DNA inserts as large as 45kb which can be
packaged efficiently into phage lambda particles (Sternberg, 1990).
Polymorphic DNA markers can then be developed from the cloned segments and subsequently
used to determine the orientation of the overlapping clones to construct the physical map.
Integration of these markers into the genetic map can be used in genetic fine mapping to
narrow the search area further (Keating, 1992).
1.4.4 The Identification of Candidate Genes
Once the minimal critical search area has been identified, the genes that reside in the
physically mapped, refined target area must be identified. Genes in this area can become
candidates by position and their candidacy is strengthened if their physiological or biochemical
function might play a role in the development of the disease, for example ion channel genes
that are candidates for LQTS (Moss, 1986, Keating, 1996). Sometimes, the search for the
disease-causing gene is accelerated by a cytogenetically detectable anomality in a patient, as
was the case in the Duchenne muscular dystrophy search (Monaco et al., 1986). In a few cases,
such as in Huntington's disease (The Huntington's Disease Collaborative Research Group,
1993) and DRPLA (Koide, et al., 1994; Nagafuchi, et al., 1994), the presence of an expanded
trinucleotide repeat has provided clues to the identification of the disease-causing gene.
However, it is unrealistic to expect these fortuitous aids in most mapping endeavors, that is
why novel coding sequences within these refined search areas must often be identified.
Methods to identify these coding sequences include the detection of Cpfi islands (Bird, 1987)
as potential sign-posts for the 5'ends of some transcription units and direct selection of cDNA,
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the hybridization of radio labelled cDNAs to arrayed genomic clones (Hochgeschwender et al.,
1989). Exon trapping, the capturing of expressed sequences from fairly large genomic
sequences (Duyck et al., 1990), and software trapping, the analyses of DNA databases (Kamb
et al., 1995), are also methods that can be used to identify coding sequences.
1.4.5 The Identification of the Disease-causing Gene
When a transcription unit is identified in the target region, it becomes a candidate for a given
disease gene based on its chromosomal location (Wicking and Williamson, 1991). Candidates
identified in this manner, as well as candidates identified by virtue of their physiological or
biochemical function, require several forms of analysis to confirm that they are the genes
which, when mutated, cause the disease.
In order to show that a candidate gene is the disease-causing gene, it must be possible to prove
that this gene is expressed in the tissues most commonly affected in the diseased individual
(Wicking and Williamson, 1991). It is also desirable to show that sequence homology exists
between the candidate gene sequence and already characterized gene sequences encoding
proteins that could be involved in the aetiology of the disease. If DNA from the affected
families is analyzed with probes from the candidate gene sequence, and no recombination
events between the closest flanking markers and the candidate gene are detected, the candidate
gene could also be considered as the disease-causing gene (Wicking and Williamson, 1991).
Additional strong evidence that the correct gene has been isolated will be provided by the
detection of mutations in DNA from patients and obligate carriers (Keating, 1992). Methods to
identify disease-associated mutations in the candidate genes include polymerase chain reaction
(PCR)- based single strand conformational (SSCP) analysis (Orita et al., 1989 a, b), PCR-
based differential gradient gel electrophoresis (PCR-DGGE) (Gejman and Gelernter, 1993),
direct sequencing and allele specific restriction enzyme analysis (ASREA). In the present
study PCR-SSCP analysis and ASREA were employed, PCR-SSCP analysis will be discussed
in section 1.4.5. 1.
Evidence that a candidate gene is the disease gene includes the cosegregation of a mutation
with the disease in one family, and the identification of unrelated affected families with
identical or other mutations in the same gene and the identification of germ line mutations in
sporadic cases of the disease and absence of these mutation in unrelated unaffected control
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individuals. Once the gene has been identified, the structure and function of the protein product
of the gene can be examined by use of biochemical and physiological techniques (Keating,
1992). The ultimate proof that a candidate gene is indeed the disease-causing gene is
correlation of structural and functional data. An example of the latter is the ability of an
unmutated copy of the gene to complement the underlying biochemical or physiological
phenotype when introduced into the mutated gene sequence or related sequences (Wicking and
Williamson, 1991).
1.4.5.1 PCR-SSCP Analysis
The PCR-SSCP analysis is the most widely used mutation screening technique to detect single
base pair changes in PCR-amplified DNA fragments from selected regions of candidate genes
(Gejman and Gelernter, 1993). This technique is based on the fact that single base pair
substitutions or sequence variations affect the mobility of single stranded DNA through
polyacrylamide gels (Orita et aI., 1989 a, b). The analysis is carried out by denaturing the PCR
amplified selected DNA region at 9SoC and then electrophoretically separating the alleles on a
non-denaturing polyacrylamide gel. Under these conditions, the single strands fold back on
themselves in a sequence dependent manner and sequence variations can frequently induce
differential electrophoretic mobility, presumably due to alternative geometrical conformations.
The mobility shift of DNA fragments bearing these single point substitutions can be markedly
affected by temperature changes and variations in the gel composition, and, therefore a variety
of different conditions are normally used to improve the resolving power (Gejman and
Gelernter, 1993). Screening is typically performed under one or more of four different gel
conditions: room temperature or 4°C in the presence or absence of 10% glycerol. However,
although this technique is widely utilized, a 100% success rate is not always achieved (Orita et
al., 1989b).
Mutation screening employing PCR-SSCP analysis is usually performed in two stages; the first
stage includes identification of the gene containing the mutation, while stage two concerns the
identification of the nature of the mutation by sequencing.
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1.5 APPLICATION OF MOLECULAR GENETICS TECHNIQUES IN TWO
FAMILIAL FORMS OF EPILEPSY
1.5.1 Progressive Myoclonus Epilepsy Type 1 (EPMI)
1.5.1.1 Linkage analysis in EPMl
As the pathogenesis of EPMl is unknown, one way of approaching the pathogenetic
mechanisms underlying the disorder is characterizing of the genes that cause the disease. To
this end, Lehesjoki et al., undertook a systematic genome search to find the causative gene by
employing linkage with polymorphic DNA markers in EPM l-affected families (Lehesjoki et
al., 1991; Lehesjoki et al., 1992; Lehesjoki et al., 1993).
Linkage analysis was performed in twelve Finnish families who were clinically diagnosed with
EPM1; these families included 68 individuals, of whom 26 were affected (Lehesjoki et aI.,
1991). A total genome search was performed and linkage was detected after 25% of the
genome was excluded by the testing of 64 markers. Linkage was detected with marker
D21S112 and confirmed with the markers BeEf and D21S154, which had been localized by
physical methods to chromosome 21q22.3. The maximum LOD score for D21S112 was 6.91 at
8 = 0.034 and for BeE! and D21S154, maximum LOD scores of 5.49 and 4.25 respectively
were derived at 8 = 0.00 (Lehesjoki et aI., 1991).
In 1992, Lehesjoki et al., (1992), in an effort to refine the search area of the EPM1 locus,
performed a linkage study in thirteen Finnish families, twelve of these families were employed
in the earlier study of this group, that initially localized the EPM 1 gene to chromosome
21q22. 3. The study included 73 individuals, of whom 28 were affected, the diagnostic criteria
used were: (i) age at onset between 6 and 15 years; (ii) tonic-clonic seizures, often presenting
as first symptom; (iii) stimulus-sensitive myoclonus; (iv) characteristic EEG findings with
generalized spike-wave and polyspike-wave paroxysms and sensitivity to photic stimulation;
(v) progressive course. In their second study, Lehesjoki and co-workers found that the two
markers that showed recombination with EPM 1 were MX1 and Cl) 18 (figure 1.4). The
maximum LOD score for linkage between EPMl and MX1 was 2.80 at 8 = 0.036 and for
eD18 it was 4.82 at 8 = 0.029. No recombinations was detected between the disease
phenotype and marker loci BeE1, D21S19, D21S42, D21S113, D21S154 and PFKL (figure
1.4) and the maximum LOD scores for linkage at these six loci at 8 = 0.00 were 5.98, l.60,
3.28, 5.42; 4.25 and 6.30 respectively. Thus, MX1 and eD18 flank the region in which EPM1
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resides, this region encompasses 20.3 cM on the genetic map (figure 1.4) (Lehesjoki et al.,
1992).
In the following year, the same group (Lehesjoki et al., 1993) found a new flanking marker,
D2IS212, that showed recombination with the disease locus, with a maximum LOD score of
7.78 at 8 = 0.02. The EPMllocus was now positioned in the 7 cM region flanked by D21S212
and CDl8 (figure 1.4) (Lehesjoki et al., 1993).
To further refine the position of the causative gene, linkage disequilibrium mapping was
applied (Lehesjoki et aI., 1993). Using this technique, twelve multiplex families were analyzed
at the linked marker loci on the EPMl-bearing chromosome. No significant evidence for
linkage disequilibrium was seen for any alleles at loci D2IS212, BCEI, D21S19, D21S42,
D2l Sl13 and CBS (figure 1.4); however, significant evidence of linkage disequilibrium was
found for loci D2lS25, D2lSl41, PFKL (CA repeat), PFKL (Kpnl), D21S154, D2ISl71 and
CDl8 (figure 1.4) indicating that the EPMllocus was likely to lie in this area.
The study was then extended to include an additional 26 families and the seven loci that
showed significant linkage disequilibrium were analyzed further (Lehesjoki et al., 1993).
Linkage disequilibrium can only be performed in populations that fulfill certain criteria,
namely, populations that have a high proportion of disease-causing alleles originating from a
single ancestral mutation sufficiently long ago for recombinantion to have significantly
reduced the region of strongest linkage disequilibrium. The Finnish population fulfills these
criteria, since the present day population of 5 million is believed to have expanded from a
small number of founders some 2 000 years ago (Lehesjoki et al., 1993). Linkage
disequilibrium mapping used this information, together with the degree of linkage
disequilibrium observed at the tested markers in a mathematical equation, to determine the
distance between the EPMllocus and these markers. Using this technique, EPM1 was mapped
to a genetic distance of within about 0.13-0.30 cM encompassed by D2lS25, PFKL and
D2lSl54 (Lehesjoki et al., 1993).
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Fig. 1.4 Ideogram and genetic map of chromosome 21 showing how the critical search area
for EPMl was narrowed from 20.3 cM to 175 kB (Compiled from Rouyer et al., 1990;
Lehesjoki et al, 1991; 1992; 1993; Virtaneva et al., 1996).
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In an effort to further narrow the region in which the gene must reside, Virtaneva and his group
used a contiguous array of cosmid, BAe and PI clones covering the critical region to search
for, and to map, new, suitably-spaced highly polymorphic genetic markers (Virtaneva et al.,
1996).
Linkage disequilibrium mapping and haplotype analysis were employed to analyze five new
markers, D21S1885, D21S2040, D21S1259, D2lS1912 and PFKL (figure 1.4) in 53 unrelated
Finnish families. In each family, only one affected individual and both parents, if available,
were considered. Todetermine if there was a single allele with a significantly higher frequency
on the disease-bearing chromosome than on normal chromosomes, the haplotypes of these 53
patients were compared with alleles on the normal chromosomes of 73 parents. Significant
linkage disequilibrium was detected for all markers studied. The frequency of the most
.
common allele on the EPMI-bearing chromosome versus the normal chromosomes were
93%/73% (D2IS1885), 96%/58% (D2IS2040), 96%/40% (D2IS1259), 93%/21% (D2IS1912)
and 79%/14% (PFKL) (Virtaneva et al., 1996).
Haplotype construction of the markers in the EPMI-critical region was performed in 88 EPMI
and 62 normal chromosomes (Virtaneva et aI., 1996). An ancestral haplotype of 3-2-4-4-2 at
the loci listed in the preceding paragraph was seen in 65 EPMI and in only 7 normal
chromosomes, historical recombination events had occurred in haplotypes in 22 EPMI-
chromosomes. As a result of the putative historical recombinations, the critical region of the
EPMI gene could be predicted to lie between the markers D2lS2040 and D21S1259 (figure
1.4) (Virtaneva et al., 1996). This region was entirely encompassed in a 750 kilobase (kb)
bacterial clone contig generated by sequence tagged site content mapping and walking. A
detailed restriction map of the contig was used to determine the distance between these DNA
markers, defining the boundaries of EPMI to about 175kb (Virtaneva et al., 1996).
1.5.1.2 Identification of disease-causing genes in EPMl
Positional cloning techniques were employed to find the disease-causing gene in the absence
of obvious candidate genes for EPMl in the critical region. Direct cDNA selection was used to
isolate segments of expressed DNA from the 175 kb region (Virtaneva et aI., 1996) and a
previously described protein, cystatin B (eSTB), a cysteine protease inhibitor, was identified
with cDNAs from BAC clone 52e10. The gene encoding eSTB had not previously been
mapped to a human chromosome; however, these data indicated that it resided in this segment
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of human chromosome 21, and based on its location it became a strong candidate for the
EPMl-causative gene (Pennacchio et aI., 1996). Previous reports that the gene encoding eSTB
was widely expressed were confirmed by demonstrating that a probe made from the cDNA
clone detected a messenger ribonucleic acid (mRNA) approximately 0.8kb in length in eight
human tissues, including heart, brain, placenta, lung, liver, skeletal muscle, kidney, and
pancreas (Pennacchio et al., 1996).
On northern blots, lymphoblastoid cells from affected individuals from four different families
had reduced levels of eSTB mRNA, compared to those in unaffected, noncarrier individuals
and carrier parents of affected individuals (Pennacchio et al., 1996). In order to explain these
findings, the gene encoding eSTB from affected individuals was sequenced. The entire
nucleotide sequence of the human gene from an unaffected chromosome was first determined,
this sequence revealed that the gene is 2500 base pair (bp) in length and contains three small
exons encoding a 98-amino acid protein. Using the nucleotide sequences, primers were
designed to amplify the gene encoding eSTB, and the amplified peR product sequence was
determined in an affected individual from each of four EPMl families. Two different
mutations were identified in the eSTB gene on sequence comparison between DNA from a
control individual and EPM 1 patients. One was a G~e transversion at the last nucleotide of
intron 1, altering the sequence of the highly conserved 3' splice site AG dinucleotide. The
second mutation, which was found in the alleles of the eSTB gene from two of the four
families, changed eGA to TGA, generating a translation stop codon at amino acid position 68
(Pennacchio et al., 1996).
The recognition site for the restriction enzyme BfaI is destroyed by the 3' splice site mutation
and a simple test to screen for this mutation could be developed, no mutant alleles were found
after screening for this change in 95 unrelated, unaffected individuals (Pennacchio et al.,
1996). The stop codon mutation was screened for by direct sequencing of peR products of 70
alleles from unaffected control individuals, no mutant alleles were found in these samples.
Pennacchio et al., succeeded in identifying the disease-causing gene in three of the four
families under study. However, in the remaining family, which had the characteristic common
Finnish haplotype, no sequence differences in the gene encoding eSTB were detected
(Pennacchio et al., 1996).
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In an effort to identify additional EPMl mutations, Lafreniere et al., (1997) performed PCR-
SSCP analysis in 20 unrelated patients and 20 controls of different ethnic groups. Three SSCP
variants were detected, however two of these conformers were the result of the two mutations
previously described by Pennacchio et al., (1996). The third SSCP variant was identified as a
novel 2bp deletion at bp 313-314, predicted to cause a frame shift, resulting in premature
termination of the nascent protein three codons down stream of the deletion. However, the
majority of the tested EPM 1 patients did not show any SSCP variants compared to controls in
each of the three exons of the eSTB gene that were examined (Lafreniere et al 1997).
Southern blot analysis was performed using a 2.5 kb HindIIUPstI fragment isolated from
cosmid Q37H6, which contains most of the eSTB gene, as probe for EPMl patients' DNA
digested with Hind III, Eco RI or Sac I (Lafreniere et al., 1997). A 600 to 900 bp larger band
was consistently found in EPMl patients' chromosomes, but not in normal chromosomes. This
larger fragment segregated with the disease and was found in all the EPM 1 chromosomes for
which no SSCP variants were detected, the size of the enlarged fragments were clearly variable
among patients, suggesting an unstable expansion (Lafreniere et al., 1997).
At the same time, the group of Virtaneva et al., (1997) also found Southern blots of PstI-
digested genomic DNA from EPMl patients to show abnormally enlarged fragments,
compared to control individuals. Sequencing of the coding region, introns and the 3' end of the
gene revealed nothing abnormal; however, both the groups of Lafreniere and Virtaneva had
some difficulties in amplifying the 5' region from exon 1 to the PstI site in EPMl patients
(Lafreniere et al., 1997; Virtaneva et al., 1997). In the controls, PCR amplification yielded
fragments of the expected size. In order to characterize the expansion, Virtaneva's group
sequenced the insert of a A clone containing the 5' region and the additional DNA material
recovered from a A vector genomic DNA library made from an EPMl patient (Virtaneva et al.,
1997). Lafrenieres' group first determined the localization of the insertion in the larger PstI
fragment by amplifying the entire eSTB-genomic DNA in several overlapping fragments
(Lafreniere et al., 1997). Primers flanking and partially overlapping this polymorphic repeat
region upstream and downstream were used to amplify DNA fragments of EPMl patients.
Sequencing of this expansion revealed a minisatellite with an 18 bp unit that was repeated
several times at the 5' region of the expansion and a repeated 15-mer unit at the 3' end of the
expansion ,(Lafreniere et al., 1997; Virtaneva et al., 1997). Sequencing across the entire
expansion was unsuccessful, as it was impossible to overcome compressions in the long repeat
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arrays. The expansion lengths ranged from 0.5 to 1.5 kb and no correlation between expansion
size and clinical disease severity was found (Virtaneva et aI., 1997).
The groups of Lafreniere and Virtaneva found that the unstable minisatellite expansIon
accounted for the majority of EPM1 patients worldwide (Lafreniere et aI., 1997; Virtaneva et
aI., 1997). Seventy-eight percent of the unrelated EPM 1 chromosomes studied by Lafreniere et
aI., harboured this DNA insertion mutation in the 5' flanking region of the eSTE gene
(Lafreniere et al., 1997). In Finland, this expansion was detected in 102/106 (96%) EPM 1
chromosomes and it accounted for 33/34 (97%) EPMl chromosomes in the Mediterranean
region (Virtaneva et al., 1997).
Thus, in summary, the eSTE gene has been identified as the EPMl-causative gene and it is
apparent from the studies performed that the main molecular defect in EPMl is absence or
reduced levels of functional CSTB protein most probably due to reduced transcription of the
eSTE gene (Lafreniere et al., 1997; Virtaneva et al., 1997). This is most probably the result of
either truncation of the protein due to the stop codon mutation (Pennacchio et aI., 1996) or the
1 deletion at bp 313-314 which causes a frame shift introducing a stop codon (Lafreniere et
al 1997). In addition, inappropriate splicing of the transcript due to the 3' splice site mutation
(Pennacchio et aI., 1996) or diminished levels of mRNA due to an unstable insertion in the 5'
flanking region of the eSTE gene (Lafreniere et al., 1997; Virtaneva et aI., 1997) could also
lead to a reduced transcription of the eSTE gene.
1.5.2 DRPLA
1.5.2.1 Linkage Analysis in DRPLA
Several cases of DRPLA had originally been reported under the diagnosis of Huntington's
disease (lID), although it was possible to differentiate DRPLA from HD through differences in
their pathological features (Kondo et aI., 1990 Nórremolle et aI., 1995). This misdiagnosis
could be attributed to the fact that the clinical features of patients with late adult onset of
DRPLA are sometimes indisguishable from the clinical features ofHD. Both these diseases are
inherited in an autosomal dominant fashion, further contributing to the difficulty in
differentiation between them (Kondo et al., 1990).
In 1990, the group of Kondo et aI., (1990) initiated a linkage analysis study to determine if
DRPLA is a distinct neurodegenerative disorder or an allelic variant of HD. The DNA
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polymorphic marker D4S10, which was proven to be linked to lID in a previous study (Gusella
et al., 1983), was used to perform linkage analysis, in four DRPLA families in affected and
unaffected subjects of age 40 years and older (Kondo et al., 1990). The locus for hereditary
DRPLA was excluded from the vicinity of D4S10 at e = 0.0125 LGD score -2.281, thus
indicating that hereditary DRPLA and lID are distinct. Although the Huntingtons locus was
excluded as a cause of DRPLA, it was still sometimes difficult to distinguish patients showing
choreoathetosis and dementia with mild cerebellar ataxia from Huntington's patients, in the
absence of pathological examination of the brain (Nagafuchi, 1994). If the locus for DRPLA
could be assigned to a specific chromosome, or the gene causing the disease was identified, it
would be easier to differentiate this disease from lID and other similar diseases (Kondo,
1990).
Two independent research groups, Koide et al., (1994) and Nagafuchi et al., (1994), continued
the search for the causative gene for DRPLA and in 1994 both of them reported that patients
suffering from DRPLA had a CAG repeat expansion in a gene termed CrG-B37 localized on
chromosome 12. The two groups used different strategies to arrive at the same conclusion.
Nagafuchi's group initiated a linkage analysis study in fourteen families with a total of 45
affected individuals using polymorphic markers mapped throughout the genome (Nagafuchi et
al., 1994). They identified the short arm of chromosome 12 as the most plausible region
containing the gene responsible for DRPLA. The disease-causing gene for DRPLA was found
to segregate with CD4, LGD score of3.61 at e = 0.00, and with F8VWF, LOD score = 3.32 at
e = 0.06, on chromosome 12p12. After the disease-causing locus was found, several genes on
chromosome 12p, potentially involved in neuronal processes, were examined as candidate
genes, including neurotrophin 3 and proline-rich protein family genes (Nagafuchi et al., 1994).
However, the group of Koide et al., did not perform linkage analysis and they started their
study by directly closing in on the causative gene by searching genes with unusual triplet
repeat expansions (Koide et al., 1994). The rationale for their approach will be discussed in the
next section.
1.5.2.2 The Identification of the DRPLA Disease-Causing gene
Koide's group's approach, to directly close in on the causative gene by searching genes with
unusual triplet repeat expansions, was based on the hypothesis that DRPLA is the result of a
unstable triplet repeat expansion (Koide et al., 1994). The disease shares genetic and clinical
features with a group of disorders in which unstable expansions of triplet repeats was
Stellenbosch University http://scholar.sun.ac.za
35
identified. These diseases include fragile X syndrome (Fu et al., 1991), spinal and bulbar
muscular atrophy (La Spada et al., 1991), myotonic dystrophy (Brook et al., 1992; Buxton et
al., 1992; Fu et al., 1992; Harley et al., 1992), HO (The Huntington's Disease Collaborative
Research Group, 1993) and spinocerebellar ataxia type 1 (Orr et al., 1993). The common
features of these disorders are: (i) considerable heterogeneity in clinical presentations and ages
at onset, even in a single pedigree, (ii) an increase in the severity of symptoms with accelerated
ages of onset in successive generations and (iii) paternal bias in the transmission of the most
severe forms (Koide et al., 1994). Given this background, Koide et al., (1994) hypothesized
that genes with trinucleotide repeats, which are expressed in human brain, may be highly
plausible candidates for DRPLA. The group ofNagafuchi et al., (1994) also changed direction
given this knowledge, and considered genes containing triplet repeats located on chromosome
12p as candidates for DRPLA.
The studies performed on the disorders in which triplet repeat expansions had been found
previously led to compilation of a catalogue of genes containing repeats of simple sequences,
by scanning databases and experimental screening of various libraries (Li et al., 1993). The
groups of Koide and Nagafuchi searched for previously published genes containing
trinucleotide repeats, through screening these databases and experimental libraries (Koide et
al., 1994; Nagafuchi et al., 1994).
Nagafuchi's group examined the CTG-B37 repeat described in such a catalogue, because it was
linked to a marker on chromosome 12 and their linkage analysis results had implicated
chromosome 12p as the candidate region (Nagafuchi et al., 1994). PCR amplification was
employed to determine whether the CTG-B37 repeat varied in DRPLA patients compared to
control individuals. PCR products from most normal individuals were in the size range of 116-
161bp and two alleles were clearly identified. However, when DRPLA patients' DNA was
analyzed, multiple indistinct DNA bands appeared in the region of 240-320bp, in addition to
DNA bands derived from the other allele that was in the normal range. The enlarged DNA
fragments were observed in all patients diagnosed with DRPLA (Nagafuchi et al., 1994).
The group of Koide et al., (1994), in their search for previously published genes containing
trinucleotide repeats, identified the same gene, B37. This CAG repeat was analyzed using the
genomic DNA from patients with various forms of hereditary ataxia. The study subjects of
Koide et al., (1994) included 22 DRPLA patients, 28 patients showing ataxia or extrapyramidal
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signs, other then DRPLA, and 61 control individuals. An enlarged peR product was observed
in only the 22 DRPLA patients.
Both these research groups subeloned the peR products corresponding to normal alleles and
expanded alleles from DRPLA patients (Koide et al., 1994; Nagafuchi et al., 1994). The eAG
repeat was found to be highly polymorphic and fifteen normal alleles, ranging from 8-25
repeats, were identified (Koide et al., 1994). DRPLA patients were all heterozygous, with one
allele in the normal range and a second expanded allele within the range of 54-68 repeat units
(Koide et al., 1994).
Koide et al., (1994) demonstrated that there was a good correlation between the degree of
expansion and age of onset and DRPLA patients with juvenile onset (onset before 20 years)
had a tendency to contain large expansions of the eAG repeat. In the pedigrees studied by
Nagafuchi, it was evident that the size of the expanded allele increased from generation to
generation when the disease was transmitted from the father. However, enlarged fragments
were almost the same, or even decreased, when the disease was transmitted from the mother
(Nagafuchi et al., 1994). Although Koide's group only analyzed five cases of paternal
transmission and two cases of maternal transmission, they came to the same conclusion as
Nagafuchi's group (Koide et al, 1994).
In 1995, Onodera et al., (1995) undertook to isolate the full-length cDNA clone of the DRPLA
gene, because of the discrepancies in the sequence reported by Nagafuchi in 1994 (Nagafuchi
et al., 1994). The nucleotide sequence described by Onodera et al., (1995) essentially agreed
with that ofNagafuchi et al., (1994), but there were dissimilarities in 15 regions. In addition to
the 15 regions, the 49 bp sequence at the 3' noncoding region was absent in Nagafuchi's
sequence and, in particular, there were gaps at nucleotide (nt) 2352, 2401, and 2449 in the
latter's sequence, which led to different deduced amino acid residues at 785-817. Onodera et
al., (1995) predicted the DRPLA cDNA to encode a 1185 amino acid protein with a predicted
molecular mass of 125 kD, named DRPLA protein (DRPLAP).
In summary, the DRPLA disease-causing locus was localized to the short arm of chromosome
12 (Nagafuchi et al., 1994). Itwas hypothesized that genes expressed in the brain with a triplet
repeat in their coding regions would be highly plausible candidates for DRPLA. This
hypothesis was made based on the similarities between DRPLA and other neurodegenerative
disorders, where triplet repeat expansions have been identified as the causative mutation,
Stellenbosch University http://scholar.sun.ac.za
37
(Nagafuchi et al., 1994; Koide et al., 1994). By screemng databases and experimental
screening of various libraries, a gene with a CAG repeat was picked up that was expanded in
DRPLA patients. The nucleotide sequence of this gene was determined and the CAG repeat
was analyzed in DRPLA patients and unaffected subjects; it was found that the CAG repeat
ranged from 8-25 repeats in normal individuals and from 54-68 repeats in DRPLA patients
(Nagafuchi et al., 1994; Koide et al., 1994).
1.5.3 Chromosome Sp linked form of epilepsy
A Japanese group investigated a form of epilepsy with similar clinical features to those seen in
FME and in their study linkage was found to the DNA marker D8S264 (personal
communication, Berkovic).
1.6 IMPORTANCE OF MAPPING EPILEPSY GENES
The advances in molecular genetics and the identification of families affected by well-defined
epilepsy syndromes have led to the localization of several disease-causing genes and even the
identification of these genes in some cases. The identification of genes influencing
susceptibility to epilepsy could facilitate early identification of at risk individuals, early
treatment and perhaps prevention of the disorder in some individuals (Ottman, 1997). Once the
mutated gene has been identified, the mechanism by which such inheritance leads to a specific
epilepsy syndrome could be investigated on a molecular, cellular and systematic level
(Delgado-Escueta et al., 1994). This can lead to a better understanding of the pathogenesis of
the disease and development of new strategies for treatment and prevention targeted at the
specific cellular or molecular defects believed to be important in seizure generation. (Dichter,
1997).
Some of the first genes identified in human epilepsy syndromes were voltage-gated or ligand-
gated ion channels (Steinlein et al., 1995; Singh et al., 1998; Charlier et al., 1998; Ryan, 1999).
Ion channel defects were also found in a number of diseases known to occur intermittently in
otherwise healthy individuals. These discoveries suggested that subtle, prevalent genetic
variations in ion channel genes could also be involved in the aetiology of the common forms of
idiopathic, epilepsies with complex modes of inheritance (Ryan, 1999). However, to date, no
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ion channel variants have been implicated convincingly in susceptibility to common epilepsies
(Ryan, 1999).
A mayor stumbling block in clarification of the aetiology of the epilepsies has been a lack of
an adequate and systematic classification (Steinlein, 1998). Characterizing the genetic
contribution to human epilepsy could play an important role in the development of a more
clinically useful classification of seizure disorders (Ryan, 1999). The increasing knowledge
from the fields of molecular genetics, in parallel with developments at a clinical level could
change the approach, from the present classification based on subdivisions into idiopathic,
cryptogenic and symptomatic categories, to more aetiologically oriented and disease specific
categories (Duchowny and Harvey, 1996). Improving the classification of epilepsy genotypes
will improve calculations of sibling risk for seizures and abnormal EEG patterns. This should,
in turn, improve the accuracy of risk assessments and facilitate genetic counseling, providing
an accurate and balanced picture of possible family burden (Delgado-Escuera et al., 1994).
Although not all epilepesies are genetic in origin, insights derived from the study of genetic
epilepsies may increase the understanding of these disorders and may help to elucidate
mechanisms and improve therapy for genetic as well as aquired forms of epilepsy.
1.7 APPLICATION OF MOLECULAR GENETICS TECHNIQUES IN LQTS
1.7.1 Linkage Analysis
1.7.1.1 Linkage ofLQTS to chromosome llp15.5
In 1991, Keating's group performed a genome wide search, in a large Utah family, in an effort
to find the disease-causing gene for the autosomal dominant form of LQTS (Keating et al.,
1991). To avoid misclassification of individuals, a conservative approach to phenotypic
assignment was used, in which the diagnosis ofLQTS was made on the basis of a QTc ~ 0.45s
in an individual with symptoms, or a QTc ~ 0.47s in the absence of symptoms. An individual
with a QTc < 0.42s was classified as unaffected and when the QTc was between 0.42 and
0.46s, in an asymptomatic individual, the disease status was classified as unknown (Keating et
al., 1991). Linkage was performed using the LINKAGE program (Lathrop and Lalouel, 1984),
with the penetrance set at 0.90, the disease frequency assumed to be 0.001 and the female and
male recombination frequency equivalent. Keating and co-workers tested 245 markers in the
family, excluding 60% of the human genome, before a linked marker was found (Keating et
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al., 1991). This was a DNA marker termed pTBB-2, defining a restriction site polymorphism at
the H-ras-1 locus, which was found to be tightly linked to the LQT locus, with a maximum
LOD score of 16.44 at a 8=0. Linkage was confirmed with a second DNA probe at H-ras-1,
pUC EJ6.6, which gave identical results (LOD score of 16.44 at 8 = 0.00) (Keating et al.,
1991). The H-ras-1 locus had previously been mapped to chromosome IIp by linkage with
other known loci and by physical mapping with somatic cell hybrids (Kidd et al., 1989). In situ
hybridization had previously confirmed this chromosomal assignment and provided
independent subregional localization of the H-ras-1 locus to the short arm of chromosome
Ilp15.5 (Jhanwar et al., 1983; de Martinville et al., 1983).
1.7.1.2 Genetic heterogeneity in LQTS
In June 1993, Benhorin and associates reported a large Israeli family, comprising 131
individuals, of whom 28 were affected, in which there was an absence of linkage between
LQTS and H-ras-l (Benhorin et al., 1993). They performed genetic analyses with 74
individuals using two different methods. The first method they used was a complex
segregation analysis that resulted in evidence for a single completely dominant allele. The
major LQTS locus and the H-ras-1 marker were used in a combined linkage and segregation
analysis, which showed that the major LQTS locus was not tightly linked to H-ras-l for this
specific family. The best recombination fraction estimate was 0.494, which was close to the
value of 0.50 that corresponds to no linkage (Benhorin et al., 1993). The second analysis was
conventional linkage analysis using the same criteria as in the study by Keating et al., (1991),
these results also excluded linkage to H-ras-I. Taken together, these data and that of Keating
et al., (1991) implicated genetic heterogeneity in LQTS (Benhorin et al., 1993).
In August of that same year, Curran and his colleagues confirmed linkage of the disease to the
short arm of chromosome Ilp15.5 in seven LQTS families and also characterized two families
that were not linked to H-ras-I (Curran et al., 1993). Linkage analysis was performed in two
multigenerational families with autosomal dominant LQTS, one of Italian descent including 16
family members (kindred 1756), and one of Polish descent comprising 15 family members
(kindred 1977). Highly polymorphic markers at the H-ras-l locus were used, as well as genetic
markers from different regions of Il p 15.5. Significant negative LOD scores were obtained at
all these loci suggesting that the gene responsible for LQTS in both these families was not
linked to H-ras-l. This data implicated locus heterogeneity for autosomal dominant LQTS and
confirmed Benhorin's findings (Curran et al., 1993).
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1.7.1.3 Linkage ofLQTS to chromosomes 7q35-36
After heterogeneity had been identified in LQTS in 1993 (Benhorin et al., 1993; Curran et al.,
1993), Keating's group initiated a study to identify new LQTS loci in 15 multigenerational
families with autosomal dominant LQTS (Jiang et al., 1994). These families were not related
and were of varying North American descent, including Polish, Italian, English, German,
Swiss, Finnish, Norwegian and Russian origin. To avoid misclassifying individuals, the same
conservative approach to phenotypic assignment was used as described in the study by Keating
et al., (1991).
The linkage analysis studies were initiated in two kindreds (1756, 1977) that were not linked to
chromosome Ilp15.5 (Curran et al., 1993). In this study, 110 STRP markers spanning the
genome, also including markers mapping near genes that were candidates for the disease based
on a physiological rationale, were used to perform genotypic analysis (Jiang et al., 1994).
Linkage was identified after 35% of the genome was excluded employing 70 markers. Linkage
was detected with DNA marker D7S483 on the long arm of chromosome 7, at e = 0.001 LOD
score 2.71, in kindred 1977 and 1.54 in kindred 1756 (figure 1.5). The combined LOD score
for both families was 4.25, suggesting that the gene responsible for LQTS was located near
D7S483 (Jiang et al., 1994).
Linkage analysis was performed on 13 other families to test the hypothesis that a gene for
LQTS mapped to the long arm of chromosome 7, seven of these families showed positive LOD
scores at D7S483 (Jiang et al., 1994) (figure 1.5). A LOD score of greater than 3 was detected
in two families and the maximum combined LOD score for the nine chromosome 7-linked
families was 19.41, corresponding to odds in favour of linkage of greater than 1019 to 1. Taken
together, these data indicated tight linkage between D7S483 (figure 1.5) and a LQTS disease
locus, which was, designated LQT2 (Jiang et al., 1994).
1.7.1.3 Linkage ofLQTS to chromosome 3p21
Six of the fifteen families included in the study of Jiang et aI., (1994) generated significantly
negative LOD scores at the genetic marker D7S483, thus indicating that these families were
not linked to the chromosome 7 locus. To confirm this result, genotypic analysis with a
neighbouring polymorphic marker, D7S505 (figure 1.5), was performed and a negative LOD
score was obtained employing this marker in all six families (Jiang et aI., 1994). None of the
15 families studied by Jiang et al., demonstrated linkage to markers on chromosome Il p 15.5,
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Fig. 1.5 Ideogram and genetic map of chromosome 7 showing the location of LQT2.
Brackets indicate the positions of the markers D7S505. D7S636, D7S642 and D7S483, which
showed significant LOD scores with the LQT2 locus. The distances between the markers are
indicated in cM (figure taken from Jiang et al., 1994).
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Fig. 1.6 Ideogram and genetic map of chromosome 3 showing the location of LQT3.
Brackets show physical locations of THRB and D3S1217. LQT3 is genetically linked to the
region between D3S1211 and D3S1767 (figure taken from Jiang et. al., 1994).
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thus excluding the LQTl locus. Thus, in these six families, the LQTl and LQT2 loci were
excluded indicating that another LQTS locus must exist (Jiang et al., 1994).
A random genome search was performed in one of these six families, in an effort to localize a
third LQTS gene and strong suggestive evidence of linkage was obtained with a microsatellite
marker at TERE on chromosome 3 (LOD score 2.75 at e = 0.05) (Jiang et al., 1994). The
genetic marker D3Sl217 that maps approximately 48 eM centromeric to TERE, also showed
distant positive linkage. Consequently, seven markers (D3Sl211, D3Sl298, D3Sl260,
D3Sll00, D3Sl767, D3S1289 and GCT4BlO) (figure l.6), mapping to the interval between
TERE and D3S12l7, were employed in linkage analysis to confirm linkage to chromosome 3
in this specific family. The markers at D3S1100 and D3S1298 were completely linked to the
LQTS phenotype, with LOD scores of 5.35 and 3.61, respectively, at e = 0.001 (Jiang et al.,
1994).
Linkage analysis was then performed in the other five families with the markers D3Sll00 and
D3Sl298. Two families were completely linked to these markers and the combined pairwise
LOD scores in the three linked families at D3Sll00 and D3Sl298 were 6.72 and 6.39,
respectively (Jiang et al., 1994). Haplotype analysis was performed in these three families to
refine the position of the locus. The identification of obligate recombinants at D3S12ll and
D3Sl767 allowed the disease-causing gene to be mapped to an estimated 17.6 eM interval
between the centromeric and telomeric flanking markers (figure 1.6). The disease-causing
locus identified in these three families was designated LQT3. However, significantly negative
LOD scores were obtained at D3Sll00 and D3Sl298 in the three other families, suggesting the
existence of further locus heterogeneity for autosomal dominant LQTS. (Jiang et al., 1994).
In summary, in a study performed by Jiang et al., (1994), not one of the fifteen
multigenerational families in whom autosomal dominant LQTS segregated who were
investigated, demonstrated linkage to the LQTl locus. Nine of the fifteen families showed
positive LOD scores with the marker D7S483, the remaining six families generated significant
negative LOD scores at this locus. Three of the remaining 6 unlinked families were linked to a
17.6 eM interval on the short arm of chromosome 3, flanked by the markers D3S1211 and
D3Sl767 telomeric and centromeric, respectively. The chromosome 7 disease-causing locus
was designated LQT2 and the chromosome 3 locus LQT3 (Jiang et al., 1994). The remaining
three unlinked families suggested the presence of further heterogeneity in LQTS.
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1.7.1.4 Linkage to Chromosome 4q25-27
The fact that there were still families that did not link to any of the previously identified loci
suggested the presence of another LQTS disease-causing locus. This led to the subsequent
linkage studies performed by Schott et al., (1995) in a four-generation family, which included
65 members, 56 of whom were still alive. The conservative approach of phenotypic analysis
was again followed (Keating et al., 1991) and the family was examined with the H-ras-l clone
pEJ6.6 (Keating et al., 1991), and anonymous markers DllS899, DllS1338, DllS907 and
CEB41 (located on chromosome 11p15.5), as well as D7S483 (located on chromosome 7) and
D3S1766 and D3S1768 (located on chromosome 3) (Jiang et al., 1994). Negative LOD scores
were derived at all these markers, clearly excluding linkage of the disease to LQTl, LQT2, and
LQT3 (Schott et al., 1995).
Consequently, a genome-wide genotypic analysis was performed with 208 selected
micro satellite markers located every 20cM and having a reported high heterozygosity rate
(Schott et al., 1995). No significant linkage was obtained for 139 markers, leading to exclusion
of 67% of the genome before positive results were obtained for markers located on
chromosome 4q25-27. Maximum LOD scores obtained for markers D4S193, D4S406,
D4S402, D4S430 and D4S1615 (figure 1.7) at e = 0 were 6.67, 6.60, 7.05, 4.89 and 4.32,
respectively. Haplotype analysis showed a recombination event at D4S430 and D4S1570, thus
positioning the candidate area between D4S1570, on the centromeric side, and D4S430 on the
telomeric side, covering 18cM (figure 1.7). This disease-causing locus was designated LQT4
(Schott et al., 1995).
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Fig. 1.7 Ideogram and genetic map of chromosome 4 showing the DNA markers in the area
of the disease gene. The LQT4 locus was located in an area of 18cM between D4S1570 and
D4S430 (Taken from Schott et. al., 1995).
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1.7.2 Identification and characterization of LQTS-causing genes
1.7.2.1 LQTS candidate genes
Although little was known about the physiology of LQTS, the disorder was most oftenly
associated with prolongation of the QT interval on ECG, which reflects a delayed
repolarization of the cardiac action potential (Welsh and Hoshi, 1995). The cardiac action
potential is composed of a depolarization phase that results from activation of voltage-
dependent sodium ion (Na+) channels, and a repolarization phase when these channels are
inactivated and voltage-dependent K+-channels are activated (Welsh and Hoshi 1995).
The repolarization-depolarization cycle consists of 5 phases (figure 1.8) (Dorney et al., 1990).
The resting membrane potential of cardiac muscle cells is about -90m V (interior negative to
exterior). Changes in the external K+ concentration affect the resting membrane potential
whereas changes in the internal Na+concentration affect the magnitude of the action potential.
When the cell has an electrical transmembrane charge of -90mV, a stimulus from a
neighbouring cell results in rapid depolarization (phase 0) of the cell. During this process, the
Na+ and calcium ion (Ca2+) channels open and Na+ and Ca2+ enter the cell until the electrical
transmembrane charge is +30mV. The cell is now depolarized and is therefore positively
charged on the inside. It is during this phase that muscle contraction occurs, with the influx of
Ca2+ from the sarcomere, which allows the binding of actin and myosin. The myocardial cell
now enters phases 1 and 2, during which the Na+channels close (phase 1) and the Ca2+ influx
is equal to K+ efflux, resulting in no net change in the transmembrane potential (phase '2).
Rapid repolarization (phase 3) of myocardial cells follows, with the closing of the Ca2+
channels preventing Ca2+ from entering the cell. Large amounts of K+ leave the cell with the
opening of the K+ channels, restoring the resting potential of the cell (Dorney et al., 1990).
Hydrolysis of adenosine triphosphate (ATP) provides energy to the Na+-IK+ pump, which
actively pumps K+ into the cell and Na+ out of the cell. The transmembrane potential returns to
-SOmVand the cell cycle goes into the resting phase ready for the next cycle.
It is clear from the cardiac action potential and the repolarization-depolarization cycle of which
it is composed that abnormal behaviour of ion channels could delay repolarization.
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PHASE 4: Resting phase
PHASE 0: Rapid depolarization
PHASE I: Early repolarization
-EJ
PHASE 2: Plateau phase
PHASE 3: Rapid repolarization
Fig. 1.8 Schematic illustration of the five phases of the repolarization depolarization
cycle.The inner and the outer circles represent the inner and outer cell membranes respectively
(IN = intracellular region). The arrows indicate the direction of the flow of the ions across the
cell membrane, the black cylinders indicate ion channels that are blocked and the clear
cylinders indicate open ion channels. During phase 3 the Na+/K+ pump is activated to actively
pump K+into the cell and Na+ out of the cell against a concentration gradient.
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Consequently, genes encoding cardiac channels, or their modulators, were considered plausible
candidate genes for LQTS (Welsh and Hoshi, 1995). Ion channels are individual proteins, or
complexes of proteins, that reside in the cell membrane (figure 1.9). The distinguishing
characteristic of ion channel proteins is that, in response to such exogenous signals as a change
in voltage across the cell membrane, they can form pores (figure 1.10) for entry or egress of
specific ions, Na+, K+, Ca2+, etc. A key feature of the cardiac cell membrane during
repolarization is that even very small changes in individual ion currents can markedly alter the
delicate balance between inward and outward current flow during repolarization, thereby
prolonging or shortening the action potential. This fundamental concept provides the basis for
understanding how subtle abnormalities in individual ion channel genes can cause LQTS
(Attali, 1996).
Cardiac K+-channels and Na+-channels became even stronger candidates, based on
experimental models in which blockades of K+-currents and potentiation of late Na+-currents
lengthened the QT interval and enhanced early afterdepolarization (Dumaine et al., 1996).
Although voltage-gated Na2+-channels are responsible for the rapid influx of Na+- ions,
accounting for the initial upstroke of the action potential, a persistent late component of inward
Na+ current could have the effect of delaying the myocardial repolarization (Dumaine et al.,
1996). Cardiac K+-channels regulate the resting membrane potential and action potential
duration (Brown, 1997). The K+ current that passes through the cardiac channels corresponds
to the sum of two distinct currents: a rapidly activating current, IKr and a slowly activating
current IKs (Attali, 1996).
Based on their strong plausibility, K+- and Na+-channels present in the critical search region of
LQTS were tested to determine if they were the disease-causing genes. Four LQTS disease-
causing genes each encoding an ion channel protein, have been identified namely; HERG
(Curran et al., 1995), SCN5A (Wang et al., 1995a), KVLQTJ (Wang et al., 1996a) and KCNEI
(Splawski et al., 1997) located on chromosome 7, 3, 11 and 21, respectively. The gene at the
chromosome 4 locus (LQT4) has not been identified.
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Intracellular c
Fig. 1.9 Example of an ion channel residing in the cell membrane. Ion channels are
composed of domains (I, II, III, IV) each containing six transmembrane segments, all of which
have important functions (figure taken from Towbin, 1995).
Pore
Fig. 1.10 Example of an ion channel pore. The domains of the ion channel assemble to form
a pore (figure taken from Roden et al., 1996).
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1.7.2.1.1 Identification of the LQT2-causing gene, BERG
As mentioned in the previous section, genes that encode ion channels, or their modulators,
became highly plausible candidates for LQTS. Based on this hypothesis and their
chromosomal location, a skeletal muscle chloride channel (CLCN1) (Koch et aI., 1992) and a
cardiac muscarinic-acetylcholine receptor (CHRM2) (Bonner et aI., 1987) became candidates
for LQT2, but subsequent linkage analyses excluded these genes (Curran et aI., 1995).
Warmke and Ganetsky (1994) identified the human-ether-a-go-go gene (HERG) (figure l.11)
and subsequently mapped it to chromosome 7 and in the study performed by Curran et aI.,
(1995) the candidacy of HERG as causative gene for LQT2 was pursued. The ether-a-go-go
(eag) gene was originally identified in Drosophila on the basis of its leg-shaking mutant
phenotype that could be attributed to an increase in neuronal excitability and transmitter
release at the neuromuscular junction (Trudeau et aI., 1995). The Drosophila eag gene encodes
a Ca2+-modulated K+-channel (Bruggeman et al., 1993); however this eag locus defines an
extended gene family in which subfamilies are divided based on sequence similarities. These
subfamilies are named:- Eag for the original isolate from Drosophila, Elk for eag-like K+-
channels and Erg for eag-related genes (Warmke and Ganetsky, 1994).
The HERG gene belongs to the Erg subfamily isolated from human hippocampus, encoding a
K+-channel with inward rectifying properties (Trudeau et aI., 1995). These inward rectifiers
belong to a large group of K+-selective ion channels that preferentially conduct inward K+-
currents at voltages negative to the K+-equilibrium potential. In the heart, these K+-channels
regulate the resting potential and contribute to the terminal phase of repolarization through
their small outward conductances (Warmke and Ganetsky, 1994). At positive voltages they
close, thus helping to maintain the plateau of the action potential. The K+ current that passes
through the cardiac delayed-rectifier channels corresponds to the sum of two distinct currents;
a rapidly activating current, her, and a slowly activating current, IKs(Attali, 1996)
To test the candidacy of HERG, Keating's group initiated genotype analyses with polymorphic
markers linked to the known LQTS loci in five new unrelated LQTS families of varying
descent, including Mexican (Spanish), German, English and Danish descent (Curran et al.,
1995). The disease phenotype in these families was linked to the polymorphic markers on
chromosome 7q35-36. Previous studies performed by this group had identified nine other
chromosome 7-linked families (Jiang et aI., 1994) and the maximum combined two-point LOD
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score for these fourteen families was 26.14. Previous studies placing LQT2 between D7S505
and D7S483 were confirmed. Given the position of LQT2, the localization of HERG was
refined, by employing two physical mapping techniques, to determine if it also maps to this
area on chromosome 7 (Curran et al., 1995). Firstly, HERG was mapped on a set of YAC
contigs constructed for chromosome 7 (Green et al., 1994), which localized the gene to the
same YAC as D7S505, a polymorphic marker that was tightly linked to LQT2. Secondly,
HERG was mapped to chromosome 7q35-36 using fluorescent in situ hybridization (FISH)
with a PI genomic clone containingHERG (Curran et al., 1995).
To determine if HERG was the LQT2 locus, PCR-SSCP analysis was used to identify mobility
shifts within this gene in the chromosome 7-linked families (Curran et al., 1995). Two aberrant
SSCP conformers were identified in DNA from patients and controls; these conformers were
cloned and sequenced. However, both mobility shifts resulted from sequence changes in which
the substitution did not affect the predicted amino acid sequence of HERG. These HERG
polymorphisms were used for genotypic analysis in the chromosome 7-linked families. No
recombination events between HERG and LQTS were identified in any of these families, and
the maximum LOD score for 14 families was 9.64 (8= 0.0). These data indicated that HERG
was completely linked to LQT2 (Curran et al., 1995).
To test the hypothesis that HERG is LQT2, further PCR-SSCP analyses were used to screen for
mutations in affected individuals of linked kindreds (Curran et al., 1995). This approach
identified two intragenic deletions in the HERG gene that were associated with LQTS in two
families and three additional aberrant SSCP conformers were identified in affected members of
three more kindreds. An aberrant conformer was also identified in a sporadic affected
individual, which was not detected in either parent. None of the aberrant conformers were
detected in more than 200 unaffected individuals. In each case, the normal and the aberrant
conformers were cloned and sequenced (Curran et al., 1995).
The one intragenic deletion was a 27 bp deletion beginning at nt 1498 that disrupted the third
membrane spanning domain (S3) of HERG, the second one was a single base deletion at nt
1261 that resulted in a frame shift in sequences encoding SI (Curran et al., 1995) (figure 1.11).
The three point mutations in the three LQT2 kindreds included a C~ T substitution at nt 1692,
which resulted in a substitution of valine for a highly conserved alanine at codon 561, altering
S5 of the HERG protein in the one kindred (figure 1.11). In the second kindred, an A~G
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transition resulted in the substitution of aspartic acid for a conserved asparagine at codon 470,
located on S2 (figure 1.11). In the third kindred, a G~C substitution was identified, which
disrupted the splice-donor sequence of intron Ill, affecting the cyclic nucleotide-binding
domain. The de novo mutation identified in the sporadic case resulted from a G~A transition
at nt 1882, which caused a substitution of serine for a highly conserved glycine at codon 628,
altering the pore-forming domain (Curran et aI., 1995) (figure 1.11).
Fig.1.11 Schematic representation of the predicted topology of the protein encoded by
BERG and the location of LQTS associated mutations. (figure taken from Curran et aI.,
1995)
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Northern blot analysis showed the strongest hybridization of the HERG probes to heart
mRNAs, with faint signals in brain, liver and pancreas, and non-specific hybridization in the
lung. These data indicated that HERG was strongly expressed in the heart, consistent with its
involvement in LQTS (Curran et al., 1995). Heterologous expression of HERG in Xenopus
oocytes revealed that the HERG current was similiar to a well characterized cardiac delayed
rectifier K'" current hJ (Sanguinetti et al., 1995).
In summary, HERG became a candidate for LQT2 based on its chromosomal location and its
physiological function, and in their report Curran et al., (1995) provided evidence in favour of
this hypothesis. They firstly confirmed the location of LQT2 to chromosome 7q35-36, and then
they mapped HERG to chromosome 7q35-36 and demonstrated that HERG is strongly
expressed in the heart. Finally, Curran and co-workers identified intragenie deletions of
HERG, associated with LQTS in two families, three point mutations in three LQTS families
and a fourth de novo point mutation in a sporadic case. Taken together, these data strongly
implicated HERG as cause of the chromosome 7-linked form ofLQTS.
1.7.2.1.2 Identification of the disease-causing LQT gene, SeN5A
As mentioned in the previous two sections, cardiac ion channels residing in the refined search
area became candidates based on their location. A neuroendocrine calcium channel gene
(CACNL) (Chin et al., 1991; Seino et al., 1992) and a gene encoding a GTP-binding protein
that modulates potassium channels (GNA12) (Weinstein et al., 1988; Magovcevic et al., 1992)
became candidates for LQT3 based on their chromosomal location, however, subsequent
linkage analysis excluded these genes (Wang et al., 1995a).
Theoretically, mutations In cardiac Na+-channel genes could also cause LQTS, because
voltage-gated Na'<channels mediate rapid depolarization in ventricular myocytes and also
conduct a small current during the plateau phase of the action potential (Wang et al., 1995a).
Subtle abnormalities ofNa+- channel function, e.g. delayed Na'<channel inactivation or altered
voltage dependence of channel inactivation, could delay cardiac repolarization, leading to QT
prolongation and arrhythmias. The cardiac sodium channel gene (SCN5A) was cloned and
characterized by Gellens et al., (1992) as a large protein of 2016 amino acids, encoded by 28
exons, with a calculated molecular weight of 227kDa (figure 1.12). The human SCN5A gene is
a member of the human voltage-gated Na+-channel gene family. Sodium-channels from
different tissues, or even different species, are highly conserved and each of these channels
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consists of four homologous domains (DI-DIY) joined by short linking intracellular domains
(IDI-2, ID2-3 and ID3-4), each domain containing six putative membrane-spanning segments
(SI-S6) (figure 1.12) (Wang et al., 1996b).
In 1995, SeN5A was mapped to chromosome 3p21 (George et. al., 1995), making it an
excellent candidate gene for LQT3. Northern blot analyses indicated that SeN5A is expressed
exclusively in the human heart (Gellens et al., 1992), further contributing to its plausibility as a
candidate for LQT3. To test the candidacy of SeN5A for involvement with LQT3, PCR-SSCP
analysis was used to identify sequence variants within this gene (Wang et al., 1995a). An
aberrant SSCP conformer was identified that was cloned and sequenced, but found not to
affect the predicted amino acid sequence of the product of SeN5A (Wang et al., 1995a).
However, this polymorphism was then used in genotypic analysis in chromosome 3-linked
families and no recombination events between SeN5A and LQTS were identified. This SSCP
anomality was identified using oligonucleotide primers designed from cDNA sequence
because at that time the genomic structure of SeN5A was unknown (Wang et al., 1995a).
Two genomic PI clones, spanning the entire gene, were isolated and characterized in order to
determine the genomic structure of SeN5A (Wang et al., 1995a). Keating's group hypothesized
that LQTS-causing mutations would be subtle and might affect delayed inactivation of
encoded Na + channnels or alter the voltage dependence of the channel inactivation. Therefore,
they focused on regions known for channel inactivation, when they designed primers for SSCP
analysis. The cytoplasmic region between DIll and DIV (Fig. 1.l3), corresponding to exons
21-23, was analyzed. An identical intragenic deletion of 9bp was identified in two LQTS
families, but was absent in 500 control individuals. This deletion disrupts the coding sequence,
resulting in a deletion of three conserved amino acids, Lys-1505-Pro1506-Gln-1507 (KPQ) in
the cytoplasmic linker between DIll and DIV. This mutation was also present in two more
families in a study performed by Wang et al., later that same year (Wang et al., 1995b). The
type and the location of the deletion supported the conclusion that SeN5A is LQT3 (Wang et
al., 1995a).
In the absence of additional anomalities in the DIll and DIV region corresponding to exons 21-
23, the sequences from predicted exons 18-23 were defined (Wang et al., 1995b). Primers were
designed to amplify sequences encoding DIV-S3-DIV-S5 (figure 1.13), the linker between
DIIl-S4 and DIlI-S5 (figure 1.12) and DIlI-S5 (Fig.1.12) itself Two point mutations were
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identified employing these oligonucleotide primers. The one was a single base substitution,
G~A at nt 5081 resulting in a substitution of a highly conserved arginine to histidine at codon
1644 in the S4 segment of DIV (figure 1.12). The second mutation was an A~G substitution
at nt 4124, which led to a substitution of an asparagine for serine at codon 1325 in the
intracellular domain between S4 and S5 of DIll (figure 1.12) (Wang et aI., 1995b).
In summary, SeN5A was identified as a highly plausible candidate for LQT3 based on its
chromo soma! location, the fact that it is a cardiac Na + channel gene and its exclusive
expression in the heart (Wang et al., 1995a). Wang et al., (1995a) provided evidence to
strengthen this hypothesis by firstly showing complete linkage between a DNA polymorpism
within SeN5A and LQTS in families with chromosome 3-linked LQTS. Secondly, they
detected an identical intragenic deletion of SeN5A in four LQTS families (Wang et aI., 1995
a,b), and missense mutations associated with LQTS in two families (Wang et al., 1995b).
Taken together, these data strongly implicated SeN5A as cause of LQT3.
Fig. 1.12 Schematic representation of the predicted topology of the protein encoded by
SeNSA and the location of an LQTS-associated deletion (figure taken from Wang et.al.,
1995).
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1.7.2.1.3 Identification of the LQTS-causing gene, KVLQTl
A candidate gene approach to identify the chromosome II-linked LQTS-causative gene was
unsuccessful. Although two K'<channel genes (KCNA4 and KCNCl) were mapped to
chromosome 11, both were excluded as candidates for LQTI by linkage analysis (Russel et aI.,
1995). Similarly, all other previously characterized cardiac K+-, Cl'-, Na+- and Ca2+-channel-
encoding genes were excluded based on their chromosomal locations (Wang et aI., 1996a).
To determine the precise localization of LQTl, Keating's group performed genotypic analysis
in a large Utah family of Northern European descent consisting of 217 individuals (Wang et
aI., 1996a). Preliminary genotypic analyses using markers at H-ras, TH,DllS454, and DllS12
(figure l.13) identified informative branches of this family (Russel et aI., 1995). Additional
genotypic analysis was performed using three highly informative polymorphic markers from
chromosome IlpI5.5, namely, DllS922, DllS1318 and DllS860. These analysis showed that
TH and DllS1318 were completely linked to LQT, however recombination events were
identified with all other markers tested, including H-ras-l, but in each case a statistically
significant positive LOD score was generated (Wang et al., 1996a).
Haplotype analysis was performed to refine the localization of LQTl in this family and nine
informative recombination events were identified, which placed LQTl in the interval between
DllS922 and DllS454 (figure l.13). Together with the studies of Russel et al., (1995), which
placed LQTl centromeric to TH, these data indicated that LQTl was located in the interval
between TH and DllS454 (figure l.13) (Wang et al., 1996a). Pulsed-field gel analysis,
employing genomic probes from chromosome IIp 15.5, was used to estimate the size of the
region containing LQTl. The probes TH,DllS551 and DllS454 hybridized to a 700 kb MluI
restriction fragment, suggesting that the region containing LQTl was less than 700kb in size.
Physical representation was achieved by screening YAC and PI libraries with the probes of
this region and the order of the markers in these clones was confirmed using fluorescent in situ
hybridization (FISH) analysis as: telomere-TH-DllS551-DllS679-DllS601-DllS454-
centromere (Wang et al., 1996a).
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Fig. 1.13 Ideogram and genetic map of chromosome 11 showing the DNA markers in the
area of the disease gene. The LQT1 locus was located in an area between TH and DllS454
(Compiled from Russel et al., 1995; Wang et al., 1996a).
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Exon amplification was performed with clones identified from the physical map to identify
candidate gene DNA sequences and database analysis revealed eight possible trapped exons
with predicted amino acid sequence similarity to ion channels (Wang et al., 1996a). Two
consensus polyadenylation signals were identified upstream of the poly (A)+ tail in the 3'
untranslated region, but the identity of the initiation codon was uncertain. The cDNA predicted
a protein with structural characteristics of potassium channels, while hydropathy analysis
suggested a topology of six major hydrophobic regions that might represent membrane-
spanning a-helices. These regions shared sequence similarity with potassium channel
transmembrane domains S1-S6 (figure 1.14). Because this gene was similar to voltage-gated
potassium channel genes and thus became a strong candidate for LQTl, it was named KVLQTl
(Wang et al., 1996a).
Northern blot analysis showed a 3.2 kb transcript of this gene in human heart, kidney, lung,
and placenta, but not in skeletal muscle, liver or brain, with the highest expression in the heart
(Wang et al., 1996a). To test the hypothesis that KVLQTI is LQTJ, PCR-SSCP analysis was
performed in the affected members of the largest LQTS family that showed linkage to
chromosome 11. The focus of the analyses was the region between S2 and S6, since these
regions might be important for KVLQTJ function. The SSCP analyses detected an anomalous
conformer in the 70 affected members of this family that was absent in the 147 unaffected
members of this kindred and the more than 200 unrelated control individuals. Linkage analysis
between this anomaly and LQTS detected a two point LGD score of 14.19 at e = 0, the
absence of recombination between LQT1 and KVLQTl implied that the tested gene and the
disease gene are completely linked (Wang et al., 1996a).
To further test the hypothesis that mutations in KVLQTJ cause LQT1, PCR-SSCP analysis was
continued in five large chromosome l l-linked kindreds, as well as smaller families and
sporadic cases (Wang et al., 1996a). SSCP anomalities were identified in affected members of
the 5 large families, as well as ten smaller families or sporadic cases that were absent in more
than 200 unrelated control individuals. The normal and aberrant conformers were cloned and
sequenced in each case and it was shown that one of the aberrant conformers resulted from a
three base pair deletion, while the rest of the conformers were the result of point mutations
(Table 2.3). Two of the 16 families in which KVLQTJ mutations were detected originated from
South Africa (Wang et al., 1996a), and it was in these two families that previous LQTS studies
in our laboratory had been performed (De Jager et al., 1996).
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The KVLQTl gene described by Keating's group early in 1996 (Wang et al., 1996a) as the
LQTl-causative gene seemed to be lacking the amino terminal domain and was also unable to
undergo functional expression. To define the complete sequence of KVLQTl a new search was
initiated. A new clone, including a putative translational start site and an ATG sequence in-
frame with the original KVLQTl was isolated after screening several cDNA libraries
(Sanguinetti et al., 1996). The new cDNA sequence predicted a 581 amino acid protein with a
complete SI domain and a 27 amino acid N-terminal region. Northern blot analysis with the
new KVLQ Tl sequence showed hybridization to a single mRNA of 3.2 kb in human pancreas,
heart, kidney, lung and placenta, but not in brain, liver or skeletal muscle (Sanguinetti et al.,
1996).
The biophysical properties of KVLQTl were unlike other known cardiac K+ channels and it
was hypothesized that KVLQTl might coassemble with another subunit to form a known
cardiac channel (Sanguinetti et al., 1996). To test this hypothesis, Chinese hamster ovary
(CHO) cells were cotransfected with KVLQTl and human minimal potassium (hminK) cDNAs.
Transfection of CHO cells with hminK alone did not induce detectable currents; however,
cotransfection of hminK with KVLQTl induced a slowly activating delayed-rectifier current
that was much larger than the current in cells transfected with KVLQTl alone. The slow
activation of current in cotransfected CHO cells was preceded by a delay that lasted several
hundred milliseconds, the current did not saturate during long depolarizing pulses, and
required a three exponential function to describe the initial delay and two phases of current
activation. Activation of cardiac IKs is, like coexpressed KVLQTl and hminK in CHO cells,
extremely slow and best described by a three-exponential function. Thus, coexpression of
KVLQTl and hminK in CHO cell induces a current with biophysical properties nearly identical
to cardiac IKs (Sanguinetti et al., 1996). At the same time, the group of Barhanin et al., (1996)
also cloned the full length mouse KVLQTl cDNA and showed that KVLQTl gene product
associates with hminK gene product to form the channel underlying the IKs cardiac current.
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Fig. 1.14 Schematic representation of the predicted topology of the protein encoded by
KVLQTl and the location of LQTS-associated mutations (figure taken from Wang et al.,
1996a).
Stellenbosch University http://scholar.sun.ac.za
60
In summary, LQTl was located to a 700kB region in the interval between TH and DllS454,
exon amplification with clones that map between these flanking markers identified the
KVLQTl gene as plausible candidate (Wang et al., 1996a). A polymorphism within the
KVLQTl gene was proven to be completely linked to LQTl in a large family and mutations in
this gene were shown to cosegregate with the disease in six large families and ten small
families or sporadic cases (Wang et al., 1996a). The KVLQTl gene encodes the channel
subunit forming the important cardiac channel IKs; however, this subunit is not sufficient by
itself to form the native IKs but requires hminK as an additional subunit (Barhanin et al., 1996;
Sanguinetti et al., 1996).
1.7.2.1.4 Identification of a fifth disease-causing locus, KCNEI
As described above, it was demonstrated that the product of KCNEI (the gene encoding hmin
K) coassembles with the product of KVLQTl to form the channel underlying the IKs current.
Based on this association, the group of Splawski et aI., (1997) hypothesized that, because
KVLQT1 mutations could cause LQTS, mutations in KCNEI could also cause this disorder. To
test this hypothesis, PCR-SSCP analysis of exons of KCNEI was performed in 282 unrelated
LQTS affected individuals. Following this mutation screening technique, two conformers was
identified in two different individuals, respectively. Both conformers were present in all
affected family members of the latter two individuals, however, they were not observed in
unaffected family members or in 200 unrelated control individuals. DNA sequencing of these
conformers revealed that one was a G to A transition at the first nt of codon 76, causing an
Asp~Asn substitution and the second one was a C to T transition in the second nt of codon
74, leading to the substitution of Ser-e-Leu, The disease gene identified in these families were
designated LQT5 (Splawski et al., 1997).
1.7.2.1.5 Summary of identified LQTS disease-causing genes
A summary of the LQTS disease-causing genes identified to date and their chromosomal
positions is shown in Table 1.2.
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Table 1.2 Identified LQTS disease genes and their chromosomal positions
Form ofLQT Chromosomal Disease-causing Reference
Position Gene
LQT1 Chromosome Il KVLQTl Wang et al., 1996a
LQT2 Chromosome 7 HERG Curren et al., 1995
LQT3 Chromosome 3 SCN5A Wang et al., 1995a
LQT4 Chromosome 4 Not identified Schott et al., 1995
LQT5 Chromosome 21 KCNEI Splawski et al., 1997
1.7.3 HYPOTHESIS TO EXPLAIN LQTS
Any hypothesis put forth to explain LQTS must account for all of its features (Jackman et al.,
1988; Zipes, 1991). The two most popular hypotheses to explain LQTS are (i) the sympathetic
imbalance hypothesis of an altered activity of the autonomic nervous system (Schwartz et al.,
1975) and (ii) the myocellular hypothesis of an abnormality of ion channel regulation
(Jackman et al., 1988), however definitive proof of either hypothesis has been elusive.
The striking adrenergic dependence of symptoms, and the beneficial effect of antiadrenergic
interventions, led to the suggestion that there was an abnormality or imbalance in the
sympathetic innervation to the heart. This led to the formulation of the sympathetic imbalance
hypothesis that suggested that there is a congenital reduction in right-sided sympathetic
activity to the heart that results in dominance of left-sided cardiac sympathetic innervation.
(Schwartz, 1975). This hypothesis could explain the abnormal sinus rate, possibly the
abnormal repolarization, and adrenergic dependence of arrhythmias and their correction by
antiadrenergic drugs (Roden et al., 1996).
The second hypothesis, that of an intrinsic abnormality in myocardial repolarization, assumes
that the cause of abnormal repolarization lies within the heart itself, perhaps an abnormal
channel protein reducing or blocking an outward repolarizing K+ current, or increasing an
inward depolarizing Ca2+ or Na+ current. This results in early afterdepolarizations, which
lengthen repolarization that could cause triggered activity and ventricular tachyarrhythmias
such as torsade de pointes (Zipes, 1991). The latter hypothesis can explain the QT
prolongation, prominent and peculiar T and U waves, T wave alternans, and ventricular
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tachyarrythmias (Jackson et al., 1988). In addition, it can also serve as the mechanism for
acquired LQTS, which the sympathetic concept cannot (Roden et al., 1996). This hypothesis
suggested a likely mechanism for the generation of torsade de pointes, and might explain why
~-adrenergic blockade is useful in management of some patients with LQTS (Keating, 1996).
Since the "sympathetic imbalance" theory was first proposed by Schwartz et al., (1975),
validity of the data supporting the concept has been questioned. Schwartz et al., (1991a)
reported that this hypothesis could account for the sinus node abnormalities and the beneficial
effects of left-sided cardiac sympathetic cardiac sympathetic denervation, but it inadequately
explains the remaining features of this disorder. Rosen asked the following questions: " If a
sympathetic imbalance lies at the root of LQTS, why, then, did successful treatment not result
in normalization of the QT interval? Why, too, if Romano-Ward Syndrome is a single
syndrome, has there been so much variability in its phenotypic expression? " (Rosen, 1995). In
contrast to the sympathetic imbalance hypothesis, data to support the myocellular hypothesis is
accumulating. Three of the LQTS-causing genes identified (HERG, SCN5A and KVLQTI),
accounting for almost 90% of known cases of LQTS globally, encoded cardiac ion channels;
thus, LQTS is due to an intrinsic abnormality in the vast majority of LQTS patients (Roden et
al., 1996).
A delay in cardiac repolarization as manifested by a prolongation of the QT interval may be
the result of an increase in action potential duration. As mentioned earlier, Na+- and K+-
channels play an important role in the cardiac action potential and it is possible that defects in
genes that encode these channels could prolong the action potential. The two delayed-rectifier
K+ currents IKrand IKs modulate action potential duration in cardiac myocytes (Brown, 1997).
The long QT syndrome is a genetically heterogenous disorder and mutations in one Na+-
(SCN5A) and two K+- channels (HERG and KVLQTI) could cause this disease. The HERG
gene encodes the major subunit of the cardiac IKr channel (Sanguinetti et al., 1995) while
KVLQTI and hminK coassemble to form the cardiac IKs channel (Barhanin et al., 1996);
Sanguinetti et al., 1996). It is evident that LQTS represents a common phenotype of a
genotypically diverse disorder, and that the underlying mechanism to explain each genetic
variant of this disorder could be individualized (Priori, 1997).
A continued depolarizing current during the plateau phase of the cardiac action potential as a
result of delayed inactivation of cardiac Na'channels could prolong the action potential
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duration and QT interval, providing a possible mechanism for how SCN5A mutations could
cause LQTS (Wang et al., 1995b). The LQTS-associated deletions identified in SCN5A are
likely to result in functional cardiac Na+-channels with altered properties, such as delayed
inactivation or altered voltage dependence of channel inactivation (Wang et al., 1995a). The
latter finding provided support for the hypothesis proposed for LQT3 and suggested new
avenues for possible therapeutic endeavors.
The mechanism in which HERG might prolong action potential duration and thus cause LQTS
is more complicated because K+ channels assemble as tetramers (MacKinnon, 1991).
Assembly of normal units with mutant HERG units might cause a dominant negative effect
that may lead to reduced channel function (Benson et al., 1996). Alternatively, channel
function could also be decreased by mutations that cause failure of HERG assembly, thereby
affecting K+ channel stoichiometry and thus reducing channel numbers. In either case, the loss
of HERG function is the pathophysiological basis for prolongation of repolarization (Benson et
al., 1996).
The mechanism underlying LQT 1 is not clear, however it is postulated that it may also act in a
dominant negative fashion, leading to loss of channel function as is the case of HERG (Attali,
1996; van den Berg et al., 1997). All the mutations (except for one 3-nucleotide in-frame
deletion) known to date in the KVLQTI gene are missense mutations (Russel et al., 1996;
,
Tanaka et al., 1997; Wang et al., 1996a; van den Berg et al., 1997). The latter evidence
provided support in favour of the dominant negative effect theory, based on the work of Russel
et al (1996) who demonstrated that missense mutations resulted in a dominant negative
suppression of K'<channel activity. The coassembly of KVLQTI and hminK provide the
inward K+-current IKs, the consequence of LQT 1 is a reduction in IKs, thus, the correct function
of KVLQTI K+-channels depends on the co-assembly with the hminK protein (Barhanin et al.,
1996; Sanguinetti et al., 1996). Therefore, mutations affecting the binding of hminK are
expected to result in a deregulation of channel function, these mutations could also influence
channel function by directly affecting pore activity or the tetrameric configuration leading to
channel disfunction. Pore mutations in KVLQTI could cause the dominant form of LQTS by
partially inactivating the subunits encoded by the normal alleles in heterozygous patients
(Wollnik et al., 1996). The reduction in the total current is sufficient to delay the repolarization
of cardiac. action potentials significantly, causing the prolonged QT intervals on ECGs
(Wollnik et al., 1997).
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Hence, despite different ion channel abnormalities, the end result is phenotypically similar,
providing a unifying explanation of the disorder (Towbin, 1995). This leads to the speculation
that the remaining defective genes are also likely to encode ion channels, either other types of
K+- and Na'vchannels or Ca2+ (and possibly Chloride-channels). This result is reminiscent of
the unifying concept described in hypertrophic cardiomyopathy, in which all the defective
genes encode various sarcomeric proteins (Towbin, 1995).
1.8 IMPORTANCE OF MAPPING OF LQTS GENES
To avoid sudden cardiac death in LQTS, early diagnosis is crucial (Keating, 1996). Once
diagnosed, patients can be treated with anti-arrhythmic drugs and/or implantable defibrillating
devices. However, the variables of QT intervals and clinical signs among carriers of mutated
LQTS genes makes pre-symptomatic diagnosis difficult (Keating, 1996). Genetic screening
using mutational analysis can improve pre-symptomatic diagnosis. The presence of a mutation
would unequivocally distinguish affected individuals and identify the gene underlying LQTS
even in small families and sporadic cases (Splawski et al., 1998)
If a LQTS-causing mutation is found in a proband, the rest of the family members could be
screened and gene carriers identified, this would allow the accuracy of the diagnosis to be
confirmed and appropriate actions to be taken. Asymptomatic gene carriers could be advised to
avoid stressful conditions and competitive sport, and, depending on the malignancy of the
disease in the family, antiadrenergic treatment could be started. Conversely, family members
identified as non-carriers could be assured that they could conduct a completely normal life
(Priori, 1997).
KVLQTl mutations account for almost 50% of the reported forms of LQT, and together with
HERG, SeN5A and the chromosome 4 locus it accounts for almost 90% of all reported
autosomal dominant forms of LQTS cases (Roden et al., 1996). This implicates a high
probability of correct diagnosis, although not 100% by genetic testing. This knowledge also
allows the possibility to perform linkage analyses in smaller families, which would normally
not be so informative if some of the genes can be excluded.
A complete characterization of LQTS genes may not only benefit all LQTS families at risk for
sudden death due to tachyarrhythmias, but may also elucidate a common physiological
mechanism of arrhythmias in this and other cardiovascular diseases (Satler et. al., 1996). When
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specific mechanisms causing arrhythmias are understood, therapeutic interventions might be
tailored to the specific genotypes and specific channel defects (Welsh and Hoshi, 1995). It is
hypothesized that Na+ channel abnormalities, which are caused by the inappropriate action of
SCN5A, can be treated with Na'<channel blockers. Raising the concentration of K+ in the
serum, which should activate the channel, might treat the LQT2 defect caused by mutations in
HERG. It is proposed that the more common KVLQTl defects may respond to drugs that open
K+-channels (Keating, 1996).
Compton et al., tested the hypothesis that administration of exogenous K+ would result in an
increase in the outward K+-current and subsequently shorten the repolarization. The group
shown that K+-therapy improves repolarization in LQT2, however, this finding requires long
term follow up (Compton et aI., 1996). Priori et aI., (1996) demonstrated that prolonged guinea
pig myocyte action potentials are abbreviated by Na+-channel blockade in in vitro LQT3
models but not LQT2 models.
Identification of LQTS-causing genes also allowed genotype-phenotype studies, to determine
if there is a differential phenotypic expression between the varied forms of LQTS. In a study
performed by Schwartz et al., (1995), the differential responses of SCN5A and HERG genes to
Na+ channel block and to the increase in heart rate were investigated and it resulted in the first
demonstration of differential responses by LQTS patients to interventions targeted to their
specific genetic defect. In the same study (Schwartz et al., 1995), it was reported that LQT2
patients had their synocopal episodes under situations of emotional stress, in contrast to LQT3
patients who have episodes either at rest or during sleep. In a study performed by Schwartz's
group in 1997 exercise related events were shown to dominate the clinical picture in LQT 1
(Schwartz et aI., 1997). These findings raised the possibility that the triggers for life-
threatening arrhythmias differ among LQTS patients, according to the specific gene mutation
involved. This study was performed in a limited population but these implications might
become legitimate if these results are confirmed in the larger LQTS population (Schwartz et
al., 1995).
In patients with LQTS, the ECG- T-wave repolarization pattern is also found to be influenced
by the specific genotype (Moss et aI., 1995). Although QT interval is the hallmark for the
clinical diagnosis of LQTS, variations in the morphological configuration of prolonged or
delayed repolarization that are specific for the different forms of LQT have been recognized by
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several investigators. Patients with mutations in the SCN5A gene have a distinctive, late
appearing T wave that is clearly different from the low-amplitude, moderately delayed T wave
observed in affected patients who are carriers of the abnormal HERG gene. Both of these
repolarization patterns are different from the broad based prolonged T wave pattern found in
patients who are carriers of the abnormal gene, KVLQTl (Moss et al., 1995).
Many new areas of research are opened up by the exciting new molecular genetic findings in
LQTS. Examples include studies of the basic biophysics of the normal and mutant KVLQTI,
SCN5A and HERG gene products, studies to identify drug therapies that might correct the
defects in these mutations, and studies to determine the relationship between clinical
phenotypes and underlying genetic defects.
1.9 THE PRESENT STUDY
As mentioned previously in section l.3, missed diagnosis and misdiagnosis of LQTS often
occur. On account of the resemblance of synocopal attacks displayed by LQTS patients with
epilepsy, the misdiagnosis as epilepsy is often made in patients with LQTS. Molecular genetic
techniques have been successfully employed in both LQTS and genetic epilepsy syndromes.
Subsequently investigations have lead to the identification of four disease-causing genes for
LQTS (Curran et al., 1995; Wang et al., 1995; Wang et al., 1996; Splawski et al., 1997) and
over one hundred disease-causing loci in the rarer forms of epilepsy which show a simple
inheritance pattern (Ryan et aI., 1999). The identification of disease-causing genes and their
associated mutations would allow an unequivocal diagnosis in both of these disorders, making
this avenue of research of vast importance to solve the differential diagnosis in both these
conditions.
Given that the establishment of the chromosomal locus is normally the first step in the
identification of the defective gene, the aim of this study was to identify the disease-causing
locus in a family in whom a form of myoclonic epilepsy segregates, as well as in three LQTS
affected families.
The epilepsy study was initiated by Dr Jonathan Carr, who previously saw a case with an
interesting form of epilepsy, which was designated F:rv1E.This index case was initially part of a
study performed on juvenile myoclonic epilepsy at Groote Schuur Hospital (Cape Town). Dr
Carr traced and contacted the family and performed clinical examinations on them. In the
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absence of obvious candidates for this form of epilepsy, Professor Berkovic in Australia was
contacted with the available clinical information to suggest candidate loci in the search for the
identification of this disease. In his response (personal communication, Berkovic), he gave
some information on a Japanese family with a similar type of disease in which linkage was
found with the STRP marker D8S264. Two more candidate forms of epilepsy were identified
by Dr Carr, namely DRPLA and EPM1. These candidates were chosen because certain clinical
features exhibited by these disorders were also present in FME. Consequently, linkage analysis
was employed with DNA markers tightly linked to these three candidate loci, viz. chromosome
8 linked epilepsy, DRPLA and EPMl, to determine their involvement in FME.
Previous work in our laboratory in five South African families of Afrikaner descent, in whom
LQTS segregates, had demonstrated that, in these families, LQTS was caused by the
Ala212Val mutation in KVLQTJ (Wang et al., 1996a; de Jager et al., 1996). On haplotype
construction with markers in the area around the KVLQTJ gene, the same haplotype was found
in all affected members of the five families investigated, suggesting the presence of a founder
effect (de Jager et al., 1996). Given this background, all new probands referred to us with the
clinical diagnosis of LQTS were first screened for the founder Ala212Vai mutation in
KVLQTI. Globally, mutations in the KVLQTJ gene account for almost 50% of all reported
cases of autosomal dominant LQTS (Roden et al., 1996) and the codon 212 encoded by this
gene seems to be a mutational hot spot with the Ala212Val mutation the most common
disease-causing mutation (Tanaka et al., 1997). These findings also contributed to the ration~le
for screening for this specific mutation in all new probands.
In the present study, if the Ala212val mutation was present in the proband, a DNA-based
diagnostic test could be delivered to the rest of the family. Families were traced and contacted
and pedigrees constructed where possible, using the probands as reference points. In families
where the KVLQTI Ala212Val mutation was absent in the probands, four of the known LQTS
loci, accounting for almost 90% of the known cases of LQTS, were investigated with linkage
analysis to determine the disease-causing locus. These loci were KVLQTI, HERG, SeNSA and
the chromosome 4 locus. If a particular disease-causing gene was to be implicated by linkage
analysis, mutation screening analyses employing PCR-SSCP analysis and ASREA would be
initiated to screen for known and novel mutations in the gene. If mobility shifts were to be
detected, these would be sequenced to determine the effect on the DNA sequence of the gene.
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This information could then be used to design DNA-based diagnostic tests to provide a more
effective way of diagnosis in South African families.
Stellenbosch University http://scholar.sun.ac.za
69
CHAPTER2
MATERIALS AND METHODS
Page
2.1 CHARACTERIZATION OF FAMILIES 70
2.2 CLINICAL DIAGNOSIS
2.2.1 Epilepsy
71
71
2.2.2 LQTS 71
2.3 MOLECULAR DNA-BASED STUDIES
2.3.1 Collection of Blood
72
72
2.3.2 Preparation of DNA samples
2.3.2.1 Isolation of genomic DNA from EDTA blood
2.3.2.2 Genomic DNA extraction from nuclei
72
72
72
2.3.3 Polymerase Chain Reaction
2.3.3.1 Non-radioactive polymerase chain reaction
2.3.3.2 Radioactive polymerase chain reaction
2.3.3.2.1 Full strand labelling
2.3.3.2.2 End-labelling
73
73
75
75
75
2.3.4 Mutation Screening Techniques
2.3.4.1 Allele specific restriction enzyme analysis
2.3.4.2 PCR-SSCP analysis
77
77
79
2.3.5 Silver Staining 81
2.3.6 Radioactive Gel Electroporesis
2.3.6.1 Preparation of gel
2.3.6.2 Electrophoresis
81
81
82
2.3.7 Autoradiography 82
2.3.8 Genotyping 82
2.3.9 Haplotype Construction 83
2.3.10 Linkage Analysis 83
2.3.11 Direct Sequencing of SSCP-conformers
2.3.11.1 Purifying DNA from gel
2.3.11.2.Direct sequencing of purified DNA
86
86
86
Stellenbosch University http://scholar.sun.ac.za
70
CHAPTER2
MATERIALS AND METHODS
2.1 Characterization of Families
These investigations followed approval from the ethical committee of the University of
Stellenbosch Medical School, and informed verbal consent was obtained from participating
adults or parents in the case of minors.
A panel of twelve unrelated LQTS affected probands had been previously established, as part
of our group's ongoing investigation of this disease in South Africa. In the epilepsy study, one
proband was identified by referral. Through the probands, other members of the families were
traced and contacted where possible, the nature of the project explained and pedigrees
constructed. Following this route, three LQTS affected families and one epilepsy family were
investigated. The three LQTS families were of different South African subpopulation groups,
namely, Mixed ancestry, Afrikaner and Indian descent and they were subsequently designated
pedigrees 167 (figure 3.10.1), 168 (figure 3.10.2) and 169 (figure 3.10.3) respectively. The
pedigree constructed in the epilepsy study was named pedigree 201 (figure 3. 1) and was of
Mixed ancestry.
The proband in pedigree 201 was initially part of a study performed on juvenile myoclonic
epilepsy at the Grootte Schuur hospital, in Cape Town. Dr Jonathan Carr (University of
Stellenbosch Medical School, Tygerberg) was particularly interested in this specific case, and
learned from the index case that he had family members who were also affected. The rest of
the family was traced and contacted and Dr. Carr performed clinical examinations on the
family members who were willing to participate in the project.
In pedigree 167, the proband was referred to Tygerberg hospital, where she was diagnosed
with LQTS. The proband and one of her maternal aunts provided the information regarding the
rest of the famil y. According to them, the mother of the proband, as well as one of her brothers
and one of her sisters, died of a "heart disease". Unfortunately, no information to confirm that
these individuals were indeed affected with LQTS was available. A clinical investigation was
performed. on the rest of the family.
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In pedigree 168, the proband was referred by her general practitioner to Dr. Paul Brink
(University of Stellenbosch, Cape Town) at Tygerberg hospital to confirm the diagnosis of
LQTS. Unfortunately, most members of this family were unwilling to participate in the
research project and only a DNA-based diagnostic test was performed in a few individuals who
were willing to take part in the study.
In pedigree 169, the proband was referred by Dr Munclinger (University of Natal, Durban) to
Dr Paul Brink to confirm the diagnosis of LQTS. After confirmation, Dr Clive Corbett
(University of Stellenbosch Medical School, Tygerberg) performed a clinical investigation of
family members who were prepared to take part in the study.
2.2 Clinical Diagnosis
2.2.1 Epilepsy
The designation Hv1E was used to describe the clinical entity, which was followed in this
study. The diagnosis of epilepsy is a clinical one, thus the diagnosis of Fl\1E was made
following a clinical examination by a physician (Dr. 1. Carr). A detailed clinical description of
Fl\1E is the subject of a study by Dr. J. Carr (manuscript in preparation). Briefly, Fl\1E was
classified as a form of myoclonic epilepsy, characterized by generalized tonic-clonic seizures,
continuous myoclonic jerks, mostly of the upper arms, distal more than proximal. The jerks
were stimulus sensitive, being more apparent when the arms were outstretched.
Electroencephalograms showed a generalized polyspike wave discharge, while mild atrophy
was seen in a computerized tomography scan.
2.2.2 LQTS
Electrocardiograms were performed on all family members participating In the research
project, and the QT values were corrected for heart rate (QTc) using Bazett's formula. The
affectedness status was determined by the diagnostic criteria described by Keating et al.,
(1991). The examining physicians either recorded the actual QTc values or categorized the
individuals as affected unaffected or equivocal according to the diagnostic criteria described by
Keating. This was based on a QTc 20.45s in symptomatic individuals or a QTc 2 0.47s in
asymptomatic individuals. Diagnosis of equivocal clinical status was made if individuals had a
QTc value between 0.42s and 0.46s in the absence of symptoms and 0.44s or less in the
presence of symptoms'. Those for whom ECGs were not available, or in whom complete
investigation was not possible, were classified as "disease status unknown".
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2.3 Molecular DNA-based Studies
2.3.1 Collection of blood
Blood was drawn from all affected individuals and their immediate family members, into four
5ml EDTA tubes, from which DNA was extracted.
2.3.2 Preparation of DNA samples
2.3.2.1 Isolation of genomic DNA from EDTA-blood
Each sample was processed in duplicate. Blood from two EDT A tubes was transferred to a
50ml plastic centrifuge tube, 20ml of ice cold cell lysis buffer (Appendix I) was added to the
blood, and the tubes were inverted a few times. The tubes were left on ice for 5-10 minutes,
before centrifuging at 3 000 r.p.m. for 10 minutes in a benchtop centrifuge (Beckman model
TJ-6). The supernatant was then discarded and the pellet resuspended in 10ml ice-cold cell
lysis buffer. The washing and centrifuging steps were repeated until a pinkish white pellet was
obtained. The pellet was resuspended in 901-11Na-EDTA (Appendix I) and 1001-1110%SDS in a
50ml volume centrifuge tube. DNA could be extracted directly from these nuclei, or they could
be frozen at -70DC until required.
2.3.2.2 Genomic DNA extraction from nuclei
The freshly prepared or thawed frozen nuclei were incubated overnight with 1001-11proteinase
K (lOmglml) at 37DC with gentle agitation. After this incubation, 2ml of sterile dH20 and
\
5001-113M NaAc (Appendix I) were added at room temperature. Thereafter, 2.5ml of
phenol/choroform (Appendix I) was added and the mixture was thoroughly mixed for 10
minutes on a rotator (Voss of Maldon, Protea Dento-Medical Services, SA) at 4DC prior to
centrifugation at 8 000-10000 r.p.m. for 10 minutes (Sorvall RC 5B Du Pont, SS34 or HB4
rotor) in glass tubes (Corex). The top aqueous layer was transferred to a fresh centrifuge tube,
taking care not to disturb the interface and the bottom layer was discarded. An equal volume of
chloroform/octanol (Appendix I) was added to the aqueous layer, which was mixed for 10
minutes on a Voss rotator and centrifuged as described earlier. Again, the top aqueous layer
was removed to a fresh tube and the DNA it contained precipitated with 2 volumes of ice-cold
96% ethanol, by gentle mixing until the white strands of DNA appeared. The DNA was
transferred with a pipette tip to a clean eppendorf tube and washed by adding lml of 70%
ethanol and microfuging (Centrifuge 5415C, AMTEC) for 3 minutes, after which the 70%
ethanol was carefully decanted. The washing step was repeated before the final pellet was
dried either by inverting the Eppendorf tube on carlton paper for an hour or drying under
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vacuum (Speed Vae, Savant SVC lOOH). The isolated DNA was then resuspended in 300-
500111of lxTris-EDTA (Appendix I) and incubated at 37°C overnight, prior to placing on a
Voss rotator for 3 days at 4°C to allow the DNA to resuspend completely. The concentration
of the DNA was determined by a spectrophotometric reading (Roy Spectronic 1201, Milton) at
260nm, where an optical density reading (OD) of 1 equaled a concentration of 50Ilg/ml.
Subsequently, the DNA concentration was adjusted to 11lg/1l1by either adding lxTE buffer
(Appendix I), if the concentration was too high, or by performing an ethanol precipitation if
the concentration was too low, followed by resuspension to give the desired concentration.
2.3.3 Polymerase Chain Reaction
2.3.3.1 Non-radioactive Polymerase Chain Reaction
Non-radioactive PCR amplification of the S1-S6 regions of KVLQTl as described by Wang et
al., (l996a) (Table 2.1) was used for PCR-SSCP analysis and ASREA. The PCR reaction was
performed in a 30111reaction volume using 200ng of template DNA, 120ng of each primer,
lOOIlM of deoxyribonucleotides (1.2111of an equimolar solution (2.5mM) of dATP, dTTP,
dGTP, dCTP) (Boehringer Mannheim, Germany), 2.5mM MgCh (Promega, USA), 5%
formamide (Sigma, USA), 0.5 U Taq polymerase (Promega, USA) and 3111 10 x Taq
polymerase buffer supplied by the manufacturer (Promega, USA). Five percent of formamide
was included in the PCR reaction mixture to increase the specificity of the primers for the
template, in order to eliminate the presence of spurious products. Each sample was overlayed
with 40111 of mineral oil (BDH Chemicals) prior to the thermocycling step to prevent
evaporation. Thermocycling was performed in a Gene E thermal cycler (Techne, UK) and
consisted of an initial denaturing step at 94°C for 5 minutes, followed by 5 cycles of
denaturation at 94°C for 30s, annealing at 64°C for 30s and elongation at 72°C for 45s. These 5
cycles were linked to 30-cycles, consisting of denaturation at 94°C for 30s, annealing at 62°C
for 30s and elongation at 72°C for 45s. A final elongation step at nOc for 10 minutes was
performed.
The success of the PCR amplification was monitored by the electrophoresis of 5111of the PCR
product mix with I III of bromophenol blue tracking dye (Appendix I) on a 1.5 % agarose gel
containing ethidium bromide (Iug/ml) (Appendix I). The molecular size markers
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Table. 2.1 DNA Sequences of the eight regions of the KVLQT1 gene analyzed
REGION SEQUENCES
l. Sl-S2 gift from M.Keating
2. S2-S3 F-GAGATCGTGCTGGTGGTGTTCT
R-CTTCCTGGTCTGGAAACCTGG
3. S3-S4 F-CTCTTCCCTGGGGCCCTGGC
R-TGCGGGGGAGCTTGTGGCACAG
4. S4 F-GGGCATCCGCTTCCTGCAGA
R-CTGGGCCCCTACCCTAACCC
5. S4-S5 gift from M.Keating
6. S5-Pore F-TCCTGGAGCCCGAACTGTGTGT
R-TGTCCTGCCCACTCCTCAGCCT
7. Pore-S6 F-CCCCAGGACCCCAGCTGTCCAA
R-AGGCTGACCACTGTCCCTCT
8. S6 F-GCTGGCAGTGGCCTGTGTGGA
R-AACAGTGACCAAAATGACAGTGAC
All sequences are given in a 5' -3' direction
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electrophoresed alongside PCR products were bacteriophage lambda DNA (Promega, USA)
digested with PstI (A PstI) (Boehringer Mannhheim, Germany) (Appendix I). The DNA
fragments were visualized on a longwave ultraviolet transilluminator (3 UVTM
Transilluuminator model LMS-26E, UK).
2.3.3.2 Radioactive Polymerase Chain Reaction
In order to genotype individuals at STRP loci prior to linkage analysis, radioactive PCR was
performed. Two methods of radioactive labeling were used, namely, full strand labeling by
incorporation and end-labeling.
2.3.3.2.1 Full Strand Labelling
Full strand labeling was used to amplify fourteen of the fifteen microsatellite markers which
were genotyped. PCR reactions were performed in a Ioul reaction volume, using 200ng of
template DNA, 50ng of each primer, 200llM of each dATP, dTTP, dGTP, (Boehringer
Mannheim, Germany) 51lM of unlabeled dCTP (Boehringer Mannheim, Germany), 0.51lCi [a-
32p]_dCTP (Arnersham, UK), 2.5mM MgCh (Promega, USA) and 0.5 U of Taq polymerase
(Promega, USA) in the buffer supplied by the manufacturer. The DNA was amplified in a
Gene E thermal cycler (Techne, UK), using the parameters for the different markers listed in
table 2.2.
2.3.3.2.2 End-Labelling
One of the micro satellite markers DIl S1318 was amplified employing end-labelling as this
marker repeatedly failed to amplify employing the full strand labelling technique. The forward
primer of the marker DllSJ318 was labeled with [y_32P]_ATP (Amersham, UK) prior to
performing the PCR reaction. The labeling reaction was performed in a 5111reaction volume
using 0.031lM forward primer, 31lCi [y_32p]_dATP (Amersham, UK), l.5U of T4
polynucleotide kinase (Promega, USA) in the buffer supplied by the manufacturer. Labeling
was performed at 37°C for 6 hours, whereafter the reaction was stopped by placing it at 94°C
for 5 minutes.
The subsequent PCR reaction was performed in a Tuul reaction volume using 200ng of
template DNA, 40ng of unlabeled forward primer, SOngof reverse primer, 200llM of each
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Table.2.2 Thermocycling parameters used for the STRP markers amplified with
radioactive PCR
DNA marker Numbe Denaturing Time Annealling Time Elongation Time
r temp. (oC) (s) temp. (oC) (s) temp. (s)
of
cycles
1 94uC 5 min - - - -
DllS1323 5 94°C 30s 59°C 30s nOc 45
25 94°C 30s 55°C 30s nOc 45
I nOc 10 min
1 94uC 5 min - - - -
D7S636 30 94°C 30s 56°C 30s 72°C 45s
1 - - - - 72°C 10 min
DllS 1331,
DllS860,
TH, I 94°C 5 min - - - -
D3S1298,
D4S402, 30 94°C 30s 55°C 30s nOc 45s
D8S264,
D8S1781, 1 - - - - 72°C 10 min
D8S504,
D21S2040,
D21S1912
&
D21S1959
DRPLA (trinuc
leotide repeat)
I 94°C 5 min - - - -
DllS1318 5 94°C 30s 52°C 30s nOc 45s
25 94°C 30s 50°C 30s nOc 45s
1 - - - - 72°C 10 min
u, -C - Grade CelsIUS
s = seconds
min = minutes
temp = temperature
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dATP, deTP, dGTP, dTTP (Boehririger Mannheim, Germany), 0.1 III of the labeled forward
primer, 2.5mM Mgeh (Promega, USA) and 0.5U ofTaq polymerase (Promega, USA) in the
buffer supplied by the manufacturer. The DNA was amplified in a Gene E thermal cycler
(Techne, UK), the thermo cycling steps used for this marker are indicated in table 2.2.
2.3.4 Mutation screening
2.3.4.1 Allele specific restriction enzyme analysis
Allele specific restriction enzyme analysis was used to screen for the presence of four of the
first ten KVLQTI mutations described by Wang et al., (1996), which affect restriction enzyme
sites (Table 2.3).
Each amplified Pf.R product, generated as described in section 2.3.3.1 was dialyzed, against
deionised H20 on a 0.0251lm millipore VS filter (Millipore), to remove peR buffer
components prior to addition of restriction enzyme buffer. The reaction was performed at room
temperature for 10 minutes by dispensing 5111of the amplified peR product onto the filter that
was floating on a dH20 surface in an ice block tray. Four microlitres of each dialysed sample
were subsequently transferred to a O.Sml Eppendorf tube, taking care not to transfer the
mineral oil situated on the periphery of the hydrophilic peR sample. Five units of the
particular restriction enzyme and 1.Sill of the appropriate lOx restriction enzyme buffer
provided by the manufacturer were added to the dialyzed sample. Water was added to a final
volume of 151l1,before the sample was digested at 370e overnight. The restriction enzyme was
inactivated by heating the reaction mixture at 650e for 10 minutes.
Fragments generated with restriction enzyme digestion were separated by gel electrophoresis.
To this end, a mixture of 5111of each digested sample and I III of bromophenol blue loading
dye was separated by electrophoresis on a 6.5 X 7cm vertical 12% polyacrylamide gel
(Appendix I) using lXTBE running buffer (Appendix I). Electrophoresis was performed at
12V/cm until the bromophenol blue had migrated the length of the gel. To ascertain the
presence of a specific mutant allele, as indicated by the restriction fragments generated, an
undigested sample was co-electrophoresed as a control, as was a digested wild type control
sample and the molecular size marker A PstI (Appendix I).
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Table. 2.3 The first ten KVLQTl mutations described by Wang et al., (1996) and the
restriction enzyme sites that they affect
MUTATION REGION RESTRICTION EFFECT ON
ENZYME ENZYME SITE
DF38W/G39ó S2 /
A49P S2-S3 Nael loss
G60R S2-S3 /
R61Q S2-S3 Pvull gam
V125M S4-S5 Styl gam
L144F S5 /
Gl77K Pore /
T1831 Pore /
A212V S6 HhaI loss
G216E S6 /
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2.3.4.2 PCR-SSCP analysis
After linkage analysis had implicated KVLQTl as disease-causing gene in pedigree 167,
mutation screening employing PCR-SSCP analysis was performed to screen for known and
novel mutations in the S1-S6 regions of this gene as published by Wang et al., (1996). Four
different gel conditions were used, namely, 5% polyacrylamide with and without glycerol and
10% polyacrylamide with and without glycerol, made up from a 30 % polyacrylamide stock
solution (Appendix I). PCR-SSCP analysis was performed on non-denaturing polyacrylamide
gels prepared between two glass plates (400 x 300 x 1mm).
To prepare the gel, glass plates (400 x 300 x 1mm) were washed with soap (Coastal
Chemicals), rinsed with H20 and then wiped with 70% ethanol to remove residual soap. One
of the plates was silanised with Wynn's™ C-thru (Wynn's Oil South Africa (Pty) Ltd) solution
to prevent the gel from sticking to the plate when the gel apparatus was dismantled. A sheet of
Gelbondn.f PAG polyester film (FMC Bioproducts, USA) was tightly fixed to the back plate.
This was performed by spraying 70% ethanol onto the plate and placing the Gelbond film with
the hydrophobic side exposed to the 70% ethanol. Trapped airbubbles were expelled by gently
rubbing across the surface of the film with a sheet of Carlton paper. The glass plates were
separated by 1mm thick spacers and sealed together with an Easy Boot gel sealing system.
(Gibco BRC, UK). The gel was cast carefully on the hydrophilic side of the Gelbond and a
lrnm thick square tooth well-forming comb was place in position and clamped. The gel was
left to set for 2-3 hours at room temperature, during the polymerization the gel covalently
bonded with the Gelbond, thereby providing a solid support for the gel that made subsequent
staining easier. After the gel had set the comb was removed, the wells cleaned under running
water and the gel assembled on a vertical electrophoresis apparatus.
The samples were prepared by mixing a 6!J.Ialiquot of the non-radioactively labeled amplified
PCR product (section 2.3.3.1) with 6!J.Iof SSCP- loading dye (Appendix I). This mixture was
denatured at 94°C for 10 minutes, after which the total volume was loaded onto the SSCP gel
and electrophoresed at 4°C in 0.5 x TBE running buffer (Appendix I) at a constant power of30
or 50 Watts, depending on the specific gel condition (Table 2.4). Under all conditions, the
bromophenol blue dye was allowed to migrate to the bottom of the glass plates; however, the
electrophoresis time varied for the different gel conditions as indicated in table 2.4. The bands
were visualized by silvër staining as described in section 2.3.5 and either air-dried or dried
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Table 2.4 Electrophoreses and gel drying conditions of SSCP gels
GEL CONDITION ELECTROPHORESED AT: GEL DRYING CONDITION
5% polyacrylamide
(+) Glycerol 50 Watts for 8-10 hours dried by hanging to drip dry
5% polyacrylamide
(-) Glycerol 50 Watts for 3-5 hours dried by hanging to drip dry
10% polyacrylamide
(+) Glycerol 30 Watts for 18-20 hours vacuum drying
10% poyacrylamide
(-) Glycerol 50 Watts for 6-8 hours dried by hanging to drip dry
O.4XMDE 50Watts for 4hours dried by hanging to drip dry
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under a vacuum on a gel drier (Slab gel drier Hoeffer SE 1160, San Francisco) depending on
the gel condition (Table 2.4). If the gel was dried under a vacuum, it was dried for 2 hours with
plastic wrap placed on the side of the gel not covered with the Gelbond.
Samples which demonstrated mobility shifts were reamplified and analyzed again under the
SSCP condition in which the mobility shift was originally detected and a O.4XMDE gel
(Appendix I) (FMC Bioproducts, USA) to confirm its presence.
2.3.5 Silver Staining
Silver staining was used to visualize the fragments generated with ASREA and PCR-SSCP
analysis. Staining was performed while gels were submerged in a suitably sized container
agitating on a orbital shaker. First the gel was treated in a 0.1% AgN03 solution (Appendix I),
for 5 minutes in the case of the smaller gels used in ASREA while the larger SSCP gels were
stained for 10 minutes, after which the solution was decanted, and the gel rinsed with dH20 to
remove residual AgN03. The gels were then placed in a developing solution (l.5% NaOH,
0.01% NaB~, 0.4% formaldehyde) (Appendix I) 10 minutes for the smaller ASREA gels and
15-25 minutes for the SSCP gels. The fragments were visualized on a white light illuminator
(EGE LAUDA model), photographed (Sony Video Graphic printer UP-860 CE) for permanent
record and the gel sealed in a plastic bag for storage.
2.3.6 Radioactive Gel Electrophoresis
2.3.6.1 Preparation of Gel
Subsequent to radioactive amplification of STRP loci, samples were electrophoresed on a 5%
denaturing polyacrylamide gel (Appendix I) to separate alleles containing different numbers of
repeat elements. To prepare the gel, glass plates (400 x 300 x lmm) were washed with soap
(Coastal Chemicals), rinsed with H20 and then wiped with 70% ethanol to remove residual
soap. One of the plates was silanised with Wynn's™ C-thru (Wynn's Oil South Africa (Pty)
Ltd) solution to prevent the gel from sticking to the plate when the gel apparatus was
dismantled. The plates were separated by 0.4 mm spacers and a Easy Boot gel sealing system
(Gibco BRC, UK) was used to seal the plates prior to pouring the gel. The gel was carefully
poured while the plates were held at a slight angle and care was taken not to trap any air
bubbles between the plates. A shark toothcomb (with the teeth facing up) was placed in
position and clamped. The gel was allowed to set at room temperature for 2-3 hours.
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2.3.6.2 Electrophoresis
The comb was removed from the gel and excess urea was rinsed from the top surface of the gel
and the comb, the gel was mounted on a vertical gel electrophoresis apparatus and the comb
was replaced with the teeth just touching the gel. The 0.5 x TBE (Appendix I) running buffer
was prepared and 1litre was preheated in the microwave to 60°C prior to pre-running the gel
for 10 minutes at 1800 V. Six microliters sequencing loading dye (Appendix I) was added to
the 10j.l1PCR product and this mixture was denatured in a heating block (Dri Block R Db-3
Techne, UK) at 94°C for 5 minutes, before loading 4j.l1 of this solution. Samples were
electrophoresed for l.5 - 2.5 hours at 1800 V depending on the size of the alleles that were to
be separated. The bromophenol blue dye front was allowed to migrate to the bottom of the
glass plates for fragments of 100-200 bp in size, while the xylene cyanol dye front was allowed
to migrate three quarters of the gel distance for fragments greater than 200 bp in size.
2.3.8 Autoradiography
After dismantling the electrophoresis apparatus, the gel was removed from the plates using a
JMM Whatman paper (Whatman TM 3MM Chromatography, Whatman International Ltd,
UK) folded double and cut to the size of the gel, after which the gel was covered with plastic
GladR wrap (Multi Foil Trading (Pty) Ltd) and dried at 80°C for 1 hour under vacuum (Slab
gel drier, Hoeffer SE1160, San Francisco). The dried gel was placed in a cassette (Okamoto)
and exposed to X-ray film (Cronex-4, Protea Medical Services, SA) for 6-18 hours, before
\
developing the X-ray film in the dark room. Following exposure, the X-ray film was developed
in a Polygon A solution (Champion Photochemistry) (Appendix I) for 1 minute and transferred
to a stop solution containing 6% acetic acid (Appendix I) for another minute. Thereafter, the
X-ray film was transferred to a fix solution (Appendix I) (M&B Suppliers) for 2 minutes. The
autoradiograph was rinsed with water and air-dried. The auto radiographs were then genotyped
and independently recorded by two investigators and were only reported after consensus was
reached.
2.3.8 Genotyping
The alleles of the STRP markers analyzed at the four LQTS and three FME candidate loci
were genotyped as follows. Autoradiographic images of radioactive PCR amplified,
electrophoretically separated alleles of each of the STRP markers were numbered in order of
decreasing size, based on this numbering system each individual were assigned a genotype.
Continuity of allele assignment between different autoradiographs was assured by designating
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certain individuals as standards, which were co-electrophoresed on each gel along with
samples amplified at that specific locus. Genotypes assigned to individuals were subsequently
compared with the family structure to ascertain the mendelian inheritance of alleles and
minimize allele labeling error.
Genotyping was performed with DNA markers at the three candidate forms of epilepsy
syndromes analyzed in the epilepsy study. The DNA markers used in this analysis were
D2lS2040, D2lSl912 and D2lSl259 at the EPMl locus, D8S264, D8S504 and D8Sl78l at
the chromosome 8p locus and the triplet repeat in the atrophin gene, which is expanded in
DRPLA-affected individuals (Tables 2.5 and 2.6).
Genotyping at the four LQTS loci analyzed was performed by using a set of nine polymorphic
microsatellite markers. The LQTl locus was genotyped by using DNA markers TH, DllS860,
DllSl3l8, DllSJ323 and DllSl33l, the LQT2 locus with marker D7S636, the LQT3 locus
with marker D3S1298 and LQT4 with marker D4S402 (Tables 2.5 and 2.6).
2.3.9 Haplotype construction
Haplotypes were constructed across the candidate loci where two or more DNA markers were
analyzed. Most likely haplotypes were constructed with reference to gene and marker order on
the respective chromosomes and were based on parental genotypes and in a family context,
assuming minimal recombination events in each kindred.
2.3.10 Linkage Analysis
Two-point linkage analyses were performed using the MLINK program of the Linkage
package (Lathrop and Lalouel, 1984). In the case of LQTS, a conservative approach to
phenotypic assignment was used, as described by Keating et al., (1991) section 2.2.2. The
phenotypic assignment in the epilepsy study was based on the diagnosis made by Dr. Carr as
discussed in section 2.2.1. A measure for the support of linkage is the LOD score, which is the
log of the probability that the data arose from two linked loci, versus the probability that the
data arose from two unlinked loci. Linkage of a marker and the disease gene is indicated by a
LOD score of +3.0 or higher, while exclusion of linkage is indicated by a value of -2 or lower.
Apenetrance ofO.9, a frequency of the disease allele ofO.OOl and equal male and female
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Table. 2.5 STRP markers analyzed by Radioactive PCR
LOCUS PRIMERS SUPPLIED BY REFERENCE
DllS1318 *UCT DNA-LAB Gyapay, G., 1994
DllSJ323 #RESEARCH GENETICS Gyapay, G., 1994
DlISl331 #RESEARCH GENETICS Gyapay, G., 1994
DlIS860 #RESEARCH GENETICS Kimberling, W.I., 1992
TH liRESEARCH GENETICS n/a
D7S636 IlRESEARCH GENETICS Gyapay, G., 1994
D3S1298 #RESEARCH GENETICS Weisenbach, J., 1992
D4S402 *UCT DNA-LAB Weisenbach, r., 1992
D8S264 #RESEARCH GENETICS :Spersonal communication
D8S504 #RESEARCH GENETICS :bpersonal communication
D8S1781 #RESEARCH GENETICS :Spersonal communication
D21S1259 *UCT DNA-LAB Virtaneva et al., 1996
D2lS2040 *UCTDNALAB Virtaneva et al., 1996
D2lS1912 *UCT DNA LAB Virtaneva et al., 1996
DRPLA (trinucleotide repeat) *UCTDNALAB
#MapPair TM primers obtained from Research Genetics, Huntsville, Alabama, USA
*Primers designed to published sequences was ordered from the University of Cape Town
DNA Lab, South Africa
$ Berkovic
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Table. 2.6 Details on the alleles of the polymorphic markers analyzed by using
radioactive peR.
MARKER SIZE HETEROZYGOS
ITY
DllS1318 123-145 bp 0.78
DllSJ323 201-207 bp 0.46
DllSJ331 191-205 bp 0.70
DllS860 154-196 bp 0.91
TH 100 bp nla
D7S636 130-168 bp 0.90
D3S1298 194-220 bp 0.88
D4S402 287-323 bp 0.92
D8S264 121-145 bp 0.85
D8S504 nla 0.72
D8S1781 nla 0.85
D21S1259 222bp 0.67
D21S2040 nla nla
D21S1912 173bp 0.80
DRPLA (trinucleotide repeat) nla nla
bp - base pair
nla - not available
Information obtained from http:\www.gdb.org\
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recombination fractions were used for both diseases, while equal allele frequencies were
assumed at all the loci in linkage calculations.
2.3.11 Direct Sequencing of SSCP conformers
2.3.11.1 Purification of DNA
In samples in which a mobility shift was confirmed, sequencing was performed to determine
the nature of any sequence variations. These samples were first reamplified by PCR in a
reaction volume scaled up to lOOIl!. A l.5% agarose gel containing ethidium bromide (lug/ml)
(Appendix I) was prepared and the teeth of the comb used were taped together to form a larger
well, that could bear a bigger volume. The total reaction volume was mixed with 10%
bromophenol blue dye and loaded on the gel. The samples were allowed to migrate 10cm from
the wells, to monitor for the presence of spurious products in the PCR amplified product. After
agarose gel electroporesis, the PCR- amplified DNA fragment was visualized on a UV-light
box, and the fluorescent DNA band of the expected size was cut out using a sterile blade. The
DNA was purified from the gel slice using the QIAGEN, QIAquick Gel Extraction Kit,
following the manufacturers' protocol and resuspended in 30JlI H20.
2.3.11.2 Direct sequencing of purified DNA
The purified DNA prepared as described in section 2.3.11.1 was sequenced by utilizing the
fmol™ sequencing kit (Promega, USA) according to the manufacturer's specifications. The
,
forward and reverse primers flanking the S2-S3 region (Table 2.1), which contained a mobility
shift were used in separate reactions to sequence 3111of purified amplified DNA. For each
sequencing reaction, four 0.5 ml reaction tubes were labeled G, A.,T and C, respectively. Two
microlitres of each termination mix, ddGTP, ddATP, ddTTP and ddCTP (Appendix I), were
aliquoted into the appropriately labeled tube, overlayed with 20JlI mineral oil and placed on
ice. Prior to continuing with the sequencing reaction, a Gene E thermal cycler (Techne, UK)
was preheated to 95°C and maintained at that temperature. A reaction mixture was prepared
which contained IJllofforward or reverse primer (l Ong/ul), I III diluted DMSO (30JlI DMSO
and 20111H20) (Appendix I), SJlI 5X sequencing grade Taq DNA polymerase buffer, 3111
purified template DNA., 1JlI [0.32 -PJ dCTP (3000Cilmmol) 5JlI H20 and 1JlI of sequencing
grade Taq DNA polymerase. Aliquots of 4JlI of this reaction mixture were added to each
termination mix (Appendix I) and the tubes immediately placed into the preheated
thermo cycler. The same thermo cycling parameters as described in section 2.3.3.1 were used,
and 4JlI of stop solution was added to each tube after completion of the thermocycling steps.
Stellenbosch University http://scholar.sun.ac.za
87
The sequences were resolved by electrophoresis through a 5% polyacrylamide sequencing gel,
which was prepared as described in section 2.3.6.1. Electrophoresis was performed as
described in section 2.3.6.2 but a 3.5f.l1 aliquot of the denatured DNA was loaded. The
sequencing gel was electrophoresed at 1800 V until the bromophenol blue dye had reached the
bottom of the gel. At this point, another denatured 3.5f.l1aliquot was loaded into unused wells
and the samples electrophoresed until the latter samples' bromophenol blue dye reached the
bottom of the gel. Thereafter, the gel was treated in the same manner as described in section
2.3.7. The dried gel was exposed to X-ray film in a cassette for 3 hours to two weeks
depending on the degree of radioactive incorporation and the isotope's activity. The sequences
were read and recorded independently on paper by two investigators and were only reported
after consensus was reached.
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EPILEPSY
3.1 LINKAGE ANALYSIS STUDY
3.1.1 Family Study
One family in which FME segregates was analyzed in the present study, the pedigree of the
three-generation family, designated 201, is shown in figure 3.1. Eleven members of this family
were analyzed, six of whom were affected. One individual (IlI:8) died following a seizure at
age 31 years. Post mortem blood was collected from this individual. With consent of the
parties involved, the brain of the latter individual was collected to assist in future analysis of
this disorder.
3.1.2 Genotypic Analysis of DNA markers
As mentioned earlier, three forms of epilepsies, viz., EPMl, DRPLA and a form of epilepsy
that shows linkage to chromosome 8p, have been identified as plausible candidates for FME.
To test the candidacy of these loci, linkage analysis, employing microsatellite markers closely
linked to these loci, was performed.
3.1.2.1 Genotypic analysis at the EPMllocus
At the EPMllocus, the DNA markers D2lS2040, D2lSl959 and D2lSl912 were used, figures
3.2.1-3.2.3 show the autoradiographs with the genotypes generated by amplification and
separation of the alleles at each of these markers. Five of the affected members of the family
were homozygous for allele 2 at D2l S2040 (figure 3.2.1). The genotype of the sixth individual
was 1/2. The genotypes of the affected members at D2lSl259 were: 4/4, 2/5, 3/4, and 4/4
(figure 3.2.2). No genotypes were generated for individuals IlI:5 and III:7 due to technical
difficulties, their DNA repeatedly failed to amplify. At D2lSl912 the genotypes of affected
individuals were 2/3, 2/6, 2/6, 6/6, 2/3 and 2/3 (figure 3.2.3). Thus, no specific allele
segregating with the disease was detected at any of the three markers analyzed. These
observations were statistically confirmed by LOD scores generated, which are reported in
section 3. 1.4.
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3.1.2.2 Genotypic analysis at the chromosome 8 locus
In a Japanese family with similar clinical symptoms to those seen in FJ\.1E,linkage to the DNA
marker D8S264 was reported (Berkovic, personal communication), therefore, this marker, as
well as the closest telomeric marker, D8S504, and centromeric marker, D8S1781, were
analyzed. The representative inheritance patterns of these markers are shown in figures 3.3.1-
3.3.3. At marker D8S504, the genotypes of the affected family members were 2/3, 3/6, 3/6,
6/6, 3/6 and 1/6 (figure 3.3.1). At marker D8S264, the genotypes of the affected family
members were 2/3, 3/5, 2/3, 3/5, 2/5 and 2/6, it is clear that there was no unique allele that
segregated with the disease at this marker locus (figure 3.3.2). At marker D8S1781, the
genotypes of five of the affected family members were 2/4, 2/4, 2/4, 1/4 and 2/4, respectively,
no genotype was generated for the affected individual, IlI:8 because its DNA repeatly failed to
amplify (figure 3.3.3). Although allele 4 was present in all affected individuals at D8S1781,
this allele was also present in one unaffected individual (III-I); thus, it is not segregating with
the disease. Thus, at the three DNA markers analyzed at the chromosome 8p-candidate locus,
no specific alleles that segregate with the disease were detected.
3.1.2.3 Genotypic analysis at the DRPLA locus
The triplet repeat in the atrophin gene was used to analyze the DRPLA locus for involvement
in FJ\.1E, figure 3.4.1 shows the autoradiograph of the genotypes derived at this marker. The
genotypes identified at the triplet repeat marker are displayed on the pedigree to show the
allelic distribution of this marker in pedigree 201 (figure 3.4.2). The genotypes of the affected
family members were 5/8, 2/4, SIS, 5/8, 3/5 and SIS, allele 5 was present in five of the six
affected individuals (figure 3.4.1). However, the latter allele was also present in unaffected
individuals, thus suggesting that it is not segregating with the disease. Individuals IlI:7, IlI:8
and IlI:9 the affected children of individual Il:7 received allele 5 from their affected father
(figure 3.4.2). In individual II:3, the genotype could be deduced as 4/5 based on the genotypes
seen in his children and the wife. The affected children of individual II:3 (III:3 and IlI:5),
received the alleles 4 and 5 respectively from their father. The results of this analysis suggest
that the tested locus is not involved in FJ\.1E.
In summary, analyzing the three candidate loci, showed that there was no allele that segregated
exclusively with FJ\.1Eat any of the DNA markers tested.
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0 Male
0 Female
•• Affected
i~ UnaffectedDeceased~.Proband
~ Not studiedDO
Fig. 3.1a The original pedigree 201 structure showing the family in which FME
segregates. Clinically affected individuals were diagnosed according to the criteria stipulated
in section 2.2.1.
11:1
111:1 111:2
11:2 11:8 11:9 11:10 11:11 11:12
0 Male
0 Female
•• Affected0® Unaffected.~Deceased~.Proband
Not studiedDO
1:1 1:2 1:3
11:4 11:5 11:6 11:7
Fig. 3.1b Pedigree 201 structure altered for LOD score analysis. Individual II:l was not
studied but is indicated in the pedigree, as genotyping data was inconsistent with individual
II:3 being>the father of individual III: 1. Individual identity numbers are shown under each
individual, these numbers are used to refer to the study subjects in further analyses.
11:3
111:3 111:4 111:5 111:6 ~1I1:7
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III:9 III:3 Il:7 IlI:5 IlI:S Ill:6 II:5 C II: 2 C III: 7 1II:1 1I:4
2 3 4 5 6 7 S 9 10 Il 12 13
.. 1
.. 2
.. 3
2/2 2/2 1/2 2/2 2/2 1/1 1/2 1/2 1/2 1/3 2/2 1/1 1/2••••• •
Fig. 3.2.1 Autoradiograph showing alleles at the EPM1 DNA marker D21S2040 in
pedigree 201 in which FME segregates. Assigned genotypes are indicated below each lane,
designated allele numbers are indicated on the right. The individual identity numbers are
shown above each lane and the lower arrowheads indicate affected individuals represented in
the specific lane.
e = standard sample used to ensure continuity of allele assignment
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IIl:9 IIl:3 IT:7 e 1lI:8 ITI:6 II:5 e 1l:2 e IIT:7 III: 1 1l:4
1 2 3 4 5 6 7 8 9 10 Il 12 13
5
4/4 2/5 3/4 2/3 4/4 liS 2/5 2/3 liS 1/4 -1- -1- 2/5
Fig. 3.2.2 Autoradiograph showing alleles at the EPMl DNA marker D21S1259 in
pedigree 201 in which FME segregates. Assigned genotypes are indicated below each lane,
designated allele numbers are indicated on the right. The individual identity numbers are
shown above each lane and the lower arrowheads indicate affected individuals represented in
the specific lane.
e = standard sample used to ensure continuity of allele assignment
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III:9 III:3 II: 7 III:5 III:8 C 11:5 C II:2 C III: 7 III: 1
2 3 4 5 6 7 8 9 10 11 12
2/3 2/6 2/6 6/6 2/3 1/6 2/7 1/2 6/7 4/7 2/3 6/7
95
Fig. 3.2.3 Autoradiograph showing alleles at the EPMl DNA marker D21S1912 in
pedigree 201 in which FME segregates. Assigned genotypes are indicated below each lane,
designated allele numbers are indicated on the right. The individual identity numbers are
shown above each lane and the lower arrowheads indicate affected individuals represented in
the specific lane.
C = standard sample used to ensure continuity of allele assignment
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II!:3 II:2 II:5II!:7 C III:6 III:8 II:7 Il!:5 III:9
1234567 8 9 10
96
Fig. 3.3.1 Autoradiograph showing alleles at the chromosome 8p DNA marker D8S504 in
pedigree 201 in which FME segregates. Assigned genotypes are indicated below each lane,
designated allele numbers are indicated on the right. The individual identity numbers are
shown above each lane and the lower arrowheads indicate affected individuals represented in
the specific lane.
C = standard sample used to ensure continuity of allele assignment
~ 1
2
~3
~
2/3 3/3 2/6 3/6 2/6 2/3 3/6 6/6 3/6 1/6
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III:9 Ill:3 II:7 Ill:5 III:8 IlI:6 C III:7 C II:5 C II:2 II: Il II: Il
2345678 9 10 Il 12 l3 14
'-1.-2.-3
4.-
'-5.-6.-7
.-8
2/3 3/5 2/3 3/5 2/5 2/5 3/8 2/6 6/7 2/8 2/4 5/6 1/5
••••• •
Fig. 3.3.2 Autoradiograph showing alleles of at the chromosome Sp DNA marker D8S264
in pedigree 201 in which FME segregates. Assigned genotypes are indicated below each
lane, designated allele numbers are indicated on the right. The individual identity numbers are
shown above each lane and the lower arrowheads indicate affected individuals represented in
the specific lane.
e = standard sample used to ensure continuity of allele assignment
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C C IT:2 II: Il II:7 III:5 III:8 III:6 III:9 III:7 IT:4 III: 1 III:3
234 5 6 7 8 9 10 11 12 13
1
2
4
2/2 2/2 2/2 -/- 2/4 2/4 -/- 1/2 2/4 1/4 1/2• • •• 2/4 2/4•
Fig. 3.3.3 Autoradiograph showing alleles of at the chromosome 8p DNA marker
D8S1781 in pedigree 201 in which FME segregates. Assigned genotypes are indicated below
each lane, designated allele numbers are indicated on the right. The individual identity
numbers are shown above each lane and the lower arrowheads indicate affected individuals
represented in the specific lane.
C = standard sample used to ensure continuity of allele assignment
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III:9 III:3II:7 HI:5 HI:8 III:6 C III:7 C 11:5 C II:2 II:Il III:1 II:4
1 2 3 4 5 6 7 8 9 10 Il 12 13 14 15
.......1--_ 1
....-_2
....--3
4
.......1--- 5
~
.~__ 7
.~__ 8
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Fig. 3.4.1 Autoradiograph showing alleles of the triplet repeat in atrophin (DRPLA) in
pedigree 201 in which FME segregates. Assigned genotypes are indicated below each lane,
designated allele numbers are indicated on the right. The individual identity numbers are
shown above each lane and the lower arrowheads indicate affected individuals represented in
the specific lane.
C = standard sample used to ensure continuity of allele assignment
5/8 2/4 5/5 5/8 3/5 2/4 2/8 5/5 1/2 2/5 4/5 2/8 3/7 5/8 4/5••••• •
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1:1 1:31:2
II
11:1 11:2 11:3 11:4 11:5 11:6 11:7 11:8 11:9 11:10 11:11 11:12
2 8 4 5 2 5 5 5
0 Male
0 Female
• • Affected
III ~ @ Unaffected
/
111:1 111:2 111:3 111:4 111:5 111:6 111:7 1118 111:9 .- @EJ2 CJ8 [J5 [J3 08 Deceased5 8 4 2 ~.Proband
DO Not studied
Fig. 3.4.2 Pedigree 201 showing the allelic distribution at the triplet repeat marker in the
atrophin gene in those individuals who participated in the linkage study. The individual
identity number and assigned genotypes are indicated below each individual. Clinically
affected individuals were diagnosed according to the criteria stipulated in section 2.2.1. Where
it was possible to deduce, the allele received from the affected parent is boxed.
100
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3.1.3 Haplotype Analysis
Where possible, haplotypes were constructed from the alleles inherited at the EPM 1 and
chromosome 8 loci (figures 3.5 and 3.6). The most likely combination of alleles received from
each parent was deduced from the available genotypes.
3.1.3.1 Haplotype analysis at the EPMllocus
At the EPMl locus haplotypes were constructed at D21S2040/D21S1259/D21S1912 (figure
3.5). The haplotypes of two affected children (II!:8 and Iil:9), of individual II:7 were
determined as 2/4/2, no genotype was generated at D21S1259 for the third affected child
(II!:7), the haplotype constructed for the latter individual was 2/-/2 (figure 3.5). It is possible
that the affected father (II:7), passed the alleles 2/4/2 to his affected children because the phase
in the father could also be deduced as 2/412. In the other branch of the family, the haplotypes
of the affected children of individual II:3 (il!:3 and II!:5) could be deduced as 2/2/2 and 2/-/6,
respectively. The results obtained with the haplotype analysis identified no definitive unique
disease-associated haplotype at the EPMllocus.
3.1.3.2 Haplotype analysis at the chromosome Sp locus
The construction of haplotypes at the chromosome 8 locus showed that the affected children
(II!:7, Iil:8 and Iil:9) of the affected father (II:7) shared the same haplotype 6/2/4 in the order
shown in figure 3.6. This combination of alleles at these three linked markers is also possible
in the affected father. In the other branch of the family, the haplotypes of the affected children
of individual II:3 were 2/3/4 and 6/3/4 in the order indicated in figure 3.6. Thus, there were no
specific disease-associated haplotype shared by all the affected individuals.
3.1.4 Two Point LOD scores
Two point LOD scores were generated using the M-LINK program of the linkage computer
package (Lathrop and Lalouel 1984). A LOD score for each marker locus tested was obtained
and these are shown in table 3.1; at all three candidate loci tested, significantly negative LOD
scores were generated. At the EPMl locus, LOD scores of -14.24, -12.83 and -6.82 were
generated at the marker loci D21S2040, D21S1259 and D21S1912, respectively, at e = 0.00
(Table 3.1). At the chromosome 8 locus, LOD scores of 0.69, -4.46 and 0.68 were generated at
the DNA markers D8S504, D8S264 and D8S1781, respectively, at e = 0.00 (Table 3.1). A
LOD score of -14.50 was generated at e = 0.00, at the DRPLA locus (Table 3.1).
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These highly negative LOD scores generated at the tested loci clearly exclude these loci as
cause of the disease in pedigree 201.
3.2. NEW AND EXTENDED PEDIGREES
During the course of the study, one new family in whom this form of FME segregates was
identified, and was later designated pedigree 202 (figure 3.7). In addition the original family,
pedigree 201, was extended (figure 3.8). However, due to time constraints no further analysis
was performed in these families during the present study.
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1:31:1 1:2
II
11:1 11:2 11:3 11:4 11:5 11:6 11:7 11:8 11:9 1110 11:11 11:12
D21S2040 2 2 I 2 I mlD21S1259 5 2 5 2 5 3 0 MaleD21S1912 6 7 2 7 6
0 Female•• Affected~0 Unaffected.6 Deceased.... ProbandIII • •111:1 111:2 111:3 111:4 111:5 111:6 Jr 111:7 111:8 111:9 DO Not studied
D21S2040 I I W' m' I m' m' m'D21S1259 5 5 4 4D21S1912 6 7 6 6 3 3 3
Fig. 3.5 Pedigree 201 showing the haplotypes inherited at the EPM1 locus. Haplotypes are
shown below each individual in the order indicated to the left of the pedigree. Clinically
affected individuals were diagnosed according to the criteria stipulated in section 2.2.1. The
names of the marker loci used in the construction of the haplotype are indicated, to the left of
the pedigree, in centromeric-telomeric order, from top to bottom. The most likely haplotypes
of the affected individuals are boxed.
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1:21:1 1:3
II
11:1 11:2 11:3 11:4 11:5 11:6 11:7 11:8 11:9 11:10 11:11 11:12
D8S504 3 3 2 3 2 6 m'D8S264 5 6 9 8 2 8 3 MaleD8S1781 2 2 1 2 2 00 Female•• Affectedi~UnaffectedDeceased
Proband
III ~.
DO Not Studied111:1 111:2 111:3 111:4 111:5 111:6 1:7 111:8 111:9
D8S504 3 3
OJ' m' 2 3 m' m' mlD8S264 9 5 5 5 2 5 6 5 3D8S1781 4 2 2 2 1 2 1 2
Fig. 3.6 Pedigree 201 showing the haplotypes inherited at the chromosome 8 locus.
Haplotypes are shown below each individual in the order indicated to the left of the pedigree.
Clinically affected individuals were diagnosed according to the criteria stipulated section 2.2.1.
The names of the marker loci used in the construction of the haplotype are indicated, to the left
of the pedigree, in telomeric-centromeric order, from top to bottom. The most likely
haplotypes of the affected individuals are boxed.
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Table 3.1 Pairwise two point LaD scores between FME and the causative loci of the 3
candidate forms of epilepsy, namely EPM1, DRPLA and the chromosome Sp locus.
CANDIDATE LaD scores derived at (8)
LOCI
Markers 0.00 0.01 0.05 0.10 0.20 0.30 0.40
EPMl
D21S2040 -14.24 -l.92 -0.65 -0.21 0.06 0.08 0.03
D21S1912 -12.83 -0.94 -0.29 -0.06 0.09 0.09 0.04
D21S1959 -6.82 -0.65 -0.05 0.13 0.18 0.12 0.04
DRPLA
CAG repeat -14.50 -4.13 -2.15 -l.32 -0.58 -.23 -0.05
Chromosome
Sp locus
D8S504 0.69 0.67 0.60 0.51 0.33 0.17 0.04
D8S264 -4.46 -2.02 -0.75 -0.30 -0.01 0.04 0.01
D8S1781 0.68 0.66 0.56 0.45 0.25 0.10 0.02
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11:2 11:1 11:611:3 11:4 1113 11:511:14
III
111:12 111:13
106
11:7 11:8 11:9 11:10 11:12
111:2 111:1 111:4 111:5 111:6 111:7 111:8 111:9 111:10 111:11 111:14
Maleo
o
DO
Female
Unaffected
•• Affected
JZ[ " Deceased<> Sex unknown
Fig. 3.7 Pedigree 202, the new family identified in whom FME segregates. Clinically
affected individuals are diagnosed according to the criteria stipulated in section 2.2.1.
Individual identity numbers are shown under each individual.
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Fig. 3.8 Extended pedigree 201 in whom FME segregates. Clinically affected individuals
are diagnosed according to the criteria stipulated in section 2.2.1.
o Male
o Female
GI (Ï) Unaffected
•• Affected
jZI' ~ Deceased
107
Stellenbosch University http://scholar.sun.ac.za
108
LQTS
3.3. FOUNDER MUTATION SCREENING
As mentioned earlier, all South African families of Afrikaner descent in which LQTS studies
were performed previously harboured the same mutation, namely the Ala212Val mutation in
the KVLQTJ gene (de Jager et al., 1996). Consequently, the approach in the present study was
to screen for the founder mutation in all new probands referred to our group with the clinical
diagnosis ofLQTS.
The Ala2l Val mutation is situated in the Sê-Pere region of the KVLQTl gene (figure l.14),
PCR-amplification of this region generated a 160bp product, which was normally cleaved into
two fragments of 130bp and 30bp by HhaI digestion (figure 3.9a). The presence of a C~A
transition at codon 212, in the case of the founder mutation, resulted in the loss of a HhaI
restriction enzyme site. Consequently, in an individual heterozygous for the founder mutation,
three fragments of 160bp, 130bp and 30bp were generated (figure 3.9a).
:1 a panel of twelve unrelated affected probands tested, the KVLQTl Ala212Val mutation was
present in four individuals, as is evident by the presence of the three fragments of 160bp,
130bp and 30bp, after HhaI digestion of the amplified PCR product (figure 3.9b). In eight of
the tested probands, only the 130bp and 30bp fragments were present, indicating the absence
of the founder mutation in these individuals (figure 3.9b). A DNA based diagnostic service
could be delivered in the four individuals who tested positive for the Ala212Val mutation.
Where possible, families were traced using the probands as a reference point, in order to,
firstly, deliver a diagnostic service to other family members who choose to have it, if the
KVLQTI Ala212Val mutation was present in the proband. Secondly, pedigrees were
constructed to provide the means to perform linkage analysis at four of the known LQTS loci
to determine the disease-causing locus in the remaining probands, in whom the Ala212Vai
mutation was absent.
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HhaI• ~ Wild type
130 30
~ Mutant
160
1 2 3 4 5 6 7 8 9 10 11 12 13 14
+--I60bp
+-- I30bp
• 30bp
Fig. 3.9 Founder mutation screening by ASREA in a panel of unrelated affected
individuals.
a) Diagrammatic representation of a HhaI restriction enzyme map of the Sé-Pere region of
KVLQTl showing the wild type and mutant expected fragment sizes in bp after restriction
enzyme digestion.
b) Panel of 12 probands tested for the KVLQTl Ala212val mutation with ASREA. LanesI-I2
contain the HhaI digested amplified Só-Pere region of twelve LQTS-affected probands,
lane 13 the positive control, HhaI digested S6 region of a LQTS affected individual
carrying the KVLQTl Ala212Val mutation. Lane 14: an undigested amplified S6 region of
KVLQTI. Individuals represented in lanes 2, 10, 11 and 12, indicated by the arrows below,
carry the Ala212Val mutation, as is evident by the presence of the three fragments of
160bp, 130bp and 30bp indicated by the arrows on the right. In individuals represented in
lanel, and lanes 3-9, the Ala212Val mutation was absent, as indicated by the presence of2
fragments of 130bp and 30bp.
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3.4. LINKAGE ANALYSIS STUDY
3.4.1 Family Study
Three pedigrees were constructed by tracing and contacting family members from the panel of
affected probands. The families were of three different population groups residing in South
Africa, namely, Mixed ancestry, Afrikaner and Indian descent. The pedigrees that were
subsequently constructed were designated pedigrees 167, 168 and 169 respectively (figures
3.10.1-3.10.3). The QTc measurements, an important criterion in the diagnosis ofLQTS, are
indicated on the family trees in figure 3.10.1-3.10.3. In figure 3.10.1 the exact QTc values of
only a few members were available, and the clinical data for the rest of the family only
indicated the disease status of the individuals as affected, unaffected or equivocal.
In pedigree 167, 25 individuals were genotyped, of whom four were affected and 21 were
unaffected (figure 3.10.1). In pedigree 168, six individuals were genotyped, of whom two were
affected and four were unaffected (figure 3.10.2). In pedigree 169, fourteen individuals were
genotyped, of whom four were affected and four unaffected, the remaining six were clinically
equivocal (figure 3. 10.3).
3.4.2 Genotypic Analysis
3.4.2.1 Mutation screening for the KVLQTl Ala212Vai mutation
In the three LQTS pedigrees constructed, mutation screening employing ASREA was
performed to screen for the KVLQTI Ala212Vai mutation, to deliver a DNA-based diagnostic
service in the remaining family members in the case where the Ala212Vai was present in the
proband. Screening for the Ala212Vai mutation was also performed in the families in whom
the Ala212Vai mutation was absent in the proband, in order to confirm that this mutation was
not responsible for the disease in any of the other family members.
In pedigree 167, the KVLQTI Ala212Vai mutation was absent in all affected members of this
family confirming the result obtained with the proband in whom the mutation was also absent
(figure 3.11.1). In pedigree 168 of Afrikaner descent, the KVLQTI Ala212Vai mutation was
present in the proband, as well as one other affected member. Three fragments of 160bp, 130
and 30bp were present in clinically affected members of the family after digestion of the
amplified S6 region with Hhal, however, only the two fragments of 130bp and 30 bp were
present in clinically unaffected individuals (figure 3.11.2). In pedigree 169 of Indian descent
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the Ala212Val mutation was absent in the proband, as well as the other affected members later
screened to confirm the latter result (results not shown).
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QTc(ms)
III
111:1 111:2 111:3 111:4 111:5 111:6 111:7 111:8 111:9 111:10 111:11 111:12 111:13 111:14 1I1:15,l11:16 111:17
QTc (ms)
IV
IV:1
v
V:1
112
401 431
IV:7 IV:8 IV:9 IV:10
0 Male
0 Female
• • Affected
IW® Unaffected.¢ Deceased
• Proband.JlIf
o 0 Not Studied
Fig. 3.10.1 Pedigree 167 of Mixed Ancestry in which the autosomal dominant form of
LQTS segregates. QTc values in the individuals who participated in the linkage analysis study
are indicated below each individual. Clinically affected individuals were diagnosed according
to the criteria stipulated in section 2 2.2. Individual identity numbers are shown under each
individual, these numbers will be used to refer to the study subjects in further analysis.
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I: 1 1:2
II
II: 1 11:2
QTc (rns) I
III
1
111:1
QTc (rns) .
111:2
11:3 11:4 11:5
388
11:6 11:7 11:10
0 Male
0 Female
II. Affected
fIJ@ Unaffected..... Proband
Not Studied00
11:8
548
11:9
111:3
511
111:4
453
111:5
415
111:6
453
Fig. 3.10.2 Pedigree 168 of Afrikaner descent in which the autosomal dominant form of
LQTS segregates. QTc values in the individuals who participated in the linkage analysis study
are indicated below each individual. Clinically affected individuals were diagnosed according
to the criteria stipulated in section 2 2.2.
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1:31:1
431
1:2
QTc (ms)
Fig. 3.10.3 Pedigree 169 of Indian descent in which the autosomal dominant form of
LQTS segregates. QTc values in the individuals who participated in the linkage analysis study
is indicated below each individual. Clinically affected individuals were diagnosed according to
the criteria stipulated in section 2 2.2. Individual identity numbers are shown under each
individual, these numbers will be used to refer to the study subjects in further analysis.
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III:16 IV:6 IV:5 IV:2 II:2 IV:3 III:7
1 2 3 4 5 6 7 8 9 10
200
164
150
94
72
+- 160bp
+-130bp
+- 30bp
Fig. 3.11.1 Founder mutation screening by ASREA in pedigree 167. Silver stained
polyacrylamide gel of the peR-amplified Só-Pere region of KVLQTJ digested with HhaI.
Lanel = lambda Psrl size marker; lane 2 = undigested amplified Sê-Pere region of KVLQTJ;
lane 3 = positive control; lane 4-10 = HhaI digested amplified Só-Pere region of clinically
affected and unaffected members of pedigree 167. Arrows below indicate the clinically
affected individuals and arrows on the right indicate the size of the fragments in bp.
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TI:8 III:4 ITI:5 III:6 TI!:3 TI:5
123456789
+- 160bp
+- 130bp
+- 30bp
Fig. 3.11.2 Founder mutation screening by ASREA in pedigree 168. Silver stained
polyacrylamide gel of the peR-amplified Só-Pere region of KVLQTl digested with HhaI.
Lanel = lambda PstI size marker; lane 2 = undigested amplified Só-Pere region of KVLQTl;
lane 3 = positive control; lane 4-9 = HhaI digested amplified Só-Pere region of clinically
affected and unaffected members of pedigree 168. Arrows below indicate the clinically
affected individuals and arrows on the right indicate the size of the fragments in bp.
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3.4.2.2 Genotypic Analysis employing DNA markers at four of the known LQTS loci
The disease-causing locus in pedigree 168 was identified as KVLQTl by genotypic analysis for
the founder mutation employing ASREA (figure 3.1l.2). However, in the other two pedigrees
the disease-causing locus remained to be elucidated. Consequently, due to genetic
heterogeneity seen in LQTS, four of the known loci, accounting for almost 90% of the known
cases ofLQTS, were analyzed by linkage analysis.
3.4.2.2.1 KVLQTllocus
The fact that the Ala212Vai mutation in the KVLQTl gene was absent in pedigree 167 and 169
does not exclude this candidate locus from being responsible for causing LQTS in these
families, as other mutations in this gene may be present. Thus, linkage analysis was performed,
with markers at this locus to determine if further mutation screening of KVLQTl was
appropriate. To this end, this locus was genotyped employing five polymorphic DNA markers;
TH, DllSl3l8, DllS860, DllSl323 and DllSl33l in bath these families (figure 3.12.1-
3.12.5 and 3.13.1-3.13.5). Representative inheritance patterns for the alleles at each of these
loci are shown in subsets of pedigree 167 (figures 3.12.1-3.12.5) and subsets of pedigree 169
(figures 3.13.1-3.13.5).
Analyzing the genotypes derived at marker locus TH in pedigree 167 showed that affected
individuals were homozygous for allele 4. However this genotype was also seen in two
unaffected individuals, (IIL7 and Ill:12; lanes 7 and 9) (figure 3.12.1). Allele 10 segregated
with the disease in the four affected individuals, as well as in two unaffected individuals (IIL7
and III: 12; lanes 2 and 4) at marker locus DllS13l8 (figure 3.12.2). At DllS860 the
genotypes of the affected individuals were 2/5, 2/4, 2/4 and 2/4, the two unaffected individuals
(III:7 and III:12 lanes 2 and 4) were homozygous for allele 2 (figure 3.12.3). The genotype of
the unaffected father in generation two, was 2/5, but the result was generated on an
autoradiograph other than the one shown in figure 3.12.3 (result not shown). Given the
genotype of the father and the children in generation three, it is possible to hypothesize that the
mother's genotype was 2/2 (figure 3.12.3). Allele 2 was present in all affected individuals,
however this allele was also seen in unaffected individuals, consistent with allele being present
in both parents. All affected individuals, as well as two unaffected individuals (II:3 and III: 10,
lanes 1 and 16), were homozygous for allele 3 at DllS1323 (figure 3.12.4). Three of the
affected individuals were homozygous for allele 2 at the DllS1331 DNA marker and the
remaining one's genotype was 2/5. Although allele 2 was present in all affected individuals,
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this allele was also seen in unaffected individuals who were heterozygous at this locus (IV:2,
V:I and II:8, lanes 8,9 and 16). Thus, in summary, in pedigree 167 at three of the tested loci
(TH, DllS1318 and DllS860) at the KVLQTllocus, alleles were shown to segregate with the
disease in all affected members, however, these alleles were also present in the same two
unaffected members (II:7 and III:I2) in each case. At the remaining two loci (D11S1323 and
D11S1331) all the affected also showed a specific allele that was present in all affected
individuals; however, this alleles was also present in other unaffected individuals.
In pedigree 169 no correlation was seen between the genotypes generated at the five tested loci
and the affected status of the study subjects. Analysing the TH locus showed that all affected
individuals had the genotype 2/3, however, this genotype was also seen in one equivocal
individual (II: 5, lane 6) and one unaffected individual (III: 5, lane 13) (figure 3.13.1). At the
D 11S1318 locus the genotypes of the affected individuals was 3/6, 3/7, 1/7 and 3/6, thus no
unique disease-associated allele was present at this locus in this specific family (figure 3.13 .2).
At the D 11S860 locus, three affected individuals were homozygous for allele 2, the fourth
affected member's genotype was 2/4, however, these genotypes were also present in
unaffected members of this family (figure 3.13.3). Three of the affected family members were
homozygous for allele 3 at the D11S1323 marker locus and the remaining one's genotype was
3/4. Although allele 3 is seen in all affected members, this allele was also present in unaffected
family members (figure 3.13.4). The genotypes of the affected family members at DNA
marker DIlS1331 were 4/4, 1/4, 1/4 and 4/4. Allele 4 was present in all affected members,
however, it does not segregate with the disease as this allele was also seen in unaffected
individuals. It was clear from the results obtained at the tested marker loci that there were no
specific allele at these marker loci that was solely present in the affected individuals and thus
could be segregating with the disease in this family.
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2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
II:4 II:8 II:7 II:3 II:9 II:2 III:7 III:IO III:12 UI:5 IlI:16 lV:5 lV:6 lV:2 lV:3 lV:4 V:l
1/2 1/1 1/1 2/4 -/- 4/5 4/4 2/5 4/4 2/4 -/- 4/4 4/4 2/5 4/4 1/3 3/4
~~ ~
Fig. 3.12.1 Autoradiograph showing alleles at the DNA marker TH in pedigree 167.
Assigned genotypes are indicated below each lane, designated allele numbers are shown on the
right. The number shown below each individual in the pedigree above the autoradiograph
corresponds to the lane number in which it is represented. The lower arrowheads indicate
affected individuals represented in the specific lane. (Note: representation of pedigree structure
has been modified to correspond with lane order).
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
III:!6 III:!2III:1O 1Il:7 III:5 IV:6 II:2 IV:5 IV:2 vt IV:3 1l:5 C IV:4 1l:4 II:8 Il:7 II:3 1l:9
7/10 S/IO tn S/lO sn 1/10 sn 1/10 sn 1/6 1/10 219 sn 2/6 217 219 219 sn 217
120
Fig. 3.12.2 Autoradiograph showing alleles at the DNA marker DIlS1318 in pedigree
167. Assigned genotypes are indicated below each lane, designated allele numbers are shown
on the right. The number shown below each individual in the pedigree above the
autoradiograph corresponds to the lane number in which it is represented. The lower
arrowheads indicate affected individuals represented in the specific lane. The allele numbers
are not in complete descending order as allele 9 and 10 were identified after assignment of the
other alleles. (Note: representation of pedigree structure has been modified to corr~spond with
lane order).
C = standard sample used to ensure continuity of allele assignment
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2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
III: 16 III: 12 III:10 1lI:7 IIl:5 IV:6 11:2 IV:5 IV:2 V:1 IV:3 II:5 C IV:4 11:3 II:4 11:7 11:8 11:9
2/5 2/2 2/5 2/2 2/2 2/4 -/- 2/4 4/5 4/5 2/4 2/2 5/5 3/5 2/2 2/2 2/2 2/2 2/2
Fig. 3.12.3 Autoradiograph showing alleles at the DNA marker DllS860 in pedigree 167.
Assigned genotypes are indicated below each lane, designated allele numbers are shown on the
right. The number shown below each individual in the pedigree above the autoradiograph
corresponds to the lane number in which it is represented. The lower arrowheads indicate
affected individuals represented in the specific lane. (Note: representation of pedigree structure
has been modified to correspond with lane order).
C = standard sample used to ensure continuity of allele assignment
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1 2 3 4 5 6 7 8 9 10 Il 12 13 14 15 16 17 18
II:3 11:7 11:8 II:9 IV:4 11:6 11:5 IV:3 v.i IV:2 IV:6 11:2 IV:5 1lI:5 IIl:7 III:lO 1lI:!2 IIl:!6
3/3 2/3 1/2 1/3 2/2 2/3 1/2 3/3 2/3 2/3 3/3• •2/3 3/3 2/3• 2/3 3/3 2/3 3/3•
Fig. 3.12.4 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
DllS1323 in pedigree 167. Assigned genotypes are indicated below each lane, designated
allele numbers are shown on the right. The number shown below each individual in the
pedigree above the auto radiograph corresponds to the lane number in which it is represented.
The lower arrowheads indicate affected individuals represented in the specific lane. (Note:
representation of pedigree structure has been modified to correspond with lane order).
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HI:lG C III:lO III:5 IV:G H:2 IV:5 IV:2 V:l IV:3 II:5 C IV:4 C II:7 II:8
7
~
2/5 3/4 3/5 3/5 2/2 4/5 2/2 2/4 2/7 2/2 3/5 3/4 3/7 3/3 3/5 2/5
Fig. 3.12.5 Autoradiograph showing alleles at the DNA marker DllS1331 in pedigree
167. Assigned genotypes are indicated below each lane, designated allele numbers are shown
on the right. The number shown below each individual in the pedigree above the
autoradiograph corresponds to the lane number in which it is represented. The lower
arrowheads indicate affected individuals represented in the specific lane. (Note: representation
of pedigree structure has been modified to correspond with lane order).
C = standard sample used to ensure continuity of allele assignment
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12 13 14
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II:2
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11:3 11:5 II:7 III:6 II:lO III:7 11:9 III:4 III:5 II: IlII:2 II: 1 III: 1
3/4 2/3 2/3
! !
2/3 2/3 2/3 3/4 2/5 4/5 2/4 3/3 2/3 1/3
Fig. 3.13.1 Autoradiograph showing alleles at the DNA marker TH in pedigree 169.
Assigned genotypes are indicated below each lane, designated allele numbers are shown on the
right. The number shown below each individual in the pedigree above the autoradiograph
corresponds to the lane number in which it is represented. The lower arrowheads indicate
affected individuals represented in the specific lane. (Note: representation of pedigree structure
has been modified to correspond with lane order).
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II:3 III:5 1II:4 II:1 III:1 II:2 II:11 1:2 III:6 II:7 II:9 III:7 II:10 II:5 C
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~3
~ll
3/6 3/11 3/3 3/7 1/7 1/7 3/11 3/10 3/6 3/6 10/6 10/11 7/11 3/6 3/7• •• •
Fig. 3.13.2 Autoradiograph showing alleles at the DNA marker DllS1318 in pedigree
169. Assigned genotypes are indicated below each lane, designated allele numbers are shown
on the right. The number shown below each individual in the pedigree above the
autoradiograph corresponds to the lane number in which it is represented. The lower
arrowheads indicate affected individuals represented in the specific lane. The allele numbers
are not in complete descending order as allele 10 were identified after assignment of the other
alleles. (Note: representation of pedigree structure has been modified to correspond with lane
order).
C = standard sample used to ensure continuity of allele assignment
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2 3 4 5 6 7 8 9 10 Il 12 13 14
1:2 II: 1 III: 1 II:2 II: 10 III:7 II:9 UI:6 II:7 C 11:5 C C 11:3
~4
2/4 2/2 2/2 2/2 2/2 2/4 2/4 2/2 2/2 -/- 2/2 2/2 2/3 2/4
Fig. 3.13.3 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
DllS860 in pedigree 169. Assigned genotypes are indicated below each lane, designated
allele numbers are shown on the right. The number shown below each individual in the
pedigree above the autoradiograph corresponds to the lane number in which it is represented.
The lower arrowheads indicate affected individuals represented in the specific lane. (Note:
representation of pedigree structure has been modified to correspond with lane order).
C = standard sample used to ensure continuity of allele assignment
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1 2 345 6 7 8 9 10 Il 12 13
II:3 IIU IlI:4 II:1 III:1 II:2 1:2 111:6 11:7 II:9 III:7 II:l 0 1I:5
3/3 3/3
~
2/3 3/3 3/3 3/3 2/3
~~
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~
Fig. 3.13.4 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
DllS1323 in pedigree 169. Assigned genotypes are indicated below each lane, designated
allele numbers are shown on the right. The number shown below each individual in the
pedigree above the autoradiograph corresponds to the lane number in which it is represented.
The lower arrowheads indicate affected individuals represented in the specific lane. (Note:
representation of pedigree structure has been modified to correspond with lane order).
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C I1:5 II:lO III:7 I1:9 I1:7 III:6 1:2 II:lI I1:2 I1I:l II: I III:4 III:5 I1:3
4/4 4/6 1/6 1/4 4/4 4/4 1/4 4/4 1/2 1/4.. .. 1/4 4/4 2/4 4/4.. ..
Fig. 3.13.5 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
DllS1331 in pedigree 169. Assigned genotypes are indicated below each lane, designated
allele numbers are shown on the right. The number shown below each individual in the
pedigree above the autoradiograph corresponds to the lane number in which it is represented.
The lower arrowheads indicate affected individuals represented in the specific lane. (Note:
representation of pedigree structure has been modified to correspond with lane order).
C = standard sample used to ensure continuity of allele assignment
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3.4.2.2.2 HERG locus
The HERG locus was genotyped at the single marker locus D7S636 and the representative
inheritance pattern of the alleles at this locus is shown in subsets of pedigree 167 in figure
3.14.l. Individuals III:16, IV:3, IV:5 and IV:6 are the affected individuals in pedigree 167. At
D7S636 the genotypes generated for these individuals are 7/11, 1/11, 7/8 and 8/11. The
assigned genotypes are displayed on the pedigree to ascertain Mendelian inheritance; no
specific allele segregating with the disease in this family was identified (figure 3.14.2)
The representative inheritance pattern of the alleles at the D7S636 locus is shown in subsets of
pedigree 169 in figure 3.15.1. The affected individuals in pedigree 169 are III: 1, II: 1, II:7 and
II:3, the genotypes generated for these individuals at D7S636 were 8/9, 4/9, 4/9 and 4/9,
respectively (figure 3.15.1). Allele 9 was present in all affected individuals, however, this
allele was also present in two equivocal family members (II:5 and Iil:4). The genotypes
generated at D7S636 in pedigree 169 are displayed on the pedigree to show the allelic
distribution of this marker in the family (figure 3.15.2).
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II:8 II:7 II:3 II:4 III:5 III:7 III:lO III:12 II:2 III:16 IV:7 IV:5 IV:6 IV:4 IV:3
2345678 9 10 Il 12 13 14 15
~ 11
1/6 1/6 6111 1/6 3111 6/7 6/7 3/6 3/7 7111 7/9 1111• • 7/8 8/9 8/11• •
Fig. 3.14.1 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
D7S636 in pedigree 167. Assigned genotypes are indicated below each lane, designated allele
numbers are shown on the right. The individual identity numbers are indicated above the lane
in which it is represented. The lower arrowheads indicate affected individuals represented in
the specific lane.
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11:1 11:6 11:7 11:9
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11:911:2 11:3
3 7 6 11
IL4
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II;;
3 11 2 2 1 6
III
N
111:5 111:17 111:19 111:19 111:24 111:25 111:26 111:27
3 11 7 6 7 6 3 6 7t] 2 11 2 3 2 3 2 3 2 3 2 3
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IV,%. IV:3 IV:4 IV:5 IV:6
9 7 8t] 8 9 lt] 8[]
V 0 Male
V,1 0 Female•• Affected
~~
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Deceased.... ProbandDO Not Studied
Fig. 3.14.2 Pedigree 167 showing the allelic distribution at the DNA marker D7S636 in
the individuals who participated in the linkage analysis study. The individual identity
number and assigned genotypes are indicated below each individual. Where it was possible to
deduce, the allele received from the affected parent is boxed. (Note: Pedigree 167 structure
was altered for LOD score analysis. Individual III:28 was not studied but is indicated in the
pedigree, as genotyping data was inconsistent with individual III: 17 being the father of IV:2).
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1:2 III:l II:l 11:2 11:7 11:5 II:3 11:9 III:6 II:lO 111:7111:4III:5 II:l1
1 2 3 4 5 6 7 8 9 10 11 12 13 14
'-1
Fig. 3.15.1 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
D7S636 in pedigree 169. Assigned genotypes are indicated below each lane, designated allele
numbers are shown on the right. The individual identity numbers are indicated above the lane in
which it is represented. The lower arrowheads indicate affected individuals represented in the
specific lane.
4/7 8/9 4/9 5/8 4/9 4/9 4/9 4/8 3/4 1/2 1/8 3/9 6/4 6/7...... ... ...
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I 1:31:1 1:2
47
II 11:11
11:1 11:2 11:3 11:4 11:5 11:6 11:7 11:8 11:9 11:10 7 64 9 5 8 4 9 4 9 4 9 4 8 I 2
0 Male
0 Female•• Affected~ @ Unaffected
y) Deceased
[TI (7) Equivocal
",.
Proband
III
111:1 111:2 111:3 111:4 111:5 111:6 111:7 0 09 8 3 9 6 4 3 4 8 I Not Studied
Fig. 3.15.2 Pedigree 169 showing the allelic distribution at the DNA marker D7S636 in those
individuals who participate in the linkage study. The individual identity number and assigned
genotypes are indicated below each individual
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3.4.2.2.3 seNSA locus
The SeN5A locus was genotyped at the marker locus D3S1298 and representative inheritance
patterns of the alleles at this locus are shown in subsets of pedigree 167 in figure 3.16.1. The
genotypes of the affected individuals were 2/8, 1/2, 2/3 and 1/8, thus there was no specific allele
that segregated with the disease, as can clearly be seen when these genotypes are displayed on the
pedigree (figure 3.16.2).
The autoradiograph showing the genotypes generated at D3S1298 in pedigree 169 is shown in
figure 3.17.1, the genotypes of the affected individuals were 6/8, 5/6, 8/9 and 8/9. No specific allele
is shown to segregate with the disease in this family at this marker locus, as can be seen when these
genotypes are displayed on the pedigree (figure 3.17.2).
3.4.2.2.4 Chromosome 4 locus
The chromosome 4 locus was genotyped at the single marker locus D4S402 and the representative
inheritance pattern of the alleles at this locus is shown in subsets of pedigree 167 in figure 3.18.1.
The genotypes generated for the affected individuals at D4S402 were 5/9, 5/6, 6/9 and 6/9 (figures
3.18.1). The assigned genotypes are displayed on the pedigree, and the fact that no specific allele
segregated with the disease in this family at this marker locus is clearly illustrated (figure 3.18.2).
The representative inheritance patterns of the alleles at the D4S402 locus is shown in subsets of
pedigree 169 (figure 3.19.1). The genotypes generated for the affected individuals at D4S402 were
5/6,2/5,6/7 and 6/7 (figure 3.19.1). When these genotypes are displayed on the pedigree, it can be
clearly seen that no specific allele segregated with the disease in this family (figure 3.19.2).
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Il:9 Il:8 Il:7 Il:3 II:4 Ill:5 Ill:7 m.io lli:12 II:2 lli:16 IV:7 IV:6 IV:5 IV:3 V:l IV:4
1 2 3 4 5 6 7 8 9 10 Il 12 13 14 15 16 17
2/4 2/4 2/4 2/8 2/8 2/8 3/8 3/7 2/7 7/8 2/8 7/8 1/2 2/3 1/8 1/8 8/8••••
Fig. 3.16.1 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
D3S1298 in pedigree 167. Assigned genotypes are indicated below each lane, designated allele
numbers are shown on the right. The individual identity numbers are indicated above the lane in
which it is represented. The lower arrowheads indicate affected individuals represented in the
specific lane.
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1:1 1:2
II
11:4 11:5 11:6 11:7 11:8 11:9
7 8 2 8 2 8 2 4 5 to 2 4 2 4 2 4
111:5
III
111:17 111:18 111:19 111:24 111:25 111:26 111:27
8 2 8 3 7 3 7 2 io 4 5 4 io 2 io 2 la 4 la 4
IV
IV:Z. IV:3 1V:4 1V:5 1V:6
7 8 1~ 8 8 3[j 1~
0 Male
V 0 Female•• AffectedV:1 ~;Unaffected1 8 Deceased
~
Proband
Not Studied
Fig. 3.16.2 Pedigree 167 showing the allelic distribution at the DNA marker D3S1298 in those
individuals who participate in the linkage study. The individual identity numbers and assigned
genotypes are indicated below each individual. Where it was possible to deduce, the allele received
from the affected parent is boxed. (Note: Pedigree 167 structure was altered for LOD score analysis.
Individual III:28 was not studied but is indicated in the pedigree, as genotyping data was
inconsistent with individual III: 17 being the father ofIV:2).
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1:2 II:1 III:l II:2 II:3 II:7 II:9 II:5 II:Il 11:10 III:7 III:6 1II:5 III:4
1 2 3 4 5 6 7 8 9 10 11 12 13 14
8/8 6/8 5/6 5/11AA 8/9 8/9 8/9 8/9 7/8 5/5 5/8 4/8 7/8 8/8A A
Fig. 3.17.1 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
D3S1298 in pedigree 169. Assigned genotypes are indicated below each lane, designated allele
numbers are shown on the right. The individual identity numbers are indicated above the lane in
which it is represented. The lower arrowheads indicate affected individuals represented in the
specific lane.
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111:1 111:2 111:3 111:4 111:5 111:6 111:7 0 Female6 5 8 8 7 8 4 8 8 5 •• Affected~ @ Unaffected
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Deceased
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0 0 Not Studied
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Fig. 3.17.2 Pedigree 169 showing the allelic distribution at the DNA marker D3S1298 in those
individuals who participate in the linkage study. The individual identity number and assigned
genotypes are indicated below each individual.
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II:9 II:8 II:7 11:3 II:4 III:5 1lI:7 III: 10 III: 12 II:2 III:6 IV:7 IV:6 IV:5 IV:4 IV:3
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
5/5 2/3 2/3 2/5 2/3 1/5 -1- 1/5 5/9 1/9 5/9 5/9 5/6 6/9 6/6 6/9.. .... ..
Fig. 3.18.1 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
D4S402 in pedigree 167. Assigned genotypes are indicated below each lane, designated allele
numbers are shown on the right. The individual identity numbers are indicated above the lane in
which it is represented. The lower arrowheads indicate affected individuals represented in the
specific lane.
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1:1 1:2
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11:4 11:5 11:6 11:7 11:8 11:9
7 8 2 8 2 8 2 4 5 10 2 4 2 4 2 4
111:5
III
111:17 111:18 111:19 111:24 111:25 111:26 111:27
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IV:~ IV:3 N:4 N:5 IV:6
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Fig. 3.18.2 Pedigree 167 showing the allelic distribution at the DNA marker D4S402 in those
individuals who participate in the linkage study. The individual identity number and assigned
genotypes are indicated below each individual. Were it was possible to deduced the alleles received
from the affected parent was boxed. (Note: Pedigree 167 structure was altered for LOD score
analysis. Individual III:28 was not studied but is indicated in the pedigree, as genotyping data was
inconsistent with individual III: 17 being the father ofIV:2).
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1:2 II: 1 III:l 11:2 11:7 II:3 11:5 11:9 1II:7 II:lO 1II:6 1II:4 1II:5
1 2 3 4 5 6 7 8 9 10 Il 12 l3
-1- 5/6 2/5 -1- 6/7 6/7 5/6 6/7 4/6 4/5 -1- 2/7 2/7
Fig. 3.19.1 Autoradiograph of a polyacrylamide gel showing alleles at the DNA marker
D4S402 in pedigree 169. Assigned genotypes are indicated below each lane, designated allele
numbers are shown on the right. The individual identity numbers are indicated above the lane in
which it is represented. The lower arrowheads indicate affected individuals represented in the
specific lane.
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Fig. 3.19.2 Pedigree 169 showing the allelic distribution at the DNA marker D4S402 in those
individuals who participate in the linkage study. The individual identity number and assigned
genotypes are indicated below each individual.
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3.4.3 Haplotype Analysis
3.4.3.1 Haplotype analysis at the KVLQTl locus
Haplotypes were constructed at the KVLQTl locus in pedigree 167 and pedigree 169 from the
genotypes generated at the five DNA markers analysed at this locus (figures 3.20 and 3.21).
Haplotype analysis at the KVLQTllocus in pedigree 167 indicated that the four affected individuals
III:16, IV:3, IV:5 and IV:6, shared the same haplotype, namely 4-10-2-3-2 at the DNA markers in
the order indicated in the figure, suggesting that this might be the disease-associated haplotype
(figure 3.20). However, this haplotype is also seen in two unaffected individuals (III:7 and 111:12).
The distance encompassed by this conserved haplotype is 8cM.
In pedigree 169, the disease status of the first generation is uncertain, this make it difficult to
determine from which side the disease is transmitted to the siblings in the second generation. In the
third generation, the haplotype of the affected child (III: 1) of individual II: 1 could clearly be
determined as 2/7/2/3/4 (figure 3.21). This haplotype was also seen in individual ILl (-/7/2/3/4);
however, it was absent in the remaining two affected individuals in this family, thus implying that
this is not the disease associated haplotype (figure 3.21).
3.4.4 Two Point LOD scores
Two point LOD scores were generated using the M-LINK program of the linkage computer
package (Lathrop and Lalouel 1984). A LOD score for each marker locus tested was obtained in
pedigree 167 and 169, respectively, and are shown in Table 3.2 and 3.3.
In pedigree 167, significant negative LOD scores of -3.13, -5.01 and -3.23 (8 = 0) were generated at
the HERG, SCN5A and the chromosome 4 loci, respectively (Table 3.2). An equivocal LOD score
ofO.92 (8 = 0) was generated at the KVLQTllocus with the DNA marker DIIS860 (Table 3.2). In
pedigree 169, significant negative LOD scores of -2.62, -2.71 and -2.68 were generated at
KVLQTl, SCN5A and the chromosome 4 loci, respectively at e = 0 (Table 3.3). An equivocal LOD
score ofO.20 was generated at the HERG locus with D7S636 at e = 0 (Table 3.3).
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11:3 116 11:7 11:8 11;9
TH 4 5 4 2 1 2 1 1 3 5 1 1 1 I
DllSI3I8 5 7 5 7 2 7 2 9 3 4 2 9 2 9
DllS860 2 5 2 2 2 2 2 2 2 4 2 2 2 2
DIISI323 2 3 3 3 2 I 2 I 2 3 2 3 2 I
DIISI33I 4 5 2 2 2 3 5 3 2 4 3 5 2 5
111:5 111:16 111:17 111:18 11119 111:24 111:25 111:26 HI:2i
TH 4 2 4 4 5 2 4 4
;~
3 I 5 I 3 I 5 I 5 1 5 1
DllSJ3I8 5 7 5 10 7 7 5 10 4 2 3 9 4 2 3 2 3 9 3 9
DllS860 2 2 2 2 2 5 2 2 5 2 2 2 42 4 2 2 2 4 2 4 2
DIISI323 2 3 2 3 3 3 2 3 3 3 3 2 3 I 2 I 3 2 3 2
DIISI33I 3 5 3 5 5 2 2 3 4 5 4 3 2 3 4 5 4 5
IV1.
~
:~TH 2 5 I 3 4 4DIISI3I8 3 7 2 6 I 10 110DllS860 4 5 3 5 4 2 4 2
DIISI323 2 3 2 2 3 3 3 3
DIISI33I 2 4 3 7 2 2 2 2
V:l 0 Male
43 0 FemaleTH 1 6
DIISI3I8 4 5 •• AffectedDllS860 2 3
~~
DIISJ323 2 7 Unaffected
DIISI33I Deceased... Proband
0 0 Not Studied
Fig. 3.20 Haplotypes across the KVLQTl locus in pedigree 167. Haplotypes are indicated below
each inidvidual, and the disease-associated haplotyped is boxed. The names of the marker loci used
in the construction of the haplotype are indicated, to the left of the pedigree, in telomeric-
centromeric order, from top to bottom. The disease-associated haplotype is boxed with a solid line
in the affected indviduals and a dotted line in the two unaffected individuals also sharing this
disease-associated haplotype. (Note: Pedigree 167 structure was altered for LOD score analysis.
Individual III:28 was not studied but is indicated in the pedigree, as genotyping data was
inconsistent with individual III: 17 being the father ofIV:2).
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Fig. 3.21 Haplotypes across the KVLQTI locus in pedigree 169. Haplotypes are indicated below
each inidvidual, and where it was possible the haplotype received from the affected parent was
boxed. The names of the marker loci used in the construction of the haplotype are indicated, to the
left of the pedigree, in telomeric-centromeric order, from top to bottom. Where possible the
haplotype received from the affected parent was boxed.
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Table 3.2 Pairwise two point LOD scores between LQTS and polymorphic markers at the
KVLQTl, HERG, SCN5A and chromosome 410ci in pedigree 167.
CANDIDATE LOD scores derived at 8
LOCUS
Marker locus 0.00 0.01 0.05 0.10 0.20 0.30 0.40
KVLQTl
DllS1318 0.25 0.29 0.40 0.46 0.43 0.29 0.10
TH -0.27 -0.18 -0.06 0.20 0.27 0.19 0.07
DllS1323 -0.11 -0.09 -0.03 0.02 0.04 0.03 0.01
DllS860 0.92 0.91 0.87 0.79 0.58 0.34 0.11
DllS1331 0.09 0.10 0.10 0.10 0.06 0.02 -0.00
HERG
D7S636 -3.12 -1.11 -0.38 -0.09 0.11 0.13 0.07
,
SCN5A
D3S1298 -5.01 -2.00 -1.14 -0.71 -0.28 -0.08 0.00
Chromosome 4
Locus
D4S402 -3.23 -1.24 -0.51 -0.20 0.04 0.10 0.05
Figures in bold highlight the weakly positive LOD scores generated at DllS860 in pedigree167
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Table 3.3 Pairwise two point LOD scores between LQTS and polymorpic markers at the
KVLQTl, HERG, SCNSA and chromosome 410ci in pedigree 169.
CANDIDATE LOD scores derived at 8
LOCI
Marker locus 0.00 0.01 0.05 0.10 0.20 0.30 0.40
KVLQTl
DllSl318 -2.62 -1.73 -0.09 -0.79 -0.46 -0.25 -0.10
TH -0.57 -0.56 -0.50 -0.43 -0.29 -0.16 -0.07
DIISl323 -0.43 -0.43 -0.42 -0.37 -0.25 -0.14 -0.06
DIIS860 -0.62 -0.61 -0.54 -0.44 -0.24 -0.10 -0.02
DUSl331 -0.29 -0.30 -0.31 -0.33 -0.29 -0.18 -0.07
HERG
D7S636 0.20 0.18 0.13 0.1 0.06 0.02 -0.02
I
SCNSA
D3S1298 -2.71 -1.53 -0.88 -0.60 -0.34 -0.19 -0.08
Chromosome 4
locus
D4S402 -2.68 -1.15 -0.50 -0.25 -0.06 0.00 0.01
Figures in bold highlight the weakly positive LOD scores generated at D7S636 in pedigree169
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3.5. MUTATION SCREENING
The results obtained through linkage analysis and haplotype analysis identified the KVLQTl gene as
the plausible candidate locus for the disease in pedigree 167. Consequently, PCR-SSCP mutation
screening analysis was initiated to search for the disease-causing mutation in this gene in this
family.
3.5.1 PCR-SSCP Analysis
In pedigree 167, the partial SI and the S2-S6 region of the KVLQTl gene were screened for known
and novel mutations by PCR-SSCP analysis using four different gel conditions namely; 5% and
10% polyacrylamide gels, with and without glycerol. Representative results of PCR-SSCP analysis
are shown in figures 3.22.1-3.22.4.
No sequence variations were detected in the regions investigated employing PCR-SSCP analysis, on
10% polyacrylamide gels with and without glycerol and 5% polyacrylamide with glycerol (figure
3.22.1-3.22.3). However, a mobility shift was detected in the S2-S3 region of KVLQTl on a 5%
polyacrylamide gel without glycerol in the three affected members of pedigree 167, which was
absent in the two unaffected members analyzed under this condition (figure 3.22.4). The PCR-SSCP
analysis of affected members of this family, as well as appropriate controls, was repeated using the
same gel condition, which again revealed the mobility shift, which was also confirmed on an MDE
gel (results not shown). After the presence of the mobility shift was confirmed following
"
reamplification and a second PCR-SSCP analysis, the region was sequenced and the result obtained
for an affected individual was compared with an unaffected individual and the normal published
sequence of the S2-S3 region of KVLQTl (figure 3.23). A G--7A transition was detected in the
intronic sequence in an affected individual (figure 3.23).
To determine the frequency of this G--7A transition detected in the affected individuals of pedigree
167, PCR-SSCP analysis was empoyed in 40 unaffected, unrelated control individuals of Mixed
ancestry. Three of the 40 subjects analyzed showed this polymorphism (results not shown).
Genotypic analysis was also performed with this polymorphism in pedigree 167. This mobility shift
was detected in all affected members of pedigree 167, as well as the two unaffected members who
shared the disease-associated haplotype; however, this mobility shift was also seen in an additional
unaffected individual (II:7). No other SSCP variants were detected in any of the regions analyzed.
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Fig. 3.22.1 PCR-SSCP analysis of the S2-S6 regions of KVLQTl in pedigree 167 on a 10%
polyacrylamide gel with glycerol. The amplified S2-S6 regions of KVLQTl gene were
electrophoretically separated on a 10% polyacrylamide gel with glycerol at 4°C and visualized by
silver staining. At each region, as indicated by the brackets,S individuals were analyzed except for
the S5-Pore region where 4 individuals were analyzed. Each region was labeled lane 1-5,
representing the 5 individuals analyzed. Lane 1= unaffected individual, lanes 2-4 = affected
individuals and lane = 5 unaffected individual. At the S5-Pore region lanes 1-2 represent unaffected
individuals and lanes 3-4 affected individuals.
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Fig. 3.22.2 PCR-SSCP analysis of the S2-S6 regions of KVLQTl in pedigree 167 on a 10%
polyacrylamide gel without glycerol. The amplified S2-S6 regions of KVLQTI gene were
electrophoretically separated on a 10% polyacrylamide gel without glycerol at 4°C and visualized
by silver staining. At each region, as indicated by the brackets, 5 individuals were analyzed except
for the Pore-S6 region where 6 individuals were analyzed. Each region was labeled lane 1-5,
representing the 5 individuals analyzed. Lane 1= unaffected individual, lanes 2-4 = affected
individuals and lane 5 = unaffected individual. At the Pore-S6 region, lane 6 = individual where
Ala212Val mutation is present. The arrow indicates the mobility shift caused by the C~T transition
that resulted in the Ala212Val mutation in KVLQT1. At the Pore-S6 region lane 1-2 represent
unaffected individuals and lanes 3-5 affected individuals
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Fig. 3.22.3 PCR-SSCP analysis of the S2-S6 regions of KVLQTl in pedigree 167 on a 5%
polyacrylamide gel with glycerol. The amplified S2-S6 regions of KVLQTl gene were
electrophoretically separated on a 5% polyacrylamide gel with glycerol at 4°C and visualized by
silver staining. At each region, as indicated by the brackets, 5 individuals were analyzed Each
region were labeled lane 1-5, representing the 5 individuals analyzed. Lane 1= unaffected
individual, lanes 2-4 = affected individuals and lane 5 = unaffected individual. At the Pore-S6
region lane 1 = individual were Ala212Vai mutation is present, lanes 2-3 = unaffected individuals
and lanes 4-6 = affected individuals. The arrow indicates the mobility shift caused by the C--t T
transition that resulted in the Ala212Vai mutation in KVLQTl.
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Fig. 3.22.4 PCR-88CP analysis of the 82-86 regions of KVLQTl in pedigree 167 on a 5%
polyacrylamide gel without glycerol.
a) The amplified S2-S6 regions of KVLQTJ gene were electrophoretically separated on a 10%
polyacrylamide gel with glycerol at 4°C and visualized by silver staining. At each region, as
indicated by the brackets, 5 individuals were analyzed, except for the S4 region where 4
individuals were analyzed. Each region was labeled lane 1-5, representing the 5 individuals
analyzed. Lane 1= unaffected individual, lanes 2-4 = affected individuals and lane 5 =
unaffected individual. At the Pere-Só and S4 regions the lane order differs, Pore-So region lane
1 = individual where Ala212Vai mutation is present, lanes 2-3 = unaffected individuals and
lanes 4-6 affected individuals. The arrow (1) indicates the mobility shift caused by the C-+ T
transition that resulted in the Ala212Val mutation in KVLQTJ. In the S4 region, lanes 1-2
represents unaffected individuals and lanes 3-4 affected individuals.
b) Enlargement of PCR-SSCP analysis of the S2-S3 region of KVLQTl in pedigree 167. Lanel=
affected individual lane 2 = unaffected control. The arrow (2) indicate the mobility shift caused by
the G-+ A transition in the intronic sequence of a heterozygous individual.
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Fig. 3.23 Sequence variation identified in the S2-S3 region of an affected individual of
pedigree 167, compared with the sequence of an unaffected individual and the normal
published sequence of this region.
(a) Partial sequence of the non-coding strand of the S2-S3 region of KVLQTl in an affected and
unaffected individual showing the G-+A transition in the intronic sequence of the affected
heterozygous (G/A) individual compared to the sequence found in a unaffected homozygous (GIG)
individual.
(b) Normal published cDNA sequence of the S2-S3 domain of KVLQTl. The coding strand is
indicated in black and the positions of the introns are shown with solid arrowheads. The non-coding
strand is shown in green and red, the red shows the sequence of the exon encoding the S2-S3 region
and the S2 and S3 transmembrane segments are underlined.
(c) Sequence of the non-coding region of the S2-S3 domain determined in an affected individual of
pedigree 167. Positions of the intron or exon boundaries are indicated with a solid arrowhead, the
G-+A transition in the intronic sequence is indicated with a clear arrowhead and the S2 and S3
transmembrane segments are underlined. The partial sequence shown in (a) is boxed. The red shows
the sequence of the exon and the blue shows the intronic sequence.
(a) Partial sequence of the non-coding strand of the S2-83 region in an affected and
unaffected individual
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(b) Normal published eDNA sequence:
5'TATGCCGCCCTGGCCACGGGGACTCTCTTCTGGATGGAGATCGTGCTG
3'ATACGGCGGGACCGGTGCCCCTGAGAGAAGACCTACCTCTAGCACGAC
S2
GTGGTGTTCTTCGGGACGGAGTACGTGGTCCGCCTCTGGTCCGCCGG
CACCACAAGAAGCCCTGCCTCATGCACCAGGCGGAGACCAGGCGGCC
CTGCCGCAGCAAGTACGTGGGCCTCTGGGGGCGGCTGCGCTTTGCCC
GACGGCGTCGTTCATGCACCCGGAGACCCCCGCCGACGCGAAACGGG
'fGGAAGCCCATTTCCATCATCGACCACATCGTGGTCGTGGCCTCCATGG
CCTTCGGGTAAAGGTAGTAGCTGGAGTAGCACCAGCACCGGAGGTACC
S3
TGGTCC TC TGCGTGGGCTCCAAG 3'
ACCAGGAGACGCACCCGAGGTTC 5'
(c) DNA Sequence of non-coding strand determined in affected individual:
'f5'gacctttggaccgcagggcagcatggactcacCGATGATGGAAAT GGCTTCC
S3
GGGCAAAGCGCAGCCGCCCCCAGAGGCCCACGTACTTGCTGCGGCAG
CCGGCGGACCAGAGGCGGACCACGTACTCCGTCCCGAAGAACACCAC
S2g
=C~A=GC=-"-,A=C~:..:o..=--,,,-==tgcaggaacagagtggacgct ctgcag caggctcg3'
S2~------------~
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3.5.2 ASREA in KVLQTl
Four of ten KVLQTl mutations described by Wang et al., (1996) which affected restriction enzyme
sites (Table 2.3) were screened for by ASREA in pedigree 167. These mutations were the Ala49Pro
and Argó lGlu, mutation both situated in the S2-S3 region, and the Va112SMet mutation in the S4-
SS region. The fourth mutation was the Ala212Vai mutation. The screening for the latter mutation
has already been described in section 3. 11.1, as this is the South African founder mutation.
For two of these mutations, namely Arg61Glu and Va112SMet, the presence of the mutation
introduced a PvuII and a Styl site, respectively. Thus, in the absence of the mutation, after digestion
with the respective restriction enzymes, only the undigested PCR fragment would be generated. To
ensure that the enzyme was active during the digestion, ideally an internal control should be
included in the reaction. For one of these mutations, Arg61Glu it was possible to design an internal
control to test the activity of the enzyme. Diluted lambda DNA was included in the reaction mixture
prior to digestion. To find a control for the Va112SMet mutation proved troublesome, as /...DNA
digested with Styl generated too many bands, some of which overlap with the expected fragment
sizes generated in the presence of Val 12SMet. Consequently, no control was included for screening
the Val12SMet mutation.
Negative controls, samples amplified from unaffected LQTS individual, were included on each gel.
Ideally, a positive control, a sample amplified from an affected person carrying the mutation in
question, would be useful to compare the generated fragment sizes and activity of the enzyme. This
type of control was included in the analysis of the Ala212val mutation, however, such samples were
not available for the other three mutations. The expected fragment sizes of both the mutant and the
wild type alleles were determined with the aid of the computer program Genepro, prior to PCR-
based restriction enzyme analysis. This, and the inclusion of a molecular weight marker on each
polyacrylamide gel, allowed the investigator to gauge the fragment sizes and the compare them with
those predicted.
3.5.2.1 Ala49Pro mutation in S2-S3 region
The PCR amplification of the S2-S3 region of KVLQTl resulted in a 240bp product normally
cleaved into two fragments of 160bp and 80bp by digestion with Nael. The presence of the G-?C
mutation causes a Ala-el-re substitution at codon 49, that would result in the loss of a Nael
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restriction enzyme site. Therfore, in an individual heterozygous for this mutation an additional
undigested 240bp fragment would be generated.
In the affected members of pedigree 167 analyzed, the G~e mutation in codon 49 was not present,
as is evident by the complete digestion of the peR product into two fragments of 160bp and 80bp
(figure 3.24).
3.5.2.2 Arg61Glu mutation in the S2-S3 region
The G~A transition causing the Arg~Glu substitution at codon 61 would introduce a Pvull
restriction enzyme site into the S2-S3 region of KVLQTl. Thus, in the absence of the mutation, only
the undigested 240bp Pf'R amplified product would be generated after digestion with PvuII, while
in an individual heterozygous for this mutation three fragments of 240bp, 150bp and 90bp would be
generated. In order to check that the enzyme was active during the digestion, an internal control of A
DNA was included in each sample digested with PvuIL
In all the individuals analyzed for the Arg61 Glu mutation, only the undigested 240bp fragment was
generated indicating the absence of the mutation, the enzyme's activity was indicated by the
digested A DNA fragments (figure 3.25).
3.5.2.3 Val125Met mutation in the S3-S4 region
The G~A transition in codon 125 would introduce a Styl restriction enzyme site into the S3-S4
region of KVLQT1. In the absence of the mutation, a single 120bp fragment would be generated
after digestion with Styl, while, in an individual heterozygous for the mutation, three fragments of
120bp, 50bp and 70bp would be generated.
However, in all individuals analyzed for the Val125Met mutation in S3-S4 region only the 120bp
fragment was generated indicating the absence of this mutation (figure 3.26).
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Figure 3.24 Allele specific restriction enzyme analysis (A8REA) of the reported Ala49Pro
mutation in the 82-83 region of KVLQTl. A representative 12% polyacrylamide gel of Nael
restriction enzyme digestion of the PCR amplified S2-S3 region of affected and unaffected
members of pedigree 167. Lane 1: marker, lane 2: undigested S2-S3 PCR amplified fragment, lanes
3-6: affected individuals and lanes 7-10 unaffected individuals
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Figure 3.25 Allele specific restriction enzyme analysis (ASREA) of the reported Arg61Glu
mutation in the S2-S3 region of KVLQTl. A representative 12% polyacrylamide gel of PvuII
restriction enzyme digestion of the PCR amplified S2-S3 region of affected and unaffected
members of pedigree 167. Lane l: A PstI, lanes 2-4: affected individuals, lanes 5-6 unaffected
individuals and lane 7: undigested S2-S3 PCR amplified fragment
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Figure 3.26 Allele specific restriction enzyme analysis (ASREA) of the reported Vall25Met
mutation in the S4-S5 region of KVLQTl. A representative 12% polyacrylamide gel of Styl
restriction enzyme digestion of the PCR amplified S4-S5 region of affected and unaffected
members of pedigree 167. Lanes 1-4: affected individuals, lanes 5-8: unaffected individuals, lane 9:
undigested S3-S4 PCR amplified fragment and lane 10: )"PstI.
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EPILEPSY
4.1 Study Design
In this study, the molecular genetic technique of linkage analysis was used to test if a rare form of
myoclonic epilepsy (F~) was the same as anyone of three candidate types of the disease, for
which the causative genes or locus had been determined. These candidate loci were assessed for
their possible involvement in the development of F~ by the generation of two point LOD scores
between the disease phenotype and DNA markers at these three test loci.
The candidate forms of epilepsy were chosen based on their clinical similarities with that exhibited
by F~. The clinical features were used as a criterion for candidate selection, because the diagnosis
of epilepsy is clinical and the classification of individual epileptic syndromes into different entities
is based on defining similarities in the type of seizure, age of onset, associated neurologic and other
clinical signs, family history, EEG findings and prognosis (Scheuer and Pedley, 1990). A form of
epilepsy linked to chromosome 8p (Berkovic, personal communication), DRPLA (Smith, 1958) and
EPM 1 (Berkovic, 1986) were identified as plausible candidates. Genetic markers closely linked to
these candidate loci were employed, to determine if the abnormal gene in F~ is the same, or in the
same chromosomal location, as in the candidate forms of epilepsy.
4.2 Linkage Analysis Study
The statistical evidence provided by the linkage analysis results indicated that the plausible
candidates tested are not the disease-associated loci in the family investigated.
At the EPMllocus, two point LOD scores of -14.24, -12.83 and -6.82 were generated at the DNA
markers D21S2040, D21S1912 and D21S1959, respectively (Table 3.1). These three markers were
completely linked to the EPMllocus in the study performed by Virtaneva et al., (1996). However,
the highly negative LOD scores generated at these markers in pedigree 201 definitely excluded this
candidate locus from being involved in F~. At DNA marker D21S2040, a LOD score of -1.92
was generated at e = 0.01 (Table 3.1), this exclusion covers a range of approximately 1%
recombination on either side of D21S2040, which corresponds to an excluded genetic distance of
lcM telomeric and centromeric to the latter marker.
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The triplet repeat in the atrophin gene was used to analyze the DRPLA locus. The choice of this
marker in the analysis was twofold, firstly, to determine if this triplet was expanded in FME
patients, as is the case in DRPLA (Koide et al., 1994; Nagafuchi et al., 1994) and, secondly, to act
as a genotypic marker for use in linkage analysis. The latter approach would allow the investigation
of the possible involvement of mutations other than the triplet repeat expansion in the atrophin gene
in the development of FME. However, this triplet repeat was not expanded in FME patients as no
single larger band was seen in affected individuals that was not present in unaffected individuals. In
fact, only two alleles, in the normal size range were seen in all affected individuals (figure 3.4.1).
The two point LOD score derived at the DRPLA locus was -14.50 at e = 0.00, thus excluding
DRPLA as the causative locus; furthermore, at e = 0.05, a LOD score of -2.15 was generated
(Table 3.1), based on this, approximately 5cM telomeric and centromeric to this marker could be
excluded from involvement in FME.
The two point LOD score generated at the DNA marker D8S264, to which linkage was found in the
Japanese family (Berkovic, personal communication), was -4.46 at e = 0.00, excluding linkage of
this marker locus to FME (Table 3.1). A LOD score of -2.02 was generated at e = 0.01 at D8S264
(Table 3.1), this corresponds to exclusion of 1% recombination on both sides of the marker and thus
an exclusion of approximately lcM telomeric and centromeric to D8S264. The two other markers
analyzed at this locus, D8S504 lcM telomeric to D8S264 and D8S1781 2cM centromeric to
D8S264, generated equivocal LOD scores of 0.69 and 0.68, respectively (Table 3.1). The latter
result could possibly be because the alleles of these markers were not very informative in this
pedigree.
4.3 Is FME a new clinical and genetic entity?
The three candidate epilepsy syndromes investigated were selected because they were the most
closely related to FME with respect to their clinical presentation. The mode of inheritance and the
age of onset of the disease made DRPLA a plausible candidate for FME. A form of epilepsy linked
to chromosome 8p was considered as candidate based on personal communication with Professor
Berkovic.
The form of epilepsy investigated in the present study was considered to be a form of PME (Carr,
personal communication) ..At least five disease groups account for most cases of PME (Berkovic,
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1986). However, based on characteristic features, four of the five disease groups could definitively
be excluded from being candidates for FME. Sialidosis type 1 was excluded based on the fact that
the characteristic clinical feature of macular cherry-red spots in fundus and painful burning hands
and feet associated with this disease were absent in FME patients. The age of onset of neuronal
ceroid-lipofuscinoses, 2-5 years in the late infantile form and 4-10 years in the juvenile type also led
to its exclusion as candidate for FME. The mode of inheritance, autosomal recessive, and the
fatality, death within 5-10 years after the first symptom, ruled out Lafora' s disease as candidate. In
MERRF the inheritance is consistent with mitochondrial (maternal) transmission, thus cancelling
out this candidate, as this mode of transmission is not seen in FME. Unlike the preceding forms of
PME, the candidature of EPMl could not be completely ruled out based on any characteristic
clinical feature. The age of onset of the disease, 6-18 years, and the fact that it is not a fatal form of
PME compared with the other forms of PME, placed it in an equivocal area where its candidacy
could not definitively be ruled out or confirmed. Superficially, its involvement as cause of FME is
unlikely, as EPMl is a recessive disorder and the mode of inheritance of FME is autosomal
dominant. However, recent findings have shown that mutations in the same genes could be
responsible for both the autosomal recessive and the autosomal dominant form of the LQTS (Wang
et al., 1996a; Neyroud et al., 1997; Splawski et al., 1997 ; Schulze-Bahr et al., 1997). As described
in the present review, the RWS and JLNS forms of LQTS share many of the same clinical features
(section 1.2.1 and 1.2.2); however, they differ with respect to mode of inheritance, RWS being
autosomal dominant and JLNS autosomal recessive and in their involvement with deafness (JerveIl
and Lange-Nielsen, 1957; Ward, 1964). The RWS patients have normal hearing while JLNS
patients present with deaf mutism. Despite the differences between RWS and JLNS, mutations in
the same two genes, KVLQTl and KCNEl, have been implicated as cause of the disease in both
disorders (Wang et al., 1996a; Neyroud et al., 1997; Splawski et al., 1997 ; Schulze-Bahr et al.,
1997). Therefore, despite the differences between EPMl and FME, EPMl was still considered as
candidate for the reasons discussed above.
In the present study, evidence was provided to definitively prove that the three candidate epilepsy
syndromes investigated were not responsible for the disease in FME. The fact that these three
highly plausible candidates were excluded from being involved in FME does not prove that this is a
new genetic entity; however, it does not exclude this hypothesis either. The definitive answer to this
question could only be provided after the disease-causing locus is identified.
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LQTS
4.4 Study Design
All South African Afrikaner families, in which previous LQTS studies were performed, harboured
the same KVLQTl Ala212Vai mutation (de Jager et al., 1996). All affected members of these
families also shared the same haplotype, suggesting the presence of a founder effect. Given this
background, the strategy of this study was to first screen for the founder mutation in all probands
referred to our group, with the clinical diagnosis of LQTS. If the founder mutation was present in
the individual tested, a DNA-based diagnostic test could be offered to the rest of the family, on
request. Where possible, family members of the probands were traced and contacted and pedigrees
constructed. In the pedigrees constructed, linkage analysis was performed at four of the known
causative loci to identify the disease-causing gene. The four loci analyzed were, HERG, KVLQTl,
SeN5A and the chromosome 4 locus, which together account for >90% of the known cases of
LQTS (Roden et al., 1996). If linkage analysis implicated a specific gene as being the causative
gene, intensive mutation screening would be performed in that gene to find the disease-causing
mutation(s).
4.5 Founder Mutation Screening
A panel of 12 clinically-affected LQTS individuals newly entered in our group's program was
screened for the presence of the Ala212Vai mutation in KVLQ Tl and in four individuals this
mutation was identified (figure 3.9). Using the probands from the panel as reference point, it was
possible to construct three LQTS pedigrees, which were of three different South African sub-
population groups, namely persons of Mixed ancestry, Afrikaner and Indian descent.
In the family of Afrikaner descent, named pedigree 168, the Ala212Val mutation was present in the
proband, thus a DNA-based diagnostic service could be provided to members of the family who
chose to have it. This finding provided further support for the founder gene effect reported by de
Jager et al., (1996) in this sub-population group. The Afrikaners are the descendents of a small
number of European settlers who arrived in South Africa in the seventeenth and eighteenth
centuries and then underwent a rapid expansion in size, largely due to natural population increase
(Jenkins, 1990). The "Great Treks", a series of migrations of these Europeans away from the coastal
areas, to establish farming communities in the interior of South Africa, took place in the first half of
the nineteenth century. The small number of European founders of the Afrikaner population in Cape
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Town, the lack of large amounts of immigration from Europe, the Great Treks and the rapid
increase in the Afrikaner population all have contributed to the genetic isolation and relative
homogeneity of this sub-population group (Jenkins, 1990). The historical background of the
Afrikaners in South Africa favoured the presence of founder effects and these have previously been
reported in several heritable disorders in this group, including familial hypercholesterolaemia,
porphyria variegata, keratolytic winter erythema and hypertrophic cardiomyopathy (Brink et aI.,
1987; Meissner et al., 1996; Starfield et al., 1997; Moolman-Smook et al., 1999).
The fact that the other two pedigrees investigated in the present study belonged to sub-population
groups other than the Afrikaners added a new dimension to the project, because previous LQTS
studies in South Africa did not include any other sub-population groups (de Jager et al., 1996). The
family of Mixed ancestry, named pedigree 167, tested negative for the KVLQTI Ala212Vai
mutation. Members of this sub-population group originated 150-300 years ago, as a result of
admixture of Black African, San, Khoi-Khoi, European and Asian groups (Moolman-Smook et al.,
1999). It is not possible to predict from which ancestral group the mutation in pedigree 167
originated because LQTS in this family is not caused by any of the reported KVLQTl mutations in
the regions investigated with PCR-SSCP analysis and ASREA. To date, LQTS has not been
reported in Khoisan or Black Africans, it is not known if this is because of the absence of the
disease in this sub-population or because clinical studies have not identified it. The other possibility
is that this is a mutation that arose de novo since the establishment of this group.
In the family ofIndian descent, named pedigree 169, the KVLQTl Ala212Vai mutation was also not
the cause of LQTS. Most Indians in South Africa are descended from people who came from India
to South Africa between 1860 and 1911 to work in the sugar plantations of what is now called Kwa-
Zulu Natal (Bhana and Bain, 1990). The LQTS has been reported in India (el Mauhoud et al., 1988;
MerChant et al., 1988; Behera, 1989), however, as far as could be determined, no disease-causing
mutations in any of the known LQTS causative genes have been identified. Thus, it is not possible
to predict the origin of the potential mutation, as it could have arisen in India; conversely it could
have arisen de novo in this sub-population after its establishment in South Africa.
4.6 Advantages and disadvantages of genetic testing
Genetic testing for the KV_LQTl founder mutation is a diagnostic service offered by our group. The
goal of our group is to establish a genetic testing service for all the known forms of LQTS. Unlike
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other disorders, where early diagnosis is of limited clinical value because no treatment is available,
molecular diagnosis in LQTS, if extended to the treatment of gene carriers, could prevent the
occurrence of sudden death (Priori, 1997). However, the impact of genetic information within a
family is enormous; those identified as being in the line of transmission of the disease may feel
guilty for having passed the "bad" genes. Individuals who were considered to be clinically
unaffected may be profoundly upset by the knowledge that they are gene carriers. Immediate
relatives of affected individuals will experience emotional and mental anguish, even if they are not
screened. Screening has an obvious advantage to the 50% in whom the test result is negative. In
addition knowledge that not all their children are affected can be extremely positive and reassuring
for affected parents (Priori, 1997).
The alternative to genetic testing is regular clinical monitoring in immediate relatives of affected
individuals for signs of the disease (Ryan et aI., 1995). However, it is because of the limitations
manifested by the clinical diagnostic criteria, that the need for genetic testing arose. Genetic testing
is not absolutely necessary in patients who have a definitive diagnosis based on established clinical
diagnostic criteria, as all the elements necessary to decide about initiation of therapy are present
(Priori et aI., 1999). However, genetic testing could prove useful in these individuals, because,
depending on the gene identified as responsible for the disease, the precipitating factors,
management and treatment varies. Alternatively, when the diagnosis of LQTS is suspected or the
patient has an equivocal diagnosis based on clinical criteria, genetic testing could be very useful in
establishing the presence of the mutated LQTS genes thereby providing a definitive diagnosis.
However, the failure to identify a mutation does not rule out the diagnosis. Genetic testing could
also prove worthwhile in a family setting where the disease-causing mutation has been identified in
the proband (Priori et aI., 1999).
Genetic testing has the potential to define with 100% sensitivity and 100% specificity the genetic
status of any member of an affected family. However for this potential to be fully expressed, all the
disease-causing genes and associated mutations must be identified (Priori et al.,1999). This has not
yet been achieved in LQTS, and therefore, clinical criteria to establish diagnosis are still very
important. However, genetic testing could provide knowledge of the gene carrier status of the tested
individuals if one of the known LQTS disease-associated mutations is present. This could provide
peace of mind in non-gen~ carriers, and knowledge for gene carriers that could allow them to adopt
a preventative lifestyle, as this disease could be fatal and sudden death could occur in individuals
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who have no idea that they had the condition. However, gene carriers identified through genetic
testing could be disadvantaged in their opportunities for employment, life insurance and loans,
which is unfortunate especially in asymptomatic gene carriers who may never express the condition
(Ryan et al., 1995).
The decision to undergo genetic testing remains with the patient, or the parents in the case of
minors. As sudden death, the most devastating consequence of this disease, could strike without
warning, it is of utmost importance to inform not only the public, but especially sufferers and their
relatives, about genetic testing, so that they can make a informed decision (Goodwin et al., 1995).
In the present study, the KVLQ Tl Ala212Vai mutation was identified in the proband of pedigree
168 of Afrikaner descent. It would have been useful to determine if this family also shares the
founder haplotype, as was identified in the previous LQTS studies in South African Afrikaner
families (de Jager et al., 1996). However, this was not possible as this family was unwilling to take
part in the study and genetic testing was performed in only a few individuals, and most of these
individuals were children from which only a small amount of blood was collected (section 3.4.2.1;
figure3.10.2). This emphasizes that the choice of receiving genetic testing remains with the patients,
and their wishes must be respected.
4.7 Linkage Analysis Study
In pedigree 167, four of the known LQTS loci were studied by linkage analysis. The results of these
analyses led to the definitive exclusion of three of these loci, namely HERG, SeN5A and the
chromosome 4 locus, with LOD scores of -3.12, -5.01 and -3.23, respectively (Table 3.2). The five
DNA markers used to analyze the KVLQTI locus all generated equivocal LOD scores, with the
highest LOD score of 0.92 at DIIS860 (Table 3.2). These five markers spanned a region of 8cM,
with the closest linked markers to KVLQTI being TH, DllSl318 and DllS860. The equivocal
LOD scores could be explained by the small number of family members who were genotyped and
the specific genotypes generated at each of the five marker loci (fig3.12.1-3.12.5). At each of the
five loci analyzed, a specific allele was identified that was present in all affected individuals,
however, in each case, the specific allele was also present in 2 other unaffected individuals (section
3.4.2.2.1 and 4.8; figure 3.12.1-3.12.5). The disease status of these two unaffected individuals will
be discussed in section 4.8.
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Given that the four loci analyzed account for 90% of the known cases of LQTS, the definitive
exclusion found at three of the four loci enhances the chance of the fourth locus being the causative
locus. Thus, the weakly positive LOD scores generated at the KVLQTI locus became relevant, and
KVLQTI is strongly implicated as the disease-causing gene in pedigree 167. However, an
alternative possibility is that this is not the disease gene and furthermore the KCNEI locus was not
analyzed at the time of this study.
In pedigree 169, three of the four tested loci could again be definitively excluded, these loci were
SCN5A, the chromosome 4 locus and KVLQTI (Table 3.3). At the KVLQTI locus, DNA markers
which were located further away from KVLQTI generated equivocal LOD scores; however, at
DIISI318, a DNA marker that was shown to be completely linked to KVLQTI in a previous study
(Wang et al., 1996a), a LOD score of -2.62 was generated. At the HERG locus, an equivocal LOD
score of 0.2 was generated with D7S636. The genotype analysis at this marker showed that allele 9
was present in all affected individuals, as well as two equivocal individuals (section 3.4.2.2.2 figure
3.15.1-3.15.2.). The latter result could explain why an equivocal LOD score was generated at
D7S636. The definitive exclusion found at three of the 4 loci made the weakly positive LOD score
generated at the HERG locus relevant and strongly suggests that this is the disease-causing locus in
pedigree 169. However, an alternative posibility is that this is not the disease gene and furthermore
the KCNEI locus was not analyzed at the time of this study. It can be speculated that the two
equivocal individuals, II:5 and IIl:4, carry the disease-causing mutation and are at risk of
developing LQTS and sudden cardiac death. A haplotype diagnosis, employing more DNA markers
closely linked to the HERG locus, could be offered to family members who require it. However,
with the caveat that until the actual disease-causing mutation has been identified no molecular
diagnosis can be given with absolute certainty.
Linkage analysis requires a single large family or multiple small families from a single genetic
isolate to be successful (Berkovic, 1997). In the present study, a relatively small family was
analyzed, thus, the equivocal LOD scores generated could be attributed to the small sample size of
the study.
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4.8 Haplotype Analysis
Haplotype analysis in pedigree 167 showed that all the affected members of this family shared the
same combination of alleles at the five DNA markers tested at the KVLQTl locus, suggesting that
this is the disease-associated haplotype (figure 3.20). However, two unaffected individuals whose
QTc fell within the normal range also shared this haplotype, suggesting that they also carried the
defective gene (figure 3.20). As mentioned earlier, the diagnosis of LQTS is difficult and often
missed by clinicians, resulting in individuals at risk of syncope and sudden death not receiving
appropriate treatment (Moss et al., 1991; Vincent et al., 1992). Thus, although definite proof of their
carrier status can only be provided after the disease-causing mutation has been found, the two
individuals sharing the disease-associated haplotype, should be treated as at risk of LQTS in the
mean time. Taken together, the haplotype analysis provided further evidence in favour for linkage
to KVLQTJ in pedigree 167.
4.9 Mutation Screening
The linkage analysis results, as well as the haplotype analysis, implicated the KVLQTl gene as
disease-causing gene in pedigree 167. Given this evidence, the six transmembrane domains of
KVLQTl, as published by Wang et al., (1996a), were screened for known and novel mutations
employing ASREA and PCR-SSCP analysis.
4.9.1 ASREA
To date, 35 different mutations have been reported in the KVLQTJ gene and the search for the
identification of more disease-causing mutations continues (Wang et al., 1996a; Russel et al., 1996;
Donger et al., 1997; van den Berg et al., 1997; Itoh et al., 1998; Saarinen et al., 1998; Splawski et
al., 1998: Neyroud et al., 1999). The KVLQTl has recently been renamed KCNQl (Neyroud et al.,
1999), however, in this report it is still referred to as KVLQTl. At the time the study was initiated,
the first ten KVLQ Tl mutations described by Wang et al., (1996a) were known and three of these
mutations, which affected restriction enzyme sites, were screened for. These mutations were the
Ala49Pro mutation situated in S2-S3 region, Arg61 Glu also in the S2-S3 region and the Val125Met
mutation in the S4-S5 region. However, none of these mutations was detected in the affected
individuals of pedigree 167. No other described mutations were screened for by ASREA, as
extensive SSCP analysis was performed in the partial SI and S2-S6 region of KVLQTl. It was
argued that if any mutation, known or novel were present in these regions it would be picked up
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with the SSCP analysis. The absence of the three mutations tested for by ASREA was also
confirmed in the results obtained with the SSCP analysis.
In two of three mutations screened with ASREA, namely Arg61Glu and Va1l25Met, the presence
of the mutation introduce a Pvull a Styl site, respectively. Thus, in the absence of the mutation, after
digestion with the respective restriction enzymes, only the undigested PCR fragment would be
generated. To ensure that the enzyme was active during the digestion, ideally an internal control
should be included in the reaction. For one of these mutations, Arg61 Glu it was possible to design
an internal control to test the activity of the enzyme. Diluted lambda DNA was included in the
reaction mixture prior to digestion. To find a control for the Va1l25Met mutation proved
troublesome, as A DNA digested with Styl generated too many bands, some of which overlapped
with the expected fragment sizes generated in the presence of Vall 25Met. Subsequently, no control
was included for screening the Val125Met mutation.
Negative controls, samples amplified from unaffected LQTS individual, were included on each
ASREA gel. Ideally, a positive control, a sample amplified from an affected person carrying the
mutation in question, would be useful to compare the generated fragment sizes and activity of the
enzyme. This type of control was included in the analysis of the Ala212Val mutation; however,
such samples were not available for the other three mutations. The expected fragment sizes of both
the mutant and the wild type alleles were determined with the aid of the computer program
Genepro, prior to PCR-based restriction enzyme analysis. This, and the inclusion of a molecular
weight marker on each polyacrylamide gel, allowed the investigator to gauge the fragment sizes and
the compare them with those predicted.
4.9.2 PCR-SSCP analysis
The main mutation screening technique used in the present study was PCR-SSCP analysis, because
of its simplicity and potential for high output of up to 100% mutation detection efficiency using
multiple conditions (Michaud et al., 1992). Four different electrophoresis conditions were used to
perform PCR-SSCP analysis, as variable conditions improve the resolution power and also increase
mutation detection sensitivity. On each gel, the PCR amplified Só-Pere region of a person
harbouring the KVLQTl Ala212Val mutation was included, this sequence variation was detected
under all four conditions, .attesting to the sensitivity of the SSCP analysis. No abnormally migrating
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bands were identified in the partial S I-S2, S3-S4, S4, S4-S5, Pore-S5, Só-Pere and S6 regions
under any of the electrophoretic conditions (figure 3.22.1-3.22.4). However, a mobility shift was
detected in all affected members of pedigree 167 in the PCR fragment derived from the S2-S3
region of the KVLQTl gene and also the two unaffected individuals that shared the disease-
asociated haplotype. However, this mobility shift was also detected in a third unaffected individual,
of pedigree 167, indicating that this is not the disease-associated mutation. This mobility shift was
repeatedly detected by PCR-SSCP under two different gel conditions. DNA sequence analysis of
the S2-S3 region revealed a G---+Atransition in the intronic sequence.
A panel of 40 unaffected control individuals of Mixed ancestry was screened for this sequence
variation and three heterozygous G/A individuals were detected. Thus, the ratio of the G:A alleles
was 0.96:0.037, indicating that this sequence variation is a non-pathological polymorphism. A
polymorphism is defined as "a Mendelian trait that exists in the population in at least two
phenotypes, neither of which occurs at a frequency less than 1% " (Cotton and Scriver, 1998).
4.9.3 Why were no mutations detected?
As discussed above, no novel or known mutations were detected employing ASREA or PCR-SSCP
analysis in KVLQTl in pedigree 167. This is in conflict with the hypothesis that KVLQTl is the
disease-causing gene in pedigree 167. However, the fact that no disease-associated mutation was
detected could be attributed to the fact that not the entire KVLQTl gene was screened in the present
study, as the complete sequence was unavailable at the time the study was initiated. Thus, although
the disease-causing mutation was not present in the regions investigated, it may be located in the
regions not analyzed. Another possible explanation why no disease-associated mutation was
detected could be because it is situated within the regulatory regions or intronic sequences
important for splicing or transcription, which were not investigated
Incomplete mutation scanning, compounded by use of only one PCR-SSCP condition, which is
reported to detect less than 80% of mutations, can thus generate a low mutation detection rate
(Cotton, 1996). However, in the present study, multiple different SSCP conditions were used, thus
the absence of mobility shifts detected most probably indicates the absence of mutations in the
regions investigated.
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4.10 Future Studies
The aim of the present study was to identify the disease-causing locus in four families with episodic
loss of consiousness, in three of these families the clinical diagnosis of LQTS was made and the
remaining family showed a form of epilepsy, termed FME.
In the epilepsy study, three highly plausible candidate forms of epilepsy were analyzed, to test if
they are responsible for the disease in FME. The results obtained through this analysis provided
irrefutable evidence that none of these three candidate epilepsy syndromes is involved in FME. This
was not unexpected, as our group's hypothesis is that this is a new clinical and genetic entity and, as
these candidates were the most closely clinically related epilepsies to FME, this result provided
evidence in favour of our hypothesis. In the absence on any other obvious candidates for this
disease, a random genome search would be the next logical step; however, this will require the
presence of a single large or multiplex small, families. To this end, the focus of the study is
currently to extend the present family and also to seek new families in whom this form of epilepsy
segregates. A second family, pedigree 202, was identified; this family lived in a small town close to
where the first family was identified. Although a common ancestor could not be identified, the
rarity of the disorder and the geographical proximity of the families make it highly likely that they
are related. A high mortality rate in of the older generation, due to homicide and other causes, and
the lack of birth records have made the task of linking the two families more difficult (J. Carr,
manuscript in preparation). However, it is possible that together the two pedigrees may strengthen
the power of future studies.
In the LQTS study, the results obtained are the first report of genetic heterogeneity in South African
LQTS families. This is also the first report of LQTS in ethnic groups other than the Afrikaners in
South Africa. In pedigree 168 of Afrikaner descent, the founder mutation, the KVLQTl Ala212Vai
mutation, was identified as cause of the disease, providing further support for the founder effect
previously reported in this sub-population group (de Jager et al., 1996). A mutation, other than this
founder mutation, in KVLQTl was implicated as the cause of the disease in the family of Mixed
ancestry. In the family ofIndian descent, HERG was implicated as the defective gene.
Although the KVLQTl gene was implicated as the disease-causing gene in pedigree 167, the
disease-associated mutation was not identified; thus, future studies should focus on finding the
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disease-associated mutation. At the time of the study, the complete sequence of KVLQTI was not
available, therefore, only part of this gene was screened for mutations. Thus, future work on this
project could include screening the regions of KVLQTl not analyzed in the present study. In
pedigree 169, HERG was implicated as the causative gene; however, no mutation screening was
performed in this gene due to time constraints.
Three pedigrees were constructed from a panel of twelve probands and new probands are
continuously added to the panel. Thus, future work could also focus on constructing more pedigrees
from this panel of affected individuals to perform linkage analysis at the other known LQTS loci.
The fifth disease-causing locus, KCNEI was not investigated because it was identified close to the
completion of the present study. Thus, future studies should also focus on analyzing its involvement
in pedigree 167 and 169 to confirm the evidence implicating KVLQTl and HERG in pedigree 167
and 169, respectively.
Currently, an easy and cost-effective DNA-based diagnostic test and an unequivocal diagnosis can
only be made if one of the reported mutations which affects restriction enzyme sites is present in the
tested individual. However, it is important to identify and characterize the disease-causing genes
and mutations found in South African LQTS families, firstly, because it could help to improve the
current DNA-based diagnostic service. In addition, although preliminarily, data are accumulating
that therapy for LQTS should be individualized for each disease-causing gene and its associated
mutation, also the precipitating factors of the different forms of the disease are diverse (Schwartz et
al., 1999 (submitted)). Thus, if the disease-causing locus and mutation is identified in a pedigree, it
could have important implications for therapy and avoidance of precipitating factors.
4.12 Conclusion
In conclusion, the results obtained in the present study paved the way for further studies to describe
and characterize precisely the two diseases studied, a task that is important because of genetic
heterogeneity seen in both these group of disorders.
The long term goal of this project is to identify the disease-causing genees) and associated
mutation(s) in the families investigated. The importance of such studies has clearly been explained,
namely, that it could facilitate early identification of susceptible individuals and early treatment of
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the disease. A presymptomatic molecular diagnosis in both LQTS and epilepsy could prove fruitful,
because in both cases treatment is available, unlike disorders where no successful treatment is
available, in which case knowing that the disease is present is of limited clinical value and may
cause distress for the patient. Molecular diagnosis would also allow for the avoidance of
misdiagnosis ofLQTS as epilepsy.
A lack of an adequate and systematic classification system has been a major stumbling block in the
clarification of the aetiology of epilepsy. Identification and characterizing of epilepsy susceptibility
genes, as was the objective in the present study, could play an important role in the development of
a more clinically useful classification of seizure disorders.
In the present study, the molecular basis of two clinical causes of loss of consciousness was
investigated, namely LQTS and FME. In the LQTS families, the application of genetic markers
allowed the differentiation between three molecular causes ofLQTS. The latter finding is useful as
the precipitating factors for the life threatening arrhythmias of LQTS differ according to the specific
gene involved (Schwartz et al., 1995). Also data are accumulating to indicate that the abnormalities
caused by the different causative genes of LQTS could be corrected by gene specific therapies
(Compton et al., 1996; Keating et al., 1996; Priori et al., 1996). In the epilepsy family, the cause of
loss of consciousness could not be determined, however, three highly plausible candidate loci were
ruled out.
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APPENDIX I
BUFFERS, SOLUTIONS AND MARKERS
1. BUFFERS
1.1 Cell Lysis Buffer
Sucrose 0.32M
Triton-X-100 1%
MgCh 5rnM
Tris-HCI (pH7.6) 10rnM
Make up to IL with dH20
1.2 50 X TAE-Buffer
Tris-OH
Glacial acetic acid
Na2EDTA
pH to 8.1 with glacial acetic acid
40rnM
20rnM
2rnM
1.3 10 X TBE-Buffer
Tris-OH (pH 8.0)
Boric Acid
Na2EDTA (pH 8.0)
89rnM
89mM
2rnM
1.4 1 X TE-Buffer
Tris-HCl (pH 8.0)
EDTA (pH 8.0)
10rnM
lrnM
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2. SOLUTIONS
2.1 SOLUTIONS FOR DNA EXTRACTION
2.1.1 Phenol:/Chloroform
Mix phenol saturated with 1 X TE, chloroform and 8 hydroxyquinoline in a ratio of
25 :24: 1. Store at 4°C.
2.1.2 Chloroform:/Octanol
Mix chloroform and octanol in a ratio 24: l. Store at 4°C.
2.1.3 NaAc
NaAc.3 H20
H20
pH to 5.2 with glacial acetic acid
40.81g
SOml
to 100ml
2.1.4 Na-EDTA
NaCI
EDTA
7SmM
2SmM
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2.2 ACRYLAMIDE GEL STOCK SOLUTIONS
2.2.1 30% Acrylamide stock solution (2.7%) cross linking for PCR-SSCP and
other polyacrylamide gels
Acrylamide
Bis-acrylamide
H20 to
30g
0.8g
100mi
First add SOmlof dH20 and mix solution on magnetic stirrer for 2 hours. Make
up to 100ml with dH20 and store at 4°C.
2.2.2 10% Ammonium persulphate (APS)
to
19
l Oml
Mix well and store at 4°C. Make fresh weekly.
2.3 GELS
2.3.1 1.5% Agarose Gels For Monitoring PCR Products
Agarose
10 X TBE
H20
Ethidium bromide (1Omglml)
1.Sg
10ml
100mi
10J.lI
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2.3.2 Gels For PCR-SSCP Analysis Under Non-Denaturing Conditions
2.3.2.1 5% Polyacrylamide gel without glycerol
30% acrylamide/0.8%
Bis-acrylamide 33ml
H2O l56ml
10 X TBE l Oml
10% APS lml
TEMED 100J.lI
2.3.2.2 5% Polyacrylamide gel with 10% glycerol
30% acrylamide/0.8%
Bis-acrylamide 33mI
H2O l36ml
10 X TBE lOml
Glycerol 20ml
10% APS lml
TEMED 100J.lI
2.3.2.3 10% Polyacrylamide gel without glycerol
30% acrylamide/0.8%
Bis-acrylamide 66ml
H2O l23ml
10 XTBE 10mi
10% APS lml
TEMED 100J.lI
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2.3.2.4 10% Polyacrylamide gel with glycerol
30% acrylamide/0.8%
Bis-acrylamide 66ml
H2O 103ml
Glycerol 20ml
10 X TBE lOml
10% APS 1ml
TE:MED lOO1l1
2.3.2.5 0.35 X MDE gel
2 X .rvIDE™Stock solution 28ml
10 X TBE 9.7ml
H2O 122ml
10% APS 1.6ml
TE:MED 16Oll1
2.3.3 12% Polyacrylamide Gel For Restriction Enzyme Mutation Analyses
30% acrylamide/0.8%
Bis-acrylamide 4ml
H2O Sml
10XTBE 1ml
10% APS 8Oll1
TE:MED 2Oll1
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2.3.4 5% Denaturing Polyacrylamide Gel
Urea
H20
30% acrylamide/0.8%
Bis-acrylamide
10 X TBE
10% APS
TEMED
33.3g
30ml
l2.75ml
7.5ml
3751ll
37.51ll
2.4 SOLUTIONS FOR ETHIDIDM BROMIDE STAINING (lOmg/ml)
Ethidium bromide
H20 to
500mg
50ml
Stir well on magnetic stirrer for 4 hours, store in a dark container at 4°C.
2.5 SOLUTIONS FOR SILVER STAINING
2.5.1 0.1% AgN03
AgN03 19
H2O to IL
Prepare fresh solution before use
2.5.2 Developing Solution
NaOH 15g
NaB~ O.lg
Formaldehyde 4ml
H2O to IL
Mix well using magnetic stirrer. Prepare fresh solution before use.
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2.6 SOLUTION FOR SEQUENCING-DMSO
2.7 SOLUTIONS FOR AUTORADIOGRAPHY
2.7.1 Developer Solution (Polygon A) (Champion Photochemistry)
Solution 1 (Champion Photochemistry)
Solution 2 (Champion Photochemistry)
H20 to
Mix well.
1.98ml
18.1ml
9900ml
2.7.2 Stop Solution
6% acetic acid (BDH)
H20
Mix well.
to
540ml
9000ml
2.7.3 Fixer Solution
Perfi.x
Hardener-S
H20
Mix well.
to
1800ml
225ml
9000ml
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2.8 LOADING DYES
2.8.1 Bromophenol Blue Loading Dye For Agarose And Polyacrylamide Gels
Bromophenol Blue 0.2%
Glycerol 50%
Tris-HCI (pH 8) 10mM
Mix by vortexing solution
2.8.2 SSCP Loading Dye
Formamide 95ml
NaOH 10mM
EDTA 20mM
Bromophenol blue 0.05g
Xylene cyanol 0.05g
Mix well. Alliquot into 2ml eppendorftubes. Store at 4°C.
2.8.3 Sequencing Stop Buffer
Formamide
Bromophenol blue
Xylene Cyanol
95%
0.01%
0.01%
2.9 SEQUENCING TERMINATION MIX
2.9.1 ddGTP
ddGTP 30llm
20llm
20llm
20llm
20llm
7-Deaza dGTP
dATP
dTTP
dCTP
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2.9.2 ddATP
ddATP
7-Deaza dGTP
dATP
dTTP
dCTP
350llffi
20llffi
20llffi
20llffi
20llffi
2.9.3 ddTTP
ddGTP
7-Deaza dGTP
dATP
dTTP
dCTP
600llffi
20llffi
20llffi
20llffi
20llffi
2.9.4 ddCTP
ddGTP
7-Deaza dGTP
dATP
dTTP
dCTP
200llffi
20llffi
20llffi
20llffi
20llffi
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MOLECULAR SIZE MARKER
BACTERIOPHAGE LAMBDA Pst I
Lambda DNA (10J..1g)
Buffer H 2J..1l
Pst I (Promega) 20U
H20 to 20J..1l
Incubate at 37°C for 2 hours, heat inactivate at 6SoC for S minutes. Load IJ..11
onto silver stained polyacrylamide gels 3J..1lon an ethidium bromide stained
agarose gel.
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Agarose
Ammonium Persulphate
Acetic acid
AgN03
Acrylamide
Bisacrylamide
Boric acid
Bromophenol blue
Chloroform
dATP
dCTP
dGTP
dTTP
DMSO
Ethanol
Ethidium bromide
EDTA
jinol™ sequencing kit
FIX solution
Formamide
Formaldehyde
Gel sealing tape
Gelbond™ PAG polymer
GLADRWRAP
Glycerol
Hhal
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APPENDIX II
LIST OF SUPPLIERS
Amersham
Seakem
Merck
BDH chemicals
Merck
BDH Chemicals
Merck
Merck
BDH Chemicals
BDH Chemicals
Boehringer Mannheim
Boehringer Mannheim
Boehringer Mannheim
Boehringer Mannheim
Sigma
Boehringer Mannheim
Sigma
Boehringer Mannheim
Promega
M&B Suppliers
Merck
Merck
Sigma
FMC
Multifoil Trading (Pty) Ltd
BDH Chemicals
Amershan
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Iso-amyl alcohol Merck
Lambda DNA Promega
Lysozyme Boehringer Mannheim
MgCl2 Sigma
Mineral oil BDH Chemicals
3MM Whatman paper Merck
NaBH4 Merck
NaCl BDH Chemicals
NaOH Merck
NaAc Merck
Octanol Merck
Proteinase K Sigma
Phenol Merck
Polycon A Champion photochemistry
Pst! Promega
Qiagen kit Strategen
Taq polymerase Promega
Temed Promega
Tris Merck
Triton XIOO BDH Chemicals
Urea BDH Chemicals
X-ray film Protea
Xylene cyanol M&B laboratory chemicals
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